

Date of Preparation: January 21, 2019



Signature

MARWAN S. ABOULJOUND, M.D., F.A.C.S., CPE, M.M.M.

Office Address:

Henry Ford Hospital
Transplant Institute and Hepatobiliary Surgery
2799 West Grand Blvd., CFP2
Detroit, MI 48202

Telephone: 1-313-916-2941

Email: maboulj5@hfhs.org

PERSONAL DATA:

Name: Marwan S. Abouljoud

Date of birth: August 4, 1960

Citizenship: American Citizen

Place of birth: Beirut, Lebanon

Spouse: Mary

Children: Moneer, October 2, 1995

Malek, March 11, 1997

Bashar, May 22, 2002

CURRENT POSITION:

Chief, Division of Transplant and Hepatobiliary Surgery
Benson Ford Chair, Henry Ford Transplant Institute

EDUCATION:

Carnegie Mellon University, Masters in Medical Management	2/2013
American University of Beirut Faculty of Medicine, Medical Degree	1985
American University of Beirut, Bachelor in Sciences	1982
International College, Beirut, Lebanon.	1979

POSTGRADUATE TRAINING:

Vision Day, Professional Development Program	10/2017
Weatherhead School of Management Case Western Reserve University	6/2014
Certificate: Coaching for Intentional Development	
Weatherhead School of Management Case Western Reserve University	2/2014
Certificate: Appreciative Inquiry	
Certifying Commission in Medical Management Physician Executive Program	11/2012
Certification: Physician Executive in Medical Management	

Weatherhead School of Management Case Western Reserve University Certification: Emotionally Intelligent Leader	6/2011
Weatherhead School of Management; Case Western Reserve University Certification: Developing Your Emotional Intelligence: Core Competencies for Great Leadership	6/2011
Weatherhead School of Management; Case Western Reserve University Certification: Power of Mindfulness	5/2011
Weatherhead School of Management; Case Western Reserve University Certification: Igniting Positive Change through Appreciative Inquiry	5/2011
Weatherhead School of Management; Case Western Reserve University Certification: Leadership, Resonance, and Renewal Instructor: Richard Boyatzis, PhD	1/2011
Weatherhead School of Management; Case Western Reserve University Certificate: Emotional Intelligence in Leadership	1/2011
International School of Robotic Surgery Ospedale Della Misericordia, Grosseto, Italy	6/2006
da Vinci Surgical System Online Training Program Intuitive Surgical Robot Online Course, University of Michigan	6/2006
da Vinci Surgical System Off-Site Training Program Intuitive Surgical Robot Hands-on Course, University of Michigan	6/2006
Split Liver Transplant Hands-on Course Hamburg, Germany	3/2000
Leadership Development for Physicians in Academic Health Centers Harvard School of Public Health, Boston, MA	10/1997
Transplantation Fellow, UCLA Pediatric Liver Transplant Program, Los Angeles, California.	6/1994
Transplantation Fellow, Baylor University Medical Center, Dallas, Texas	1993 - 1994
Transplantation Fellow, University of Alabama at Birmingham. Birmingham, Alabama.	1992 - 1993
Visiting Resident, Division of Organ Transplantation, New England Deaconess Hospital, Boston, Massachusetts.	2/1990
General Surgery, Henry Ford Hospital, Detroit, Michigan	1988-1992
General Surgery, University of Michigan Hospitals. Ann Arbor, Michigan	1986-1988
Research Fellow, University of California, San Francisco, California	1985-1986
Externships:	
Montreal General Hospital, McGill University	2-3/1985
University of Michigan Hospitals, Ann Arbor	9/1985

FACULTY APPOINTMENTS:

Professor, Clinical Educator, FTA, Wayne State University 11/4/2015 School of Medicine	
Associate Professor, Clinical Educator, FTA, Wayne State University School of Medicine	4/1/2008

HOSPITAL OR OTHER PROFESSIONAL APPOINTMENTS:

Nominating Committee, Board of Governors	2018-Present
Chair, Search Committee for Chair of Department of Urology	2018-Present
Search Committee for SVP and Chief Human Resources Officer	2016-2017
Search Committee for Physician Director of the Heart and Vascular Institute	2015-2016
Chair, Medical Staff Quality Committee, Henry Ford Medical Group (HFMG)	2014-2015
Chair, Search Committee for Emergency Medicine Chair Search Committee	2014
Chief Medical Officer, Henry Ford Medical Group	2013-2015
HFHS Multidisciplinary Provider System Council	2013-2015
Search Committee for CEO of Henry Ford West Bloomfield Hospital	2013
Executive Committee Member, Henry Ford Center for Cancer Surgery	2012-2015
Director of Physician Affairs, Henry Ford Medical Group	2012-2013
Co-Chair, Henry Ford Medical Group and Henry Ford Health Network Finance Committee	2012-2015
Member, Henry Ford Medical Group and Henry Ford Health Network Finance Committee	2007-Present
Chair, Henry Ford Medical Group & Health System ESR Steering Committee	2012-2015
Director, Physician Leadership Development Programs	2011-Present
Chairman, Board of Governors, Henry Ford Medical Group	2010-2011
Search Committee for CEO of Henry Ford Hospital and Detroit Campus	2010
Search Committee for Chairman, Department of Internal Medicine	2010
Chair, CEO Evaluation Committee, Henry Ford Medical Group	2009-2013
Chair, Sub-Committee, To Develop New CEO Evaluation Tool	2007-2010
HFHS Healthcare Equity Advisory Group	2009-Present
Vice Chair, Board of Governors, Henry Ford Medical Group	2008-2010
Chair, Professional Standard & Conduct Committee, HFMG	2008-2010
System Diversity Workgroup Committee, Henry Ford Health System	2008-Present
Board of Governors Professional Standards & Conduct Committee, HFMG	2007-2015
Board of Governors Vice-Chair, Nominating Committee, HFMG	2007-2014
Board of Governors, Henry Ford Medical Group (HFMG)	2006-2014
Fellowship Program Director (first at HFH), Henry Ford Transplant Surgery	2004-2010
Search Committee – Chief of Vascular Surgery	2004
Chairs’ Council, Henry Ford Hospital and Medical Group	2003-Present
Henry Ford Hospital Transplant Institute	2003-Present
Clinical Forum Committee	
Executive Work Group	
Quality Assurance Committee	
Steering Committee	
Outreach and Networking Committee	
Director, Henry Ford Transplant Institute, Henry Ford Hospital	2003-Present
Referring Physician Blue Chip Initiative Group – Henry Ford Hospital	2003
Specialty Marketing Task Force – Henry Ford Hospital	2003
Benson Ford Chair, Transplantation Surgery, Henry Ford Hospital	1998-Present
Committee Visitor Program, Henry Ford Hospital & Medical Group	1995
Blood Product Usage Work Group, Henry Ford Hospital & Medical Group	1995
Division Chief, Transplantation Surgery, Henry Ford Hospital	1995-Present
Strategic Planning Committee, Henry Ford Hospital & Medical Group	1995

Surgical Director, Liver Transplant Program, Henry Ford Hospital
Organ Procurement Committee, Henry Ford Hospital & Medical Group

1994-2008
1994-Present

CMO ACCOMPLISHMENTS:

Developed a physician and midlevel provider onboarding program
Restructured orientation and acculturation of newly employed physicians
Initiated development programs:

- 1- Physician Leadership Institute: 7 day program over 8 months with Capstone business project. 5 years running.
- 2- Fundamentals in Leadership: 1 day program for physicians and midlevel providers
- 3- Time Management, Emotional Intelligence, Appreciative Inquiry and Team Emotional and Social Inventory workshops
- 4- Developed workshop on Effective Communications in Healthcare for Patient Safety
- 5- Quality and Effectiveness Workshop for Healthcare Professionals
- 6- Practice Development Workshop for specialty and primary care physicians and midlevel providers
- 7- Joint Commission with Provider Professional Practice Evaluation and Peer Review (OPPE/FPPE/Peer Review – No citations)
- 8- Developed policies and executed processes for OPPE, FPPE and Peer Review
- 9- Initiated and chaired Medical Staff Quality Committee
- 10- Developed Medical Group CEO Evaluation Tool for the Board of Governors
- 11- Initiated process to develop Mindful Practices in Medicine
- 12- Initiated process to develop program for physician coaching and career planning
- 13- Initiated process to develop program for women in healthcare
- 14- Initiated process to develop program for career transitions: Time, Health and Wealth
- 15- Initiated process for the IDEAS Club: A forum to discuss and develop advanced system strategies across a healthcare system, to promote system alignment, culture development and actions as one.
- 16- Initiated internal study of physician ergonomics in practice

MAJOR PROFESSIONAL SOCIETIES:

Academy of Surgery of Detroit
American Association for the Study of Liver Diseases
American Board of Surgery, Director, July 1, 2015 thru June 30, 2021
American College of Surgeons, Fellow, October 1997
American Hepato-Pancreato-Biliary Association
American Medical Association
American Medical Group Association
American Society of Transplant Surgeons
American Society of Transplantation
American Surgical Association (Fellow April 2017)
Arab-American Medical Association
Detroit Surgical Association
Detroit Academy of Surgery
Great Lakes Transplant Association

International Liver Transplantation Society
 Michigan State Medical Society
 Society for Organ Sharing
 Society for Surgery of the Alimentary Tract
 Transplant Society of Michigan, Gift of Life Michigan
 The International Transplantation Society
 Wayne County Medical Society

LICENSURE AND BOARD CERTIFICATION:

FMGEMS: Part I, San Francisco	1/1985
FMGEMS: Part II, Beirut, Lebanon	7/1985
ECFMG Certificate # 389-496-1	2/1986
FLEX Parts I and II, New York	6/1986
Diplomat of the American Board of Surgery, Certificate # 38025	
Issued	2/10/1993
Recertified	10/18/2002
Recertified	12/1/2012
Expired	7/1/2023
DEA Registration # BA 2861006, valid through	6/30/2018
Michigan permanent medical license # 4301050791, valid through	1/31/2019
Alabama permanent medical license # 16203, expired	1996

HONORS/AWARDS:

Alkebu-Lan Village Community Partner Award, 41 st Anniversary Celebration	2018-2019
Fred Whitehouse Lifetime Achievement Award, Henry Ford Medical Group	10/25/2017
American University of Beirut Surgical Alumni Association of North American Outstanding Service Award	2017
Received at ACS Congress, San Diego CA	
Hour Detroit Top Doc: Organ Transplantation, Transplant and Hepatic Surgery 2016, 2015, 2014, 2013, 2012, 2010, 2009, 2008, 2007, 2006, 2005, 2004, 2003, 2002	2017
Best Doctors in America	2017-2018
Arab American of the Year Award, ACCESS 42 nd Annual Anniversary Dinner	4/2013
America's Top Doctors, Castle Connolly Medical LTD: 2015, 2014, 2013, 2012, 2011, 2010, 2009, 2008, 2007, 2006, 2005	2016
Patient Choice Awards US News and World Reports: 2009, 2008	2012
Focus on People Award as a member of the HFHS Leadership Academies Team	2011
Focus on People Award as a member of the HFHS Retirement Program Redesign Team	2011
MOTTEP Vanguard Award from the Gift of Life Michigan Minority Organ Tissue Transplant Education Program	3/25/2011
Distinguished Physician of the Year Award by the National Arab American Medical Association	2010
Focus on People Award as a member of the Small Bowel & Multivisceral	2010

Transplant Team	
Excellence in Medical Services & Advocacy Award, the American Arab Anti-Discrimination Committee	2009
Arab American Professional of the Year by the Arab American Professionals Network of the American Arab Chamber of Commerce	2007
Champion of Organ Donation, International Association for Organ Donation	2004
Shadow of a Leader Recognition, Henry Ford Health System	2003
Each Patient First	
Benson Ford Chair in Transplantation Surgery, Henry Ford Hospital	7/1998
Charles Johnston Award: Awarded by the Detroit Surgical Association for best clinical paper presentation.	5/1991
Alpha Omega Alpha Honor Society	6/1985
B.S. degree with Distinction	1982
Dean's Honor List, college and medical school.	
Haddad Memorial Scholarship Award, full tuition during medical school	
Stephen Penrose Honor Award for scholastic achievements	6/1979
International College First Scholar Award	6/1979

SERVICE:

Patient Care:

Staff, Henry Ford Hospital, 1994-present
Liver Transplant: peri-operative and postoperative care
Kidney Transplant: peri-operative and postoperative care
Pancreas Transplant: peri-operative and postoperative care
Vascular Access
Hepatobiliary Surgery

Professional Consultation:

1. American University of Beirut Medical School Department of Surgery Review Committee. Beirut, Lebanon, September, 2017.
2. Piedmont Medical Center, Atlanta Georgia. Invited consultant to the Liver Transplant Program at Piedmont Medical Center to assist with their first adult living donor liver transplant procedure at Piedmont. April 24, 2017.
3. Baylor University Medical Center, Dallas, Texas. Invited consultation to Baylor University Medical Center Leadership Team; the set-up, pros, cons, governance and recruitment for developing a Faculty Practice Plan for physicians and surgeons of BUMC. November 13, 2012.
4. Munson Medical Center Tumor Board Conference: Guest Expert for Munson's Cancer Registry, February 13, 2009.
5. Medical University of South Carolina: Transplant Programs and Outreach Development. 2005.
6. Piedmont Medical Center, Atlanta, Georgia: Liver Transplant Program Development. 2004.
7. American University of Beirut Medical Center: Development of Live-Donor Liver Transplant Program. 2002.
8. Iranian Surgical Association: Logistics of Liver Transplant Program Development in a 3rd World Country. 2001.

9. American University of Beirut Medical Center: Development of Radio Frequency Ablation Program. 2001.
10. Methodist Medical Center, Dallas, Texas: Liver Transplant Program Development. 2000.
11. University of Texas Galveston Medical Center: Liver Transplant Program Review. 1995.

Scholarly Service:

Reviewer of Abstracts:

American Association for the Study of Liver Diseases
 American Society of Transplant Physicians – abstract reviewer, liver
 American Transplant Congress – abstract reviewer, liver
 World Transplant Congress

Reviewer of Manuscripts & Invited Editorial:

1. American Journal of Transplantation
2. Clinical Transplantation
3. Journal of Vascular Surgery, ad hoc reviewer
4. American Journal of Transplantation: Invited Editorial on Manuscript AJT-O-13-00422.R2, “Assessing Variation in the Costs of Care Among Patients Awaiting Liver Transplantation”, July, 2013. Editorial Manuscript AJT-E-13-01007, “**Sicker Patients with End Stage Liver Disease Cost More: a Quick Fix?**” M. Abouljoud, K. Brown, D. Nerenz. American Journal of Transplantation, 2014 Jan;14(1):9-10. DOI: 10.1111/ajt.12498. Epub 2013 Oct 24.
5. Liver Transplantation: Invited Referee/Reviewer for Manuscript ID LT-09-214, April 2009
6. American Journal of Transplantation, Manuscript, Ad Hoc Reviewer, Jan. 2008
7. Transplantation – 2003 ad hoc reviewer
8. Graft – ad hoc reviewer
9. Liver Transplantation: member of editorial review board - 1999

OTHER PROFESSIONAL SERVICE:

1. Integration of the multidisciplinary structure of the liver transplant program.
2. Expansion of the liver transplant program at Henry Ford Hospital to a leadership position in clinical volume and outcomes.
3. Establishment of a quality outcome and improvement database for the liver and kidney transplant programs.
4. Oversight of the development of an active endovascular lab for vascular hemodialysis access maintenance.
5. Achieving Center of Excellence status for the liver transplant program at Henry Ford Hospital, allowing for participation in national contracts.
6. Development of an active laparoscopic living donor nephrectomy program.
7. Pioneering liver split transplantation in Michigan.
8. Development of successful program in living donor adult-adult liver transplantation.
9. Development of an educational program for living kidney donation with doubling of living donation rates within 2 ½ years of implementation.
10. Pioneering radiofrequency ablation therapy for liver tumors in Michigan.
11. Development of an active whole organ pancreas transplant program.

12. Implementation of growth strategies in kidney transplantation resulting in the growth of the program from 50 transplants to more than 110 transplants per year.
13. Development of transplant surgery fellowship approved by the American Society of Transplant Surgeons.
14. Establishment of an active hepatobiliary surgery program with a statewide referral base.
15. Development and implementation of infrastructure and operations of fully integrated Henry Ford Transplant Institute.
16. Laparoscopic liver surgery program.
17. Development and establishment of the Robotic Liver Surgery Program.
18. Performed the first living donor liver transplant in the State of Michigan. Initiated the Living Donor Liver Program at Henry Ford Hospital (1999).
19. Initiated the Intestinal and Multivisceral Transplant Program at Henry Ford Hospital, first in the State of Michigan.
20. Started the Liver Cancer Registry at Henry Ford Hospital.
21. Started the Liver Cancer Clinic and Tumor Board Registry at Henry Ford Hospital.
22. Development and implementation of the Pediatric Liver Transplant Program, Pediatric Kidney Transplant Program and Pediatric Heart Transplant Program in collaboration with Children's Hospital of Michigan.

NATIONAL AND INTERNATIONAL BOARDS AND COMMITTEES:

American Board of Surgery, Director	7/2015-6/2021
Ad Hoc Finance Committee	2018
Certifying Exam Committee	2015
Diplomates Committee	2015
Transplant Advisory Committee	2015
MOC Redesign Group ("Sprint Taskforce")	6/2017
Chair, Diplomats Committee	6/2018
American Association for the Study of Liver Diseases	
Liver Surgery & Transplantation Publications Committee Member	1997-2012
American Medical Group Association, Public Policy Committee	2014-Present
American Society of Transplant Surgeons	
Board Chair and Founding Member, Transplant Accreditation and Certification LLC (TACC)	2016
Joint Society Work Group Chair (ASTS, AST, NATCO, OPTN, HRSA)	2014
ASTS-Genentech Scientist Scholarship Reviewer	2015
2014, 2013, 2012	
Councilor Liaison to the ASTS Membership/Workforce Committee	2012
Councilor-at-Large	2011-2014
Member, Education Committee	1/2011
Member, Business Practice Committee	1/2011
Awards Committee, 2009-present	
Transplant Program Reviewer for Fellowship Reaccreditation: (10 programs reviewed in 2006; 2 programs reviewed in 2007)	2006-2007
Fellowship Training Committee Co-Chair	2007-2014
Reimbursement Committee	2007-present
Chair, Business Practice Advisory Committee	2007-2009

Education/Fellowship Committee American Society of Transplantation	2005-2014
Joint Steering Committee Work Group, UNOS Proposed Policy on Living Liver Donation	6/2012-6/2013
Ad Hoc Investment Committee	2011
Abstract Review Committee	1999-2006
Co-Chair, Scientific Session American Transplant Congress	2003
Liver and Intestine Committee Co-Chair	2000-2001
Liver and Intestine Committee Chair	2001-2002
Produced the current online patient education module for liver transplant education	
Structured the foundation for an upcoming single topic symposium	
Chairman, scientific session: Liver Transplantation; Immunosuppression	5/1997
Council Member, Government Relations, Appointed	3/2014
American University of Beirut, President, Surgical Alumni Association	2010-2011
American University of Beirut, Vice President, Surgical Alumni Association	2009-2010
Arab American Medical Association National Member	
National Arab American Medical Association	
Steering Committee Member, NAAMA NextGen	2018-present
United Network for Organ Sharing	
UNOS and OPTN:	
UNOS and OPTN Board of Directors Councilor	6/2013-6/2015
Associate Councilor	2011-2013
Elected OPTN/UNOS Membership and Professional Standards Committee	7/2011-6/2013
Region 10 Representative	
Appointed Policy Compliance Subcommittee Member	7/2011-6/2013
Vice Chair, Operations Committee	6/2007
TTSN Member, Transplantation Transmission Sentinel Network	9/2007
Advisory Group	
World Transplant Congress Session Chair, Boston, MA	7/22-27/2006
“Organ Donation around the World”	

STATE AND LOCAL BOARDS AND COMMITTEES:

Arab-American Medical Association	
Executive Secretary	2002
President of Michigan Chapter	2001-2002
Michigan Board member	1998-present
Donate Life Coalition of Michigan	
Michigan Department of Health	2009-2013
Expert Member, Heart, Lung and Liver Transplantation Services Standards Advisory Committee (HLLSAC)	
Certificate of Need (CON) Commission	
Organ and Tissue Donor Advisory Committee Member, Appointed by Secretary of State Terri Lynn Land	2003
Transplant Society of Michigan, Gift of Life Michigan	
Finance Committee	2010
President	2004

President-elect	2002-2003
Chair, legislative committee	2000-2012
Board of Directors	1996-
present	
Liver and Pancreas Committee	1994-2014
Bylaws Committee	
Legislative Committee	
Education Committee	

TEACHING:

Weekly Didactic Rounds and Case Reviews with Medical Students, Residents, PA's, NP's, RN's and Senior Staff.

Weekly Liver Transplant Selection Committee Meetings and M&M Conference.

Weekly Kidney Transplant Selection Committee Meetings and M&M Conference.

Bi-Monthly Pancreas Transplant Selection Committee Meetings and M&M Conference.

Monthly Divisional Transplant and Hepatobiliary Morbidity and Mortality Conference.

Monthly Transplant and Hepatobiliary Journal Club.

Quarterly Resident Lectures: liver transplantation, liver cancer, portal hypertension, and transplant immunology.

Symposia & CME Programs:

1. Master Class in Liver Disease (MCLD), 10th Annual. Invited Faculty. Dr. Rela Institute & Medical Centre, Chennai, India, Mar 1-2, 2019.
2. Physician Leadership Academy 2017, Class #9. Graduation. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 12/8/2017.
3. Physician Leadership Academy 2017, Class #8. Peer to Peer Business Plan. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 11/9/2017.
4. ASTS 2017 Program Directors Meeting. Transplant Surgery Fellow Wellness. Faculty, Facilitator, Speaker. Hilton Chicago O'Hare, Chicago, IL, 11/3/2017.
5. Physician Leadership Academy 2017, Class #7. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 10/19/2017.
6. ASTS Fellows Symposium. Topic: Transplant Accreditation and Certification Update from the TACC. Faculty. Salt Lake City, UT, Oct 2017.
7. Fundamentals Leadership Academy 2017. Faculty. Henry Ford One Ford Place, 9/22/2017.
8. Physician Leadership Academy 2017, Class #6. Faculty. Henry Ford One Ford Place, 9/21/2017.
9. Physician Leadership Academy 2017, Class #5. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 8/17/2017.
10. Physician Leadership Academy 2017, Class #4. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 7/20/2017.
11. Physician Leadership Academy 2017, Class #3. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 6/22/2017.
12. Physician Leadership Academy 2017, Class #2. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 5/18/2017.
13. Physician Leadership Academy 2017, Class #1. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 4/13/2017.

14. Physician Leadership Academy 2016, Class #9 and Graduation. Facilitator, Speaker, Faculty. Henry Ford One Ford Place, 12/14/2016.
15. Physician Leadership Academy 2016, Class #8, Peer to Peer Business Plan. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 11/10/2016.
16. Physician Leadership Academy 2016, Class #7, Business Plan and Appreciative Inquiry. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 10/20/2016.
17. Physician Leadership Academy 2016, Class #6. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 9/23/2016.
18. Fundamentals Leadership Academy 2016, Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 9/20/2016.
19. Physician Leadership Academy 2016, Class #5. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 8/26/2016.
20. Physician Leadership Academy 2016, Class #4. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 7/15/2016.
21. Physician Leadership Academy 2016, Class #3. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 6/30/2016.
22. Physician Leadership Academy 2016, Class #2. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 5/26/2016.
23. Physician Leadership Academy 2016, Class #1. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 4/27/2016.
24. Physician Leadership Institute 2015 Class #7, Presentations and Graduation. Henry Ford One Ford Place, 12/16/2015.
25. Physician Leadership Institute 2015 Class #6. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 11/17/2015.
26. Physician Leadership Institute 2015 Class #5. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 10/21/2015.
27. 2015 HFHS Jubilee: Department of Surgery Centennial McClure Surgical Forum. Invited Speaker. "International Medical Graduates and the American Dream". Henry Ford Hospital, October 10, 2015.
28. 2015 HFHS Jubilee: A Century of Innovations and Advancements in Care. Invited Speaker. "Trailblazing Milestones in Robotic Surgery at Henry Ford Hospital". Henry Ford Hospital, 10/9/2015.
29. Physician Leadership Institute 2015 Class #4. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 9/23/2015.
30. Quality and Effectiveness Workshop 2015. Faculty, Facilitator, Speaker, Henry Ford One Ford Place, 7/31/2015.
31. Physician Leadership Institute 2015 Class #3. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 6/30/2015.
32. Physician Leadership Institute 2015 Class #2. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 5/20/2015.
33. Infections in Transplant Recipients & Immunocompromised (Non-HIV) Patients. Faculty, Speaker, "Emerging Trends in Solid Organ Transplantation". Henry Ford Hospital Innovation Institute, 5/16/2015.
34. Physician Leadership Institute 2015 Class #1. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 4/23/2015.

35. Fundamentals of Physician Leadership. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 3/17/2015.
36. Physician Leadership Institute 2014 Class #7, Presentations and Graduation. Henry Ford One Ford Place, 12/12/2014.
37. Physician Leadership Institute 2014 Class #6. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 11/19/2014.
38. Physician Leadership Institute 2014 Class #5. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 10/29/2014.
39. Practice Building Workshop. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 10/23/2014.
40. Fundamentals of Physician Leadership. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 10/10/2014.
41. Physician Leadership Institute 2014 Class #4. Faculty, Facilitator, Speaker. Henry Ford One Ford Place, 9/30/2014.
42. ASTS Leadership Development Program. Transplant Centers, Institutes and Institutional Relationships. Faculty, Instructor/Speaker. Northwestern University Kellogg School of Management, Evanston, IL, 9/7/2014-9/10/2014.
43. Quality and Effectiveness Workshop. Faculty, Facilitator, Speaker. Henry Ford One Ford Place Gilmour, 9/5/2014.
44. ASTS Advanced Leadership Development Program, Part III. American Society of Transplant Surgeons Closing Session, Faculty, Planning Committee, Presenter. San Francisco, CA, July 27, 2014, in conjunction with the World Transplant Congress.
45. Physician Leadership Institute 2014 Class #3. Lead Faculty: Appreciative Inquiry, Facilitator. June 25, 2014, Henry Ford One Ford Place.
46. Physician Leadership Institute 2014 Class #2. Faculty, Facilitator. May 29, 2014, Henry Ford One Ford Place, Gilmour Center.
47. Physician Leadership Institute 2014 Class #1. Faculty, April 29, 2014, Henry Ford One Ford Place, Gilmour Center.
48. Fundamentals of Physician Leadership. Faculty, Facilitator, Presenter. March 28, 2014, Henry Ford One Ford Place, 3rd Floor Nursing Room.
49. ASTS Advanced Leadership Development Program, Part II. American Society of Transplant Surgeons, Four-part interactive Webinar Series. Faculty, Planning Committee, Presenter. Webinar #3 “Staff Development/Mentorship: How to Grow Clinical and Administrative Leaders”. January 16, 2014.
50. Physician Leadership Institute 2013 Class #7: Business Plan and Graduation. December 13, 2014, Henry Ford One Ford Place, Gilmour Center.
51. Physician Leadership Institute 2013 Class #6: Time Management. M. Abouljoud, L. Jensen. Sept. 27, 2013, Henry Ford One Ford Place, 3rd Floor Nursing Conference Room.
52. Physician Leadership Institute 2013 Class #5: Diversity Influencer. Faculty, Facilitator. September 12, 2013, Henry Ford One Ford Place, 5C00.
53. Physician Leadership Institute 2013 Class #4: Management Skills. Faculty, Facilitator. July 26, 2013, Henry Ford One Ford Place, 3C51.
54. Workforce and Leadership Development, “How this Baldrige Winner Develops the Workforce and Physician Leaders”. M. Abouljoud, K. Oswald. Faculty and Presenter. The Institute for Healthcare Improvement Leaders Network, May 30, 2013. Henry Ford Hospital.

55. ASTS Advanced Leadership Development Program, Part I. American Society of Transplant Surgeons, “Cultivating Innovative and Effective Leadership within a Complex Medical Environment”. Planning Committee, Faculty and presented 2 lectures: “Competing in a World of Accountable Care Organizations (ACO) and Value-Based Purchasing (VBP)” and “Approaches to Compensating the Incentivizing Transplant Professionals”. Kellogg School of Management, Evanston, IL, April 28-30, 2013.
56. Physician Leadership Institute. Henry Ford Medical Group, Faculty, Organizer, Presenter, “HFMG Physician Leadership”, and “Why E.I. is so important”. One Ford Place, April 26, 2013.
57. Physician Leadership Institute. Henry Ford Medical Group, “Process Improvement and Safety”. Developer, Co-Director, and Member of Quality Leadership Panel. Birmingham Conference Center, September 30, 2011.
58. ASTS Leadership Development Program. Organizing Committee Faculty and Keynote Speaker. Transplant Centers, Institutes and Institutional Relationships. Northwestern University Kellogg School of Management, James L. Allen Center, Evanston, IL, September 11-13, 2011.
59. Physician Leadership Institute. Henry Ford Medical Group, “Leadership and Emotional Intelligence”. Developer, Co-Director, and Presenter. April 1, 2011, Fairlane Club, Dearborn, Michigan.
60. Recent Innovations in Solid Organ Transplantation. Henry Ford Medical Association 2010 Jubilee Reunion, “Advances in Patient Care, Education and Research at Henry Ford Hospital”, October 22, 2010, Detroit, Michigan.
61. ASTS Leadership Development Program; Accelerate Your Leadership. Organizing Committee Faculty and Guest Speaker. Transplant Centers, Institutes and Institutional Relationships. Northwestern University Kellogg School of Management, James L. Allen Center, Evanston, IL, November 7-9, 2010.
62. Business Practice Seminar Presentation – Transplant Contracting: How Do You Recover the Hospital/Surgeons Costs? Chair and Speaker. The American Society of Transplant Surgeons 10th Annual Winter Symposium, Ft. Lauderdale, Florida, January 15, 2010.
63. Building a Successful Physician Outreach Program. Henry Ford Health System Out-State Growth Strategy Physician Steering Committee Meeting Presentation, November 18, 2009.
64. Business Practice Seminar – Transplant Center Models: From Design to Practice. Chair and Moderator. The American Society of Transplant Surgeons 9th Annual Winter Symposium, Marco Island, Florida, January 14-20, 2009.
65. ABC’s and Alphabet Soup. ASTS Medicare 101 Workshop. Chair and Speaker. The American Society of Transplant Surgeons 8th Annual State of the Art Winter Symposium. Marco Island, Florida, January 24-27, 2008.
66. Long-Term Management of the Transplant Recipient for Health Care Providers Symposium. Conference Chairman; 5.5 AMA PRA Category 1 Credits, Novi Sheraton, Novi, Michigan, October 17, 2008.
67. 2007 Trends and Indications for Transplantation. Conference Chair; 5.75 AMA PRA Category 1 Credits, Novi Sheraton, Novi, Michigan, October 19, 2007.
68. The 1st Annual USA-Qatari International Cancer Symposium: State of the Art Therapy of Adult and Childhood Cancers. Organizing Committee. Al Sheraton Hotel, Doha, Qatar, April 29-May 1, 2007.

69. The 4th Annual World Summit on Organ Donation. A CME symposium, Organizing Committee. The Ritz-Carlton Hotel, Dearborn, Michigan, April 19-20, 2007.
70. The 3rd Annual Michigan Conference on Organ Donation: Overcoming Barriers to Transplantation: Racial, Economic, Medical & Legal. A CME symposium, *Moderator*. Marriott Renaissance Center, Detroit, Michigan, April 27, 2006.
71. The 2nd Annual Michigan Conference on Organ Donation: New Frontiers in Organ Donation. A CME symposium, *Conference Chairman*; 6.25 AMA CME hours. In collaboration with the International Association for Organ Donation and Gift of Life Michigan. Hyatt Regency, Dearborn, Michigan, April 21, 2005.
72. 8th International Symposium of the Arab American Medical Association. A CME symposium, *Conference Chairman*; 20 AMA CME hours. Beirut, Lebanon, June 28, 2004.
73. The Michigan Conference on Organ Donation: 50 Years of Sharing Life. A CME symposium, *Conference Chairman*; 6.25 AMA CME hours. In collaboration with the International Association for Organ Donation, Gift of Life Michigan. Ritz Carlton, Dearborn, Michigan, April 22, 2004.
74. Advanced Liver Cancer: Therapeutic Strategies in the New Millennium. A CME symposium, *Director*. Henry Ford Liver Transplant Program. Ritz Carlton, Dearborn, Michigan, September 18, 2003.
75. Transplantation 2001, Update for Healthcare Providers and Insurers. A CME symposium, *Program Director*. Henry Ford Liver Transplant Program. Novi, November 2001.
76. The Checks and Balances of Organ Donation. A CME symposium, *Program Co-Director*. Henry Ford Transplant Center. Dearborn, Michigan 1999.

Trained Transplant Fellows:

Abbas Al-Kurd, MD	2018-2020
Joel Stracke, DO	2017-2019
Hirak Pahari, MD	2016-2018
Krishna Putchakayala, MD	2015-2017
Kazuhiro Takahashi, MD	2014-2016
Mahmoud Tabbal, MD	2013-2015
Ioannis Theodoropoulos, MD	2012-2014
Shunji Nagai, MD	2011-2013
Lloyd Brown, MD	2010-2012
Vrishali Patil, MD	2009-2011
Ahmad Abou Abbass, MD	2008-2010
Robert Slater, MD	2007-2009
Ayman Al Harakeh, MD	2006-2008
Mohamad Almarastani, MD	2005-2007
Lauren Malinzak, MD	2004-2006

Research Mentoring:

Mohammad Raoufi, MD
 David Morris, MD
 Wesley Blake Vanderlan, MD (“von Riedenauer”)
 Augustine Salami, MD

Mazen El Atrache, MD
Mohammad Almarastani, MD
Shahab Toursavadkahi, MD
Robert Slater, MD
Ali Cheaito, MD
Lloyd Brown, MD
Shunji Nagai, MD
Wendy Bertges Yost, PhD
Michelle Jesse, PhD
Mohamed Safwan Mohamed Ilias, MD

GRANT SUPPORT:

Role: Principal Investigator, Percent Effort: 0%

Title: International Randomized Trial to Evaluate the Effectiveness of the Portable Organ Care System (OCS™) Liver For Preserving and Assessing Donor Livers for Transplantation (OCS™ Liver PROTECT Trial).

Evaluate the effectiveness of a portable organ care system in liver to preserve and assess donor livers intended for transplantation.

Source: TransMedics

2015–2018

Total Direct Costs: \$120,000

Role: Principal Investigator, Percent Effort: 5%

IM 103027

Title: “Belatacept evaluation of nephroprotection and efficacy as first-line immunosuppression trial – Extended Criteria Donors.”

Evaluated Belatacept as first-line immunosuppressive therapy versus standard treatment in kidney transplant recipients receiving a kidney from an extended criteria donor.

Source: Bristol-Myers Squibb Sponsored Study,

2007–2015

Total Direct Costs: \$811,850.

Role: Principal Investigator, Percent Effort: 5%

IM 103008

Title: “Belatacept evaluation of nephroprotection and efficacy as first-line immunosuppression trial.”

Evaluated Belatacept as first-line immunosuppressive therapy versus standard treatment in kidney transplant recipients receiving a kidney from a standard criteria or a living donor.

Source: Bristol-Myers Squibb

2007-2015

Total Direct Costs: \$338,922

Role: Principal Investigator, Percent Effort: 5%

IM-034

Title: “A randomized, open-label, multicenter, parallel-group study of Belatacept-based Corticosteroid-free regimens in renal transplantation.”

A pilot study that evaluated Belatacept in combination with Thymoglobulin and corticosteroid free regimen as first-line immunosuppressive therapy in kidney transplant recipients.

Source: Bristol-Myers Squibb

2010-2013

Total Direct Costs: \$103,520

Role: Co-Principal Investigator, Percent Effort: 1%

1263-301

Title: "A randomized, double-blind, double-dummy study to assess the efficacy and safety of prophylactic use of Maribavir vs. Oral Ganciclovir for the prevention of cytomegalovirus in recipients of orthotropic liver transplants."

Compared Maribavir versus oral ganciclovir for prevention of CMV infections in liver transplant recipients. Highest enroller.

Source: Viropharma

2008-2010

Total Direct Costs: \$276,661

Role: Co-Principal Investigator, Percent Effort: 1%

02-0-158

Title: "A phase 3 randomized, open-label, comparative, multicenter study to assess the safety and efficacy of Prograf (tacrolimus)/MMF, modified release (MR) tacrolimus/MMF and Neoral (cyclosporine)/MMF in de novo kidney transplant recipients."

Evaluated safety and efficacy of the standard immunosuppressive therapy with cyclosporine or tacrolimus versus the modified release version of tacrolimus in kidney transplant recipients.

Source: Fujisawa

2003-2010

Total Direct Costs: \$442,867

Role: Co-Principal Investigator, Percent Effort: 1%

03-0-165

Title: "A phase 2, randomized, open-label, parallel group, multicenter study to assess the safety and efficacy of Prograf/FK778 and Prograf/MMF in de novo kidney transplant recipients."

Evaluated the safety and efficacy of an investigational drug FK778 in addition to tacrolimus versus CellCept plus tacrolimus in kidney transplant recipients.

Source: Fujisawa

2004-2007

Total Direct Costs: \$74,329

Role: Co-Principal Investigator, Percent Effort: 1%

CFTY720 0125

Title: "A one-year, multi-center, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral

and corticosteroids versus mycophenolate mofetil (MMF, Cellcept) combined with full-dose Neoral and corticosteroids, in de novo adult renal transplant recipients.”

Evaluated the safety and efficacy of an investigational drug FTY720 combined with reduced-dose or full-dose Neoral and corticosteroids versus mycophenolate mofetil combined with full-dose Neoral and corticosteroids, in kidney transplant recipients.

Source: Novartis

2003-2006

Total Direct Costs: \$131,404

Role: Principal Investigator, Percent Effort: 5%

Title: An unrestricted educational grant to study quality of life after liver transplantation.

Evaluated patient quality of life after liver transplantation.

Source: Novartis

2005

Total Direct Costs: \$100,000

Role: Co-Principal Investigator, Percent Effort: 1%

OLN-452

Title: “Conversion to Neoral in liver transplant recipients intolerant to Tacrolimus.”

Evaluated the safety of efficacy of tacrolimus in patients that were unable to tolerate cyclosporine post transplantation. Lead Center.

Source: Novartis

1996-2000

Total Direct Costs: \$150,000

Role: Principal Investigator, Percent Effort 5%

Title: “Oral versus intravenous Ganciclovir for prevention of cytomegalovirus in liver transplant recipients.”

Evaluated the safety of efficacy of oral versus intravenous ganciclovir for prevention of CMV infection post liver transplantation.

Sponsor: Roche

1996

Total Direct Costs: \$10,000

Role: Co-Principal Investigator, Percent Effort: 1%

Title: “The Use of Clindamycin and Cefazolin in infected musculocutaneous and random-pattern flaps.”

Evaluated the use of clindamycin and cefazolin intraoperatively.

Source: The Upjohn Company

1985

PUBLICATIONS:

1. Safwan M, Nwagu U, Collins K, Abouljoud M, Nagai S. Should all Status 1A patients be prioritized over high MELD patients? Concept of Risk Stratification in Extremely Ill Liver Transplant Recipients. Accepted for publication in Transplantation 21 Jan 2019.

2. Jesse M, Shkokani L, Eshelman A, De Reyck C, Abouljoud M, Lerut J. Transplant Surgeon Burnout and Marital Distress in the Sandwich Generation: The Call for Organizational Support in Family Life. *Transplant Proc.* 2018 Dec;50(10):2899-2904. doi: 10.1016/j.transproceed.2018.01.053. Epub 2018 Mar 9. Impact factor 0.806.
3. Jesse M, Kulas M, Unitis J, Beltran N, Abouljoud M. Acupuncture in Living Liver and Kidney Donors: A Feasibility Study. In press. *The Journal of Integrative Medicine.* Nov 2018. <https://doi.org/10.1016/j.joim.2018.11.007> Impact factor 2.70.
4. Nagai S, Chau L, Schilke R, Safwan M, Rizzari M, Collins K, Yoshida A, Abouljoud M, Moonka D. Effects of Allocating Livers for Transplantation Based on Model for End-Stage Liver Disease-Sodium Scores on Patient Outcomes. *Gastroenterology.* 2018 Nov;155(5):1451-1462.e3. doi: 10.1053/j.gastro.2018.07.025. Epub 2018 Jul 26. Impact factor 20.773.
5. Nagai S, Safwan M, Collins K, Schilke R, Rizzari M, Moonka D, Brown K, Patel A, Yoshida A, Abouljoud M. Liver Alone or Simultaneous Liver-Kidney Transplant?: Pre-Transplant Chronic Kidney Disease and Post-Transplant Outcome. 2018. DOI 10.1111/tri.13275. *Transpl Int.* Impact factor 0.01.
6. Sulejmani N, Nagai S, Safwan M, Rizzari M, Raoufi M, Abouljoud M, Ramesh M. Brincidofovir as Salvage Therapy for Adenovirus Disease in Intestinal Transplant Recipients. *Pharmacotherapy.* 2018 Feb 19. doi: 10.1002/phar.2094. [Epub ahead of print]. Impact factor 2.932.
7. Florman S, Vincenti F, Durrbach A, Abouljoud M, Bresnahan B, Duro Garcia V, Mulloy L, Rice K, Rostaing L, Zayas C, Calderon K, Meier-Kriesche U, Polinsky M, Yang L, Medina Pestana J, Larsen C. Accepted for publication. Outcomes at 7 Years Post-Transplant in Black versus Non-Black Kidney Transplant Recipients Administered Belatacept or Cyclosporine in BENEFIT and BENEFIT-EXT. *Clin Transplant.* 2018 Feb 20, PMID: 29461660 DOI: 10.1111/ctr.13225. Impact factor 1.844.
8. Jesse M, Shkokani L, Eshelman A, De Reyck C, Abouljoud M, Lerut J. (in press) Transplant Surgeon Burnout and Marital Distress in the Sandwich Generation: The Call for Organizational Support in Family Life. *Transplant Proc.* Impact factor 0.908.
9. Abouljoud M, Ryan M, Eshelman A, Bryce K, Jesse M. (in press). Leadership Perspectives on Integrating Psychologists into Specialty Care Clinics: An Evolving Paradigm. *J Clin Psychol Med Settings.*
10. Penwell-Waines L., Ward W., Kirkpatrick H., Smith P., Abouljoud M. Perspectives on Healthcare Provider Wellbeing: Looking Back, Moving Forward. *J Clin Psychol Med Settings.* 2018 Mar 13. doi: 10.1007/s10880-018-9541-3. Impact factor 0.9.
11. Safwan M, Nagai S, Collins K, Rizzari M, Yoshida A, Abouljoud M. Impact of Abdominal Shape on Living Liver Donor Outcomes in Mini-Incision Right Hepatic Lobectomy: Comparison among Three Techniques. *Liver Transpl.* DOI: 10,1002/lt.25001. Impact factor 3.91.
12. Safwan M, Collins K, Abouljoud M, Salgia R. Outcomes of Liver Transplantation in Patients with Prior History of Bariatric Surgery. *Liver Transpl* 2017 Nov;23(11):1415-1421. Impact factor 3.91.
13. Safwan M, Collins K, Abouljoud M. Outcome of Liver Transplantation in Patients with Prior Bariatric Surgery. Manuscript ID LT-17-173.R2 accepted for publication 7/23/2017. *Liver Transpl.* Impact factor 3.91.

14. Takahashi K, Nagai S, Putchakayala K, Safwan M, Goshu M, Li A, Kane W, Singh P, Rizzari M, Collins K, Yoshida A, Abouljoud M, Schnickel G. Prediction of Biliary Anastomotic Stricture after Deceased Donor Liver Transplantation: The Impact of Platelet Counts. Accepted for publication. *Transpl Int*. 2017 Oct;30(10):1032-1040. doi: 10.1111/tri.12996. Epub 2017 Jul 13. Impact factor 2.835.
15. Jesse M, Abouljoud M, Eshelman A, De Reyck, C, Lerut J. Professional Interpersonal Dynamics and Burnout in European Transplant Surgeons. *Clin Transplant*. 2017 Apr;31(4). doi: 10.1111/ctr.12928. Epub 2017 Mar 19. Impact factor 1.844.
16. Takahashi K, Nagai S, Putchakayala K, Safwan M, Li A, Kane W, Singh P, Collins K, Rizzari M, Yoshida A, Schnickel G, Abouljoud M. Prognostic Impact of Postoperative Low Platelet Count after Liver Transplantation. *Clin Transplant*. 2016 Dec 19. DOI: 10.1111/ctr.12891. [Epub ahead of print] PMID: 27992667
17. Safwan M, Nagai S, Abouljoud M. Portal Vein Inflow from Enlarged Coronary Vein in Liver Transplantation: Surgical Approach and Technical Tips: A Case Report. *Transplant Proc*. 2016 Nov;48(9):3070-3072. DOI: 10.1016/j.transproceed.2016.05.001. PMID: 27932149. Impact factor 0.867.
18. Jesse M, Rubinstein E, Eshelman A, Wee C, Tankasala M, Li J, Abouljoud M. Lifestyle and Self-Management by those Who Live It: Patients Engaging Patients in a Chronic Disease Model. *Perm J*. 2016 Summer; 20(3):15-207. E-pub 07/13/2016. dx.DOI.org/10.7812/TPP/15-207. PMID: 27455056. Impact factor 0.00.
19. Paulson D, Shah M, Miller-Matero L, Eshelman A, Abouljoud M. Cognition Predicts Quality of Life among Patients with End Stage Liver Disease. *Psychosomatics*. 2016 Mar 29. pii: S0033-3182(16)30002-0. DOI: 10.1016/j.psym.2016.03.006. PMID: 27184728.
20. Miller-Matero L, Bryce K, Hyde-Nolan M, Dykhuis K, Eshelman A, Abouljoud M. Health Literacy Status Affects Outcomes for Patients referred for Transplant. *Psychosomatics*. 2016 Apr 4. pii: S0033-3182(16)30003-2. DOI: 10.1016/j.psym.2016.04.001. PMID: 27231187.
21. Takahashi K, Obeid J, Burmeister C, Bruno D, Kazimi M, Yoshida A, Abouljoud M, Schnickel G. Intrahepatic Cholangiocarcinoma in the Liver Explant after Liver Transplantation: Histologic Differentiation and Prognosis. [Ann Transplant](#). 2016 Apr 12;21:208-15.
22. Yip J, Bruno D, Burmeister C, Kazimi M, Yoshida A, Abouljoud M, Schnickel G. Deep Vein Thrombosis and Pulmonary Embolism in Liver Transplant Patients: Risks and Prevention. *Transplant Direct*. 2016 Mar 1;2(4):e68. DOI: 10.1097/TXD.0000000000000578. PMID: 27500259.
23. Miller-Matero L, Hyde-Nolan ME, Eshelman A, Abouljoud M. Health Literacy in Patients Referred for Transplant: Do Patients have the Capacity to Understand? *Clin Trans*, 2015;29(4), 336-342. Impact factor 1.486.
24. Bisordi J, Abouljoud M. Physician Leadership Initiatives at Small or Mid-Size Organizations. *ScienceDirect Healthcare* 2015 <http://DOI:10.1016/j.hjdsi.2015.08.008>.
25. Abouljoud M, Whitehouse S, Langnas A, Brown K. Compensating the Transplant Professional: New Models for New Times. Manuscript AJT-V-14-01020.R1, *Am J Transplant*, Feature Cover, March 2015;15(3):601-605. Impact factor 6.19.
26. Sood A, Abdullah N, Abdollah F, Abouljoud M, Trinh Q, Menon M, Sammon J. Rates of Kidney Transplantation from Living and Deceased Donors for Blacks and Whites in the United States, 1998 to 2011. *JAMA Intern Med*. 2015 Oct;175(10):1716-8. DOI: 10.1001/jamainternmed.2015.4530. PMID: 26322565

27. Jesse M, Abouljoud M, Hogan K, Eshelman A. Burnout in Transplant Nurses. *Prog Transplant*. 2015 Sep;25(3):196-202. DOI: 10.7182/pit2015213. PMID: 26308777
28. Jesse M, Eshelman A, Abouljoud M. Determinants of Burnout among Transplant Surgeons: A National Survey in the United States. Manuscript AJT-B-14-00813.R1, *Am J Transplant*, 15(3):772-778, March 2015. Impact factor 6.19.
29. Monaghan K, Gonzalez H, Levin A, Abouljoud M, Gordon S. Post-Transplant Course of Hepatitis C after Living Donor Liver Transplantation in Association with Polymorphisms near IFNL3. Manuscript JICR-2014-0111.R1 accepted for publication, *J Interferon Cytokine Res*, September 2014. DOI: 10.1089/jir.2014.0111. Impact factor 3.899. *Study conception, design, supervise implementation, manuscript writing.*
30. Abouljoud M, Whitehouse S, Langnas A, Brown K. Compensating the Transplant Professional: Time for a Model Change. Manuscript AJT-V-14-01020 accepted for publication, *Am J Transplant*, September 2014. Impact factor 6.19.
31. *Nagai S, Yoshida A, Facciuto M, Moonka D, Abouljoud M, Schwartz M, Florman S. Ischemia Time Impacts Recurrence of Hepatocellular Carcinoma after Liver Transplantation. Manuscript HEP-14-0010.R3 accepted for publication, *Hepatology*, August 2014. Impact factor 11.19. *Study conception, design, supervise implementation, manuscript writing.*
32. Miller-Matero L, Eshelman A, Paulson D, Armstrong R, Moonka D, Brown K, Abouljoud M. Beyond Survival: How Well Do Transplanted Livers Work? A Preliminary Comparison of Standard-Risk, High-Risk, and Living Donor Recipients. *Clin Transplant*, 28, 691-698. Impact factor 1.486.
33. Abouljoud M, Brown K, Nerenz D. Sicker Patients with End Stage Liver Disease Cost More: a Quick Fix? An editorial on assessing variation in the costs of care among patients awaiting liver transplantation. *Am J Transplant*, 14(1):9-10, 2014 Jan. UI: 24165228. Impact factor 6.19.
34. *Nagai S, Yoshida A, Kohno K, Altshuler D, Nakamura M, Brown K, Abouljoud M, Moonka D. Recurrent Hepatitis C: The Bane of Transplant Hepatology. *Hepatology* 2014;59:21-23. Impact factor 11.19. *Study conception, design, supervise implementation, manuscript writing.*
35. *Nagai S, Yoshida A, Kohno K, Altshuler D, Nakamura M, Brown K, Abouljoud M, Moonka D. Peri-Transplant Absolute Lymphocyte Count as a Predictive Factor for Advanced Recurrence of Hepatitis C after Liver Transplantation. *Hepatology* 59(1):35-45, 2014 Jan. UI: 23728831. Impact factor 11.19. *Study conception, design, supervise implementation, manuscript writing.*
36. Abouljoud M, Brown K, Nerenz D. Sicker Patients with End Stage Liver Disease Cost More: a Quick Fix? Editorial Manuscript AJT-E-13-01007 Article published online 12/20/2013, *Am J Transplant*. Impact factor 6.19.
37. Miller L, Paulson D, Eshelman A, Bugenski M, Brown K, Moonka D, Abouljoud M. Mental Health Affects Quality of Life and Recovery after Liver Transplantation. *Liver Transpl* 19(11):1272-1278, 2013 Nov. UI: 23959592. Impact factor 3.793.
38. Parasuraman R, Venkat KK, Abouljoud M, Samarapungavan D, Rocher L, Koffron A. Renal Allograft Outcome in Recipients of Positive-Crossmatch Combined Liver-Kidney Transplantation. *Transplant Proc*, 45(9):3269-72, 2013 Nov. UI: 24182798. Impact factor 0.984. *Study conception, design, supervise implementation, manuscript writing.*
39. *Brown L, *Abou Abbass A, *Nagai S, *Patil V, Abouljoud M, Getzen T, Yoshida A, Kazimi M, Kim D. Thrombolysis of Portal Vein Thrombosis after Splenectomy Following

- Liver Transplantation. *Liver Transpl*, 19(3):346-8, 2013 Mar. UI: 23408382. Impact factor 3.793. *Study conception, design, supervise implementation, manuscript writing.*
40. *McGonigal K, Bajjoka I, Abouljoud M. Tenofavir/Emtricitabine Therapy for the Prevention of Hepatitis B Recurrence after Liver Transplantation. *Pharmacotherapy*, 33(9):e170-6, 2013 Sept. UI: 23744810. Impact factor 2.204. *Study conception, design, supervise implementation, manuscript writing.*
 41. Abouljoud M, Whitehouse S. Transplant Programs, Centers, and Institutes: What does it All Mean? *Curr Opin Organ Transplant*, 18(2):229-34, 2013 Apr. UI: 23385887. Impact factor 2.379.
 42. *Nagai S, Abouljoud M, Kazimi M, Yoshida A. Emergent Non-Conventional Mesosystemic Shunt for Diffuse Porto-Mesenteric Thrombosis: Sparing Patients from Liver/Multivisceral Transplantation. *Liver Transpl*. 19(6):661-3, 2013 Jun. UI: 23584802. Impact factor 3.793. *Study conception, design, supervise implementation, manuscript writing.*
 43. *Salami A, Kuriakose P, Qureshi W, Yoshida A, Moonka D, Abouljoud M. Frequency and Predictors of Venous Thromboembolism in Orthotopic Liver Transplant Recipients: A Single Center Retrospective Review. *Transplant Proc*. 45(1):315-9, 2013 Jan-Feb. UI: 23267811. Impact factor 0.984.
 44. Abouljoud M, Klintmalm G, Whitehouse S. Transplant Organizational Structures: Viewpoints from Established Centers. *Am J Transplant*. 12(10):2623-9, 2012 Oct. UI: 22823895. Impact factor 6.19.
 45. *Nagai S, Brown L, Yoshida A, Kim D, Kazimi M, Abouljoud M. Mini-Incision Right Hepatic Lobectomy With and Without Laparoscopic Assistance for Living Donor Hepatectomy. *Liver Transpl* 2012 Oct;18(10):1188-97. DOI: 10.1002/lt.23488. Impact factor 3.793. *Study conception, design, supervise implementation, manuscript writing.*
 46. *Nagai S, *Brown L, Yoshida A, Kim D, Kazimi M, Abouljoud M. Mini-Incision Right Hepatic Lobectomy With and Without Laparoscopic Assistance for Living Donor Hepatectomy. *Am J Transplant* January 2012, 2(12):87. Impact factor 6.19. *Study conception, design, supervise implementation, manuscript writing.*
 47. Bajjoka I, Makowski C, *Churchill D, Abouljoud M. Belatacept Post Kidney Transplantation. *Journal of Pharmacy Technology*, pg. 106, Volume 28, May/June 2012. Impact factor 0.00.
 48. *Salami A, Qureshi W, Kuriakose P, Moonka D, Yoshida A, Abouljoud M. Frequency and Predictors of Venous Thromboembolism in Orthotopic Liver Transplant Recipients: A Single Center Retrospective Review. *Transplant Proc* 2013 Jan-Feb;45(1):315-9. DOI: 10.1016/j.transproceed.2012.06.060. Epub 2012 Sep 19. Impact factor 0.984.
 49. Fleming J, Malinzak L, Abouljoud M. Effect of Standardized Medication-Order Forms on Medication Errors after Liver or Kidney Transplantation. *Am J Health Syst Pharm*. 69(11):916-7, 2012 Jun 1. UI: 22610018. Impact factor 2.205.
 50. Abouljoud M, Klintmalm G, Whitehouse S. Transplant Organizational Structures: Viewpoints from Established Centers. *Am J Transplant*, 2012 Oct;12(10):2623-9. DOI: 10.1111/j.1600-6143.2012.04189.x. Epub 2012 Jul 23. Impact factor 6.19.
 51. *El-Atrache M, Abouljoud M, Sharma S, *Abou Abbass A, Yoshida A, Kim D, Kazimi M, Moonka D, Brown K. Transjugular Intrahepatic Portosystemic Shunt Following Liver Transplantation: Can Outcomes Be Predicted? *Clin Transplant*. 26(4):657-61, 2012 Jul-Aug. UI: 22309034. Impact factor 1.486. *Study conception, design, supervise implementation, manuscript writing.*

52. *Toursavadkoshi S, Abouljoud M. Outcome with Surgical Repair of Extra-Hepatic Portal Vein Aneurysms. *Ann Vasc Surg*, 25(8):1140.e1-5, 2011 Nov. UI 21835580. Impact factor 1.029.
53. Sofi A, Alaradi O, Abouljoud M, Nawras A. Aberrant Right Hepatic Duct Draining Into the Cystic Duct: Clinical Outcomes and Management. *Gastroenterol Res Pract*, 2011:458915. DOI: 10.1155/2011/458915. Epub 2011 Apr 7. Impact factor 1.502. *Study conception, design, supervise implementation, manuscript writing.*
54. Patel H, Patel A, Abouljoud M, Divine G, Moonka D. Survival after Liver Transplantation in patients who Develop Renal Insufficiency. *Transplant Proc* 42(10):4167-70, 2010 Dec. UI: 21168654. Impact factor 0.984. *Study conception, design, supervise implementation, manuscript writing.*
55. Jabbour N, Singhal A, Bag R, Abouljoud M. Contracting and Reimbursement in Transplantation. *Journal Health Care Finance*, Summer 2010 Vol. 36, (4):51-64. Impact factor 0.00.
56. Parasuraman R, Abouljoud M, Jacobsen G, Reddy G, Koffron A, Venkat KK. Increasing Trend in Infection-Related Death-Censored Graft Failure in Renal Transplantation. *Transplantation*, 2011 Jan 15;91(1):94-9. *Study conception, design, supervise implementation, manuscript writing.*
57. Kim D, Abouljoud M, Parasuraman R. The Role of Microscopic Hematuria in the Evaluation of Urologic Malignancy in Renal Transplant Recipients. *Transplant Proc* 42(5):1641-2, 2010 Jun. UI: 20620491. Impact factor 0.984. *Study conception, design, supervise implementation, manuscript writing.*
58. Feng Z, Tang J, Kim D, Brown K, Abouljoud M, Gordon S, Yoshida A, Huang M, Divine G, Moonka D. Renal Insufficiency after Liver Transplantation in the MELD Era Compared to the Pre-MELD Era. *Clin Transplant* 23(5):6347-42, 2009 Sep-Oct. UI: 19573089. Impact factor 1.486. *Study conception, design, supervise implementation, manuscript writing.*
59. Moonka D, Castillo E, Kumer S, Abouljoud M, Divine G, Pelletier S. Impact of Model for End-Stage Liver Disease on Patient Survival and Disease-Free Survival in Patients Receiving Liver Transplantation for Hepatocellular Carcinoma. *Transplant Proc* 41(1):216-8, 2009 Jan-Feb. UI: 19249517. Impact factor 0.984. *Study conception, design, supervise implementation, manuscript writing.*
60. Castillo E, Pelletier S, Kumer S, Abouljoud M, Divine G, Moonka D. Incidental Hepatocellular Carcinoma after Liver Transplantation: Population Characteristics and Outcomes. *Transplant Proc* 41(1):219-21, 2009 Jan-Feb. UI: 19249518. Impact factor 0.984. *Study conception, design, supervise implementation, manuscript writing.*
61. *Vanderlan WB, Zhang Z, Abouljoud M. Duodenal Enteroglucagonoma Revealed by Differential Comparison of Serum and Tissue Glucagon Reactivity with Siemens' Double Glucagon Antibody and DakoCytomation's Polyclonal Rabbit Anti-Human Glucagon: A Case Report. *J Med Case Rep* 2010 Jun 15;4:178. DOI: 10.1186/1752-1947-4-178. Impact factor 0.40.
62. *Vanderlan WB, Abouljoud M, Yoshida A, Kim D. Experience with Recipient Splenic Artery Inflow in Adult Liver Transplantation: A Case Series. *Cases J* 2008 Aug 11;1(1):82. DOI: 10.1186/1757-1626-1-82. Impact factor 0.00. *Study conception, design, supervise implementation, manuscript writing.*
63. Moonka D, Milkovich K, Rodriguez B, Abouljoud M, Lederman M, Anthony D. Hepatitis C Virus-Specific T-Cell Gamma Interferon and Proliferative Responses Are More Common in

- Perihepatic Lymph Nodes than in Peripheral Blood or Liver. *J Virol* 82(23):11742-8, 2008 Dec. UI: 18715927. Impact factor 4.648. *Study conception, design, supervise implementation, manuscript writing.*
64. *Vanderlan WB, Bansal A, Abouljoud M. Adult Portal Hypertension Secondary to Post-Traumatic Extrahepatic Portal Vein Thrombosis Treated with Rex Shunt. *J Trauma* 66(1):260-3, 2009 Jan. UI: 19131837. Impact factor 1.722.
 65. *Vanderlan WB, Abouljoud M, Yoshida A, Kim D. Experience with Recipient Splenic Artery Inflow in Adult Liver Transplantation: A Case Series. *Cases J* 2008 Aug 11;1(1):82. DOI: 10.1186/1757-1626-1-82. Impact factor 0.00. *Study conception, design, supervise implementation, manuscript writing.*
 66. Bajjoka I, Hsaiky L, Brown K, Abouljoud M. Preserving Renal Function in Liver Transplant Recipients with Rabbit Anti-Thymocyte Globulin and Delayed Initiation of Calcineurin Inhibitors. *Liver Transpl* 14(1):66-72, 2008 Jan. UI: 18161842. Impact factor 3.793.
 67. Bajjoka I, Hsaiky L, Brown K, Abouljoud M. Preserving Renal Function in Liver Transplant Recipients with Rabbit Anti-Thymocyte Globulin and Delayed Initiation of Calcineurin Inhibitors. *Liver Transpl* 2008 Jan;14(1):66-72. Impact factor 3.793.
 68. *von Riedenauer WB, Shanti C, Abouljoud M. Resection of Giant Liver Adenoma in a 17-year-old Adolescent Boy Using Veno-Venous Bypass, Total Hepatic Vascular Isolation and In Situ Cooling. *J Pediatr Surg* 42(8):E23-7, 2007 Aug. UI: 17706483. Impact factor 1.311.
 69. Abouljoud M, Arenas J, Yoshida A, Kim D. New Application of Bipolar Vapor Plasma Coagulation System for Laparoscopic Major Liver Resections. *Surg Endosc* 22(2):426-9, 2008 Feb. UI: 17593438. Impact factor 3.313.
 70. Silva HT, Yang HC, Abouljoud M, Kuo P, Wisemandle K, Bhattacharya P, Dhadda S, Holman J, Fitzsimmons W, First M. One-Year Results with Extended-Release Tacrolimus/MMF and Cyclosporine/MMF in De Novo Kidney Transplant Recipients. *Am J Transplant* 2007 Mar;7(3):595-608. Epub 2007 Jan 11. Impact factor 6.19. *Study conception, design, supervise implementation, manuscript writing.*
 71. *Morris D, Ladin D, Abouljoud M. Successful Internalization of a Chronic Biliary Cutaneous Fistula after Liver Transplantation: Deepithelializing the Fistula Tract. *J Gastrointest Surg* 11(4):538-41, 2007 Apr. UI: 17436141. Impact factor 2.391.
 72. *Meyer T, Eshelman A, Abouljoud M. Neuropsychological changes in a large sample of liver transplant candidates. *Transplant Proc* 38(10):3559-60, 2006 Dec. UI: 17175330. Impact factor 0.984.
 73. Silva H, Yang H, Abouljoud M, Kuo P, Wisemandle K, Bhattacharya P, Dhadda S, Holman J, Fitzsimmons W, First M. One Year Results with Tacrolimus/MMF, Modified-Release Tacrolimus/MMF and Cyclosporine/MMF in De Novo Kidney Transplant Recipients [Erratum appears in *Am J Transplant*. 2007 Jun;7(6):1682]. *Am J Transplant* 7(3):595-608, 2007 Mar. UI: 17217442. Impact factor 6.19. *Study conception, design, supervise implementation, manuscript writing.*
 74. Kim D, *Kwon D, Salem R, Ma C, Abouljoud M. Successful Embolization of Hepatocellular Carcinoma with Yttrium-90 Glass Microspheres Prior to Liver Transplantation. *J Gastrointest Surg* 10(3):413-6, 2006 Mar. UI: 16504888. Impact factor 2.391.
 75. *Morris D, Ladizinsky D, Abouljoud M. Successful Internalization of a Chronic Biliary Cutaneous Fistula after Liver Transplantation: Deepithelializing the Fistula Tract. *J Gastrointest Surg* 2007 Apr;11(4):538-41. Impact factor 2.391.

76. Abouljoud M, Kim D, Yoshida A, Arenas J, Jerius J, Malinzak L, Raoufi M, Brown K, Moonka D. Impact of Aberrant Arterial Anatomy and Location of Anastomosis on Technical Outcomes after Liver Transplantation. *J Gastrointest Surg* (9):672-8, 2005 May-Jun. UI: 15862262. Impact factor 2.391.
77. Abouljoud M, Yoshida A, Kim D, Jerius J, Arenas J, Raoufi M, Brown K, Moonka D. Transjugular Intrahepatic Portosystemic Shunts for Refractory Ascites after Liver Transplantation. *Transplant Proc* 37(2):1248-50, 2005 Mar. UI:15848685. Impact factor 0.984.
78. *Bertges-Yost W, Eshelman A, Raoufi M, Abouljoud M. National Study of Burnout among Transplant Surgeons in North America. *Transplant Proc* 37(2):1399-401, 2005 Mar. UI: 15848732. Impact factor 0.984.
79. Kim D, Pantelic M, Yoshida A, Jerius J, Abouljoud M. Cavernous Hemangioma Presenting As Budd-Chiari Syndrome. *J Am Coll Surg* 200(3):470-1, 2005 Mar. UI: 15737860. Impact factor 4.454.
80. Parasuraman R, Atallah N, Venkat KK, Yoshida A, Abouljoud M, Khanal S, Greenbaum A. Rapid Progression of Native Renal Artery Fibromuscular Dysplasia Following Kidney Donation. *Am J Transplant* 4(11):1910-4. 2004 Nov. UI: 15476494. Impact factor 6.19. *Study conception, design, supervise implementation, manuscript writing.*
81. Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M, Courtney A. Use of Yttrium-90 glass microspheres for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. *J Vasc Interv Radiol* 15(4):335-345. 2004 Apr. UI: 15064336. Impact factor 2.149. *Study conception, design, supervise implementation, manuscript writing.*
82. Lam P, Yoshida A, Brown K, Abouljoud M, Bajjoka I, Dagher F, Moonka D. The efficacy and limitations of sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors. *Dig Dis Sci* 49(6):1029-35. 2004 Jun. UI: 15309896. Impact factor 2.55. *Study conception, design, supervise implementation, manuscript writing.*
83. Abouljoud M, Kumar M, Brayman K, Emre S, Bynon J. OLN-452 Study Group. Neoral rescue therapy in transplant patients with intolerance to Tacrolimus. *Clin Transplant* 16(3):168-72. 2002 Jun. UI: 12010138. Impact factor 1.486.
84. Abouljoud M, Escobar F, Douzdzian V, Moonka D, Shick L, Brown K. Successful strategy for reducing biliary complications after liver transplantation. *Transplant Proc* 33(5):2714-5, 2001 Aug. UI: 11498136. Impact factor 0.984.
85. Gottschlich M, Ardema K, Burd E, Nakhleh R, Brown K, Abouljoud K, Hirst K, Moonka D. The use of hepatitis c viral RNA levels in liver tissue to distinguish rejection from recurrent hepatitis C. *Liver Transpl* 7(5):436-41, 2001 May. UI: 11349265. Impact factor 3.793. *Study conception, design, supervise implementation, manuscript writing.*
86. Deshpande V, Burd E, Aardema K, Ma C, Moonka D, Brown K, Abouljoud M, Nakhleh R. High levels of hepatitis C virus RNA in native livers correlate with the development of cholestatic hepatitis in liver allografts and a poor outcome. *Liver Transplant* 7(2):118-24, 2001 Feb. UI: 11172395. Impact factor 3.793. *Study conception, design, supervise implementation, manuscript writing.*
87. Abouljoud M, Kumar MSA, Brayman K, Emre S, Bynon S. Conversion to Neoral provides effective rescue therapy for liver and kidney transplant patients intolerant of Prograf. *Transplant Proc* 33(1-2):1027-8. 2001 Feb-Mar. UI: 11267175. Impact factor 0.984.

88. *Morris D, Abouljoud M. Short-term results of radiofrequency ablation in liver tumors. *Am J Surg* 179(6):527, 2000 Jun. UI: 11041819. Impact factor 2.406.
89. Douzdjian V, Escobar F, Kupin W, Venkat KK, Abouljoud M. Cost-utility analysis of living-donor kidney transplantation followed by pancreas transplantation versus simultaneous pancreas-kidney transplantation. *Clin Transplant* 13(1 Pt 1):51-8. 1999 Feb. UI: 10081635. Impact factor 1.486.
90. Ardema K, Nakhleh R, Terry L, Burd E, Ma C, Moonka D, Brown K, Abouljoud M. Tissue quantitation of hepatitis C virus RNA with morphologic correlation in the diagnosis of recurrent hepatitis C in human liver transplants. *Mod Pathol* 12(11):1043-1049. 1999 Nov. UI: 10574601. Impact factor 6.364.
91. Ardema K, Nakhleh R, Terry L, Burd E, Ma C, Moonka D, Brown K, Abouljoud M. Quantitation of hepatitis C virus RNA in liver tissue of allografts: correlation with histologic features and liver function tests. *Transplant Proc* 31(1-2):477-478. 1999 Feb-Mar. UI: 10083198. Impact factor 0.984.
92. Bajjoka I, Bailey E, Vazquez J, Abouljoud M. Combination antifungal therapy for invasive aspergillosis in liver transplant recipients: report of two patients. *Pharmacotherapy* 19(1):118-123. 1999 Jan. UI: 9917086. Impact factor 2.204.
93. Kupin W, Venkat KK, Goggins M, Abouljoud M, Escobar F, Mozes M. Benefit of Angiotensin II Receptor Blockade in the Treatment of Post-transplant Polycythemia in Renal Transplant Recipients. *Transplant Proc* 29(1-2):207-208. 1997 Feb-Mar. UI: 9122965. Impact factor 0.984. *Study conception, design, supervise implementation, manuscript writing.*
94. Kupin W, Nakhleh R, Lee M, Venkat KK, Goggins M, Mozes M, Escobar F, Abouljoud M. Separate risk factors for the development of transplant glomerulopathy vs chronic tubulointerstitial rejection. *Transplant Proc* 29(1-2):245-6. 1997 Feb-Mar. UI: 9122982. Impact factor 0.984.
95. Abouljoud M, Brown K, May E, Baliad P, Escobar F, Mozes M. Cost-Effective Management of Acute Rejection in Liver Transplant Recipients: A Managed Care Perspective. *Transplant Proc* 29:1557-1559. 1997 Feb-Mar. UI: 9123423. Impact factor 0.984.
96. Abouljoud M, Levy M, Rees C, Diamond N, Lee S, Mulligan D, Goldstein R, Husberg B, Gonwa T, Klintmalm G. A comparison of treatment with Transjugular intrahepatic Portosystemic shunt or distal splenorenal shunt in the management of refractory variceal bleeding prior to liver transplantation. *Transplantation* 59(2):226-229. 1995 Jan 27. UI: 7839445.
97. Abouljoud M, Deierhoi M, Hudson S, Diethelm A: Risk factors affecting second renal transplant outcome with special reference to primary allograft nephrectomy. *Transplantation* 60(2):138-144. 1995 Jul 27. UI: 7624955.
98. Mulligan D, Goldstein R, Crippin J, Abouljoud M, Levy M, Husberg B, Gonwa T, Foster B, Tillery G, Klintmalm G. The use of anti-hepatitis C virus seropositive organs in liver transplantation. *Transplant Proc* 27(1):1204-1205. 1995 Feb. UI: 7878850. Impact factor 0.984. *Study conception, design, supervise implementation, manuscript writing.*
99. Levy M, Jennings L, Abouljoud M, Mulligan D, Goldstein R, Husberg B, Gonwa T, Klintmalm G. Quality of life improvements one, two, and five years after liver transplantation. *Transplantation* 59(4):515-518. 1995 Feb 27. UI: 7878756.
100. Abouljoud M, Levy M, Klintmalm G. FK-506 U.S. Multicenter Study Group. Hyperlipidemia after liver transplantation: long term results of the FK-506/Cyclosporine A

U.S. Multicenter Trial. Transplantation Proc 27(1):1121-1123.1995 Feb. UI: 7533360. Impact factor 0.984.

101. Levy M, Goldstein R, Husberg B, Gonwa T, Backman L, Abouljoud M, Mulligan D, Klintmalm G. Baylor Update: Outcome analysis in liver transplantation. Clin Transpl 161-73, 1993. UI: 7918148. Impact factor 1.486. *Study conception, design, supervise implementation, manuscript writing.*
102. Abouljoud M, Obeid F, Horst M, Sorensen V, Fath J, Chung S: Arterial injuries of the thoracic outlet: a ten year experience. Am Surg 59(9):590-5. 1993 Sep. UI: 8368667. Impact factor 0.918.

Review Articles:

1. Abouljoud M, Yoshida A, Dagher F, Moonka D Brown K. Living donor and split-liver transplantation: an overview. Transplant Proc 35(7):2772-4, 2003 Nov. UI: 14612114. Impact factor 0.984.
2. Abouljoud M, Escobar F, Douzdjian V, Bajjoka I, Moonka D, Shick L, Brown K. Recurrent disease after liver transplantation. Transplant Proc 33(5):2716-9. 2001 Aug. UI: 11498137. Impact factor 0.984.

Books and Chapters:

1. Galusca D, Abouljoud M. Management of Hepatorenal Syndrome, Renal Insufficiency Intraoperatively - Intraoperative CRRT? AHPBA Practical Management of Dilemmas Textbook, Chapter 97, September 2018.
2. Abouljoud M, Malinzak L, Bruno D. Surgical Options for the Management of Portal Hypertension. Curr Hepatology Rep, DOI 10.1007/s11901-015-0276-4, July 2015.
3. Bajjoka I, Abouljoud M. Transplantation pharmacy practice. Encyclopedia of Clinical Pharmacy, 2003.
4. *Morris D, *Anagnostopoulos P, *Pipinos I, Escobar F, Abouljoud M. Veno-venous bypass of central occlusions for salvaging hemodialysis grafts and fistulae: Long-term results. Vascular Access VII. Editor: Mitchell L. Henry, Precept Press, 2001.
5. Abouljoud M, Levy M: Principles of brain death diagnosis. Organ Procurement and Preservation. Editors: GB Klintmalm, MF Levy, RG Landes & Co, 1999.
6. Abouljoud M, Klintmalm G: Tacrolimus immunoprophylaxis and rescue therapy in liver transplantation. Principles of Drug Development and Autoimmunity, 1996.
7. Abouljoud M, Klintmalm G: FK-506 in Liver Transplantation. FDA monograph, May, 1994.
8. Mathes S, Abouljoud M: Wound Healing, Chapter 16 in Clinical Surgery, Davis J.H., Drucker W.R., Foster R.Jr et al. 1987, C.V. Mosby.

Case Reports:

1. Kim D, Pantelic M, Yoshida A, Jerius J, Abouljoud, M. Cavernous Hemangioma Presenting as Budd-Chiari Syndrome. J Am Coll Surg 200(3):470-1, 2005 Mar. UI: 15737860. Impact factor 4.454.

2. Podila P, Abouljoud M, Peterson C, Brown K. Focal nodular hyperplasia and nodular transformation of the liver associated with congenital porto-caval shunt and progression to hepatocellular carcinoma. *Am J Gastroenterol* 91:2035, 1996. Impact factor 9.213.
3. Podila P, Nattakom T, Abouljoud M, Brown K. FK 506 Associated thrombotic thrombocytopenic purpura following liver transplantation. *Am J Gastroenterol* 91:2034, 1996. Impact factor 9.213.
4. Abouljoud M, Cruz C: Obstruction of peritoneal dialysis catheters by fallopian tubes (letter). *Peritoneal Dialysis International*. 14(1):90, 1994. Ui: 8312426. Impact factor 2.199.
5. Abouljoud M, Cruz C, Dow R, Mozes M: Peritoneal dialysis catheter obstruction by a fallopian tube: a case report. *Peritoneal Dialysis International*. 12(2):257-8. 1992. UI: 1586691. Impact factor 2.199.
6. Abouljoud M, Nathanson S: Use of polypropylene mesh to stabilize the "floating humerus" after total scapulectomy. *Surgery* 110(5):905-8. 1991 Nov. UI: 1948661. Impact factor 3.105.

Educational Materials (including computer programs):

1. Residents' Manual, 1995, 2002, 2005
2. <http://www.henryford.com> Online Liver Transplant Manual, Select "Organ Transplants", and then "Liver Transplantation"
3. http://www.a-s-t.org/patient_education/english/liver.pdf - Online Liver Transplant Patient Manual, American Society of Transplantation Website. Release date November 1, 2000. Authors: **Marwan Abouljoud, Editor**, Robert Brown Jr, Robert Fontana, Amy Friedman, Rafik Ghobrial, Tarek Hassanein, Norman Kneteman, Kris Kowdley, David Mulligan, Anthony Post, Vinod Kumar Rustgi, Thomas Schiano.
4. Adult Liver Transplantation from a *Living Donor* brochures
5. Radio Frequency Ablation Therapy for Liver Cancer brochures
6. TransNotes© quarterly newsletter

Published Abstracts:

1. Collins K, Thompson R, Putschakayala K, Malinzak L, Denny J, Rizzari M, Yoshida A, Nagai S, Kim D, Abouljoud M. Public Health Service Increased Risk (PHSIR) Kidneys: Outcomes and Establishing Best Practices. *Am J Transplant*, Abstract P-6, 17(S2):26, Jan 2017.
2. Pahari H, Nagai S, Takahashi K, Tinney F, Putschakayala K, Malinzak L, Denny J, Rizzari M, Yoshida A, Collins K, Abouljoud M, Kim D. Risk Factors and 2 Year Outcomes of Low Estimated Glomerular Filtration Rate in the Immediate Post-Operative Period for Living Kidney Donors. *Am J Transplant*, Abstract P-75, 17(S2):57, Jan 2017.
3. Tinney F, Yessayan L, Williamson S, Abouljoud M, Patel A. Characterization of Vascular Lesions in Living Donor Renal Transplant Implant Biopsies. *Am J Transplant*, Abstract P-78, 17(S2):59, Jan 2017.
4. Takahashi K, Nagai S, Putschakayala K, Kane W, Safwan M, Rizzari M, Collins K, Yoshida A, Schnickel G, Abouljoud M. Multifactorial Risks for Low Regeneration at the Early Phase After Living Donor Liver Transplantation. *Am J Transplant*, Abstract P-94, 17(S2):65, Jan 2017.

5. Nagai S, Takahashi K, Collins K, Putchakayala K, Safwan M, Rizzari M, Yoshida A, Abouljoud M. Is it Safe to Use Older Donor Liver Grafts for Older Recipients? Am J Transplant, Abstract P-102, 17(S2):68, Jan 2017.
6. Safwan M, Yoshida A, Collins K, Rizzari M, Moonka D, Brown K, Patel A, Abouljoud M, Nagai S. An Argument for Expanding the Criteria for Simultaneous Liver and Kidney Transplant: Pre-Liver Transplant Glomerular Filtration Rate Less Than 30 mL/min for Greater Than 2 Weeks Has Worse Outcomes. Am J Transplant, Abstract P-105, 17(S2):69, Jan 2017.
7. Safwan M, Abouljoud M, Salgia R. Outcome of Liver Transplantation in Patients with Prior Bariatric Surgery. Am J Transplant, Abstract P-106, 17(S2):70, Jan 2017.
8. Putchakayala K, Nagai S, Safwan M, Takahashi K, Abouljoud M. Implementation of Operative Bundles May Decrease Complications. Am J Transplant, Abstract P-139, 17(S2):81, Jan 2017.
9. Putchakayala K, Zanini M, Takahashi K, Francis-Bajjoka I, Abouljoud M. Hypercoagulability Persists up to 3 Months After Partial Hepatectomy. Am J Transplant, Abstract P-140, 17(S2):81, Jan 2017.
10. Safwan M, Rizzari M, Collins K, Yoshida A, Skorupski S, Fagoaga O, Abouljoud M, Nagai S. Effect of Preformed Donor-Specific Antibodies in Intestine/Multivisceral Transplantation. Am J Transplant, Abstract P-156, 17(S2):90, Jan 2017.
11. Safwan M, Ramesh M, Rizzari M, Collins K, Yoshida A, Sulejmani N, Abouljoud M, Nagai S. Brincidofovir for Adenovirus Disease in an Intestinal Transplant Patient. Am J Transplant, Abstract P-157, 17(S2):90, Jan 2017.
12. Jesse M, Rubinstein E, Eshelman A, Wee C, Tankasala M, Li J, Abouljoud M. Lifestyle and Self-Management by Those Who Live It: Patients Engaging Patients in a Chronic Disease Model. Per J. 2016 Jul 13;20(3). DOI: 10.7812/TPP/15-207.
13. Takahashi K, Putchakayala K, Malinzak L, Denny J, Yoshida A, Abouljoud M, Kim D. Is Ketarolac Really Safe for Living Donor Nephrectomy? Am J Transplant Jan 2016;16(S1):50 Abstract P-56.
14. Jesse M, Habra R, Mekaru S, Goldstein E, Eshelman A, Abouljoud M. Living Liver Donors: Disparity, Distress, and Sleep. Hepatology 2015; 62:486A-487A. Impact factor 11.055.
15. Jesse M, Abouljoud M, Hogan K, Eshelman A. Burnout in Transplant Nurses. Prog Transplant 2015 Sep;25(3):196-202. DOI: 10.7182/pit2015213.
16. Sood A, Abdullah N, Abdollah F, Abouljoud M, Trinh Q, Menon M, Sammon J. Rates of Kidney Transplantation from Living and Deceased Donors for Blacks and Whites in the United States, 1998 to 2011. [JAMA Intern Med](#). 2015 Oct;175(10):1716-8. DOI: 10.1001/jamainternmed.2015.4530.
17. Abouljoud M, Whitehouse S, Langnas A, Brown K. Compensating the Transplant Professional: Time for a Model Change. Manuscript AJT-V-14-01020.R1 is the feature cover story of the Am J Transplant, March 2015. Impact Factor 6.19.
18. *Yip J, Bruno D, Burmeister C, Kazimi M, Yoshida A, Abouljoud M, Schnickel G. Deep Vein Thrombosis and Pulmonary Embolism in Liver Transplant Patients: Risks and Prevention. Abstract # P-102, Am J Transplant, 1(15):92-93, 2015. Impact factor 6.19. *Study conception, design, supervise implementation, manuscript writing.*
19. *Takahashi K, Bruno D, *Tabbal M, Kazimi M, Yoshida A, Abouljoud M, Schnickel G. Platelet Count and Risk of Biliary Stricture after Liver Transplant. Abstract # P-141, Am J

- Transplant 1(15):104-105, 2015. Impact factor 6.19. *Study conception, design, supervise implementation, manuscript writing.*
20. Jesse M, Eshelman A, Abouljoud M. Determinants of Burnout among Transplant Surgeons: A National Survey in the United States. Manuscript AJT-B-14-00813.R1, Am J Transplant 2015 Feb 12. DOI: 10.1111/ajt.13056. [Epub ahead of print]. Impact factor 6.19.
 21. Monaghan K, Gonzalez H, Levin A, Abouljoud M, Gordon S. Post-Transplant Course of Hepatitis C after Living Donor Liver Transplantation in Association with Polymorphisms near *IFNL3*. Manuscript JICR-2014-0111.R1, J Interferon Cytokine Res. 2015 Apr;35(4):313-6. DOI: 10.1089/jir.2014.0111. Epub 2014 Oct 24. Impact factor 3.899. *Study conception, design, supervise implementation, manuscript writing.*
 22. *Nagai S, Yoshida A, Facciuto M, Moonka D, Abouljoud M, Schwartz M, Florman S. Ischemia Time Impacts Recurrence of Hepatocellular Carcinoma after Liver Transplantation. Manuscript HEP-14-0010.R3, Hepatology, 2014 Aug 7. DOI: 10.1002/hep.27358. [Epub ahead of print]. Impact factor 11.19. *Study conception, design, supervise implementation, manuscript writing.*
 23. Mittal C, Hassan S, Arshad S, Jeepalyam S, Bruni S, Miceli M, Jacobsen G, Abouljoud M, Bajjoka I, Ramesh M, Alangaden G. Clostridium difficile Infection in Liver Transplant Recipients: A Retrospective Study of Rates, Risk Factors and Outcomes. Am J Transplant 2014; XX: 1-7; DOI: 10.1111/ajt.12798. Impact factor 6.19. *Study conception, design, supervise implementation, manuscript writing.*
 24. *Theodoropoulos I, *Nagai S, Schnickel G, Bruno D, Kazimi M, Yoshida A, Abouljoud M. Sinusoidal Dilatation after Liver Transplant. A Predictor of HCV Recurrence? Am J Transplant 2(14):101, 2014. Impact factor 6.19.
 25. *Nagai S, Yoshida A, Kohno K, Altshuler D, Nakamura M, Brown K, Abouljoud M, Moonka D. Peritransplant Absolute Lymphocyte Count as a Predictive Factor for Advanced Recurrence of Hepatitis C after Liver Transplantation. Hepatology 2014;59:35-45. Impact factor 11.19. *Study conception, design, supervise implementation, manuscript writing.*
 26. *Nagai S, Yoshida A, Kohno K, Altshuler D, Nakamura M, Brown K, Abouljoud M, Moonka D. Recurrent Hepatitis C: The Bane of Transplant Hepatology. Hepatology 2014;59:21-23. Impact factor 11.19. *Study conception, design, supervise implementation, manuscript writing.*
 27. *Nagai S, Schnickel G, *Theodoropoulos I, Bruno D, Kazimi M, Brown K, Yoshida A, Abouljoud M. Liver Transplantation for Patients with Pretransplant Undetectable Hepatitis C RNA: Can Eradication of Virus Guarantee Superior Outcome? Transplantation, 2014 Apr 27;97(8):e45-7. DOI: 10.1097/TP.0000000000000059.
 28. *Nagai S, Abouljoud M, Kazimi M, Yoshida A. Emergent Non-Conventional Meso-Systemic Shunt for Diffuse Porto-Mesenteric Thrombosis: Spare the Chance for Liver/Multivisceral Transplantation. Liver Transpl June 2013, 19(6):661-663. Impact factor 3.793. *Study conception, design, supervise implementation, manuscript writing.*
 29. *Salami A, Qureshi W, Kuriakose P, Moonka D, Yoshida A, Abouljoud M. Frequency and Predictors of Venous Thromboembolism in Orthotopic Liver Transplant Recipients: A Single-Center Retrospective Review. Transplant Proc 45(1):315-319, January 2013 (online 20 September 2012). Impact factor 0.984.
 30. Winston S, Saliba F, Blumberg E, Abouljoud M, Garcia-Diaz J, Goss J, Clough L, Avery R, Limaye A, Ericzon G, Navasa M, Troisi R, Chen H, Villano S, Uknis M, for the 1263-301 Clinical Study Group. Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily

for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial [Erratum appears in Am J Transplant. 2013 Feb; 13(2):529]. Am J Transplant 12(11):3021-30, 2012 Nov. UI: 22947426. Impact factor 6.19. *Study conception, design, supervise implementation, manuscript writing.*

31. *El-Atrache M, Abouljoud M, Divine G, Yoshida A, Kim D, Kazimi M, Moonka D, Brown K. Recurrence of Non-Alcoholic Steatohepatitis and Cryptogenic Cirrhosis Following Orthotopic Liver Transplantation in the Context of the Metabolic Syndrome. Clin Transplant 26(5):E505-12, 2012 Sep-Oct. UI: 23061759. Impact factor 1.486. *Study conception, design, supervise implementation, manuscript writing.*
32. *El-Atrache M, Abouljoud M, Sharma S, *Abou Abbass A, Yoshida A, Kim D, Kazimi M, Moonka D, Brown K. Transjugular Intrahepatic Portosystemic Shunt Following Liver Transplantation: Can Outcomes Be Predicted? E-publication head of print, Clin Transplant 2012 Feb 6. DOI: 10.1111/j.1399-0012.2011.01594.x. Published online August 2012. Impact factor 1.486. *Study conception, design, supervise implementation, manuscript writing.*
33. *Nagai S, Brown L, Yoshida A, Kim D, Kazimi M, Abouljoud M. Mini-Incision Right Hepatic Lobectomy with and without Laparoscopic Assistance for Living Donor Hepatectomy. Liver Transpl 18(10):1188-97, 2012 Oct. UI: 22685084. Impact factor 3.793.
34. Abouljoud M, *El-Atrache M, Yoshida A, Kim D, Kazimi M, Moonka D, Brown K. Outcomes and Patterns of Recurrence of Hepatocellular Carcinoma after Liver Transplantation: A Single Center Experience. Am J Transplant January 2012, Supplement 2, Volume 12, p82, Abstract P-50. Impact factor 6.19.
35. Patel H, Parekh R, Abouljoud M, Divine G, Batra S. Adult Living Donor Liver Transplantation – 10 Year Donor Safety Experience. Hepatology, Volume 54, Number 4 (Suppl.), October 2011, Abstract #653, P676A. Impact factor 11.19. *Study conception, design, supervise implementation, manuscript writing.*
36. *Slater R, Jabbour N, *Abou Abbass A, *Patil V, Hundley J, Kazimi M, Kim D, Yoshida A, Abouljoud M. Left Renal Vein Ligation: A Technique to Mitigate Low Portal Flow from Splenic Vein Siphon during Liver Transplantation. Am J Transplant 11(8):1743-7, 2011 Aug. UI: 21668639. Impact factor 6.19.
37. *Slater R, *Frame N, *Patil V, *Brown L, Kazimi M, Kim D, Yoshida A, Abouljoud M. Reduction in Hypersplenism after Liver Transplantation Is Independent of Caval Implantation Technique. Am J Transplant January 2011, 11(1):84. Impact factor 6.19.
38. Abouljoud M. Beverly & Wilshire: The Expensive Transplant Candidate. Am J Transplant January 2011, 11(1): 54, Abstract WS-8. Impact factor 6.19.
39. Abouljoud M. Innovative Approaches to Compensating and Incentivizing the Transplant Professional: The Virtual RVU. Am J Transplant January 2011, 11(1):51, Abstract BPS-2. Impact factor 6.19.
40. Sofi A, Abouljoud M, Alaradi O, Nawras A. Aberrant Right Hepatic Duct Draining into the Cystic Duct: Clinical Outcomes and Management. Gastroenterol Res Pract 2011:458915. DOI: 10.1155/2011/458915. Epub 2011 Apr 7. Impact factor 1.502. *Study conception, design, supervise implementation, manuscript writing.*
41. *Slater R, Mossa-Basha F, Peterson E, *Abou Abbass A, *Patil V, Hundley J, Kazimi M, Kim D, Abouljoud M, Yoshida A. Outcomes of Non-Liver Related Surgical Procedures (NLRSP) after Liver transplant (OLT). Am J Transplant January 2010, 10(suppl1): p73. Impact factor 6.19. *Study conception, design, supervise implementation, manuscript writing.*

42. *Slater S, Mossa-Basha F, Abouljoud M, Peterson E, Yoshida A, Hundley J, Kazimi M, *Abou Abbass A, *Patil V, Kim D. Post-Operative Hernias after Liver Transplant (OLT) with the Use of Sirolimus. Am J Transplant January 2010, 10(suppl1): p73. Impact factor 6.19. *Study conception, design, supervise implementation, manuscript writing.*
43. *Slater R, *Abou Abbass A, *Patil V, Hundley J, Kazimi M, Kim D, Yoshida A, Abouljoud M. Splenic Vein Siphon: An Under-Recognized Cause of Low Portal Flow in Liver Transplant (OLT). Am J Transplant January 2010, 10(suppl1): p73. Impact factor 6.19.
44. *Cheaito A, Abouljoud M. Impact of Preoperative Tumor Volume and Staging of HCC on Transplant Outcomes. Am J Transplant January 2010, 10(suppl1): p68. Impact factor 6.19.
45. Abouljoud M, *El-Atrache M, Yoshida A, Kim D, Hundley J, Kazimi M. Recurrence of Non-Alcoholic Steato-Hepatitis (NASH) and Cryptogenic Cirrhosis (CC) Following Liver Transplantation (LT) in the Context of Metabolic Syndrome. Am J Transplant January 2010, 10(suppl1): p67. Impact factor 6.19.
46. *Abou Abbass A, Abouljoud M, Getzen T, Yoshida A, Hundley J, Kazimi M, *Slater R, *Patil V, Kim D. Portal Vein Thrombosis (PVT) after Splenectomy in a Liver Transplant (LT) Patient. Am J Transplant January 2010, 10(suppl1): p66. Impact factor 6.19. *Study conception, design, supervise implementation, manuscript writing.*
47. Kim D, Goggins M, Eisenbrey AB, Skorupski S, Malinzak L, Denny J, Yoshida A, *Abou Abbass A, *Patil V, *Slater R, Hundley J, Kazimi M, Abouljoud M. Deceased Donor Kidney Transplantation (DDT) without Prospective Crossmatch (PC). Am J Transplant January 2010, 10(suppl1): p62. Impact factor 6.19.
48. *Cheaito A, Abouljoud M. Effect of RFA and Tace on Recurrence of HCC after Liver Transplantation. Am J Transplant January 2010, 10(suppl1): p59. Impact factor 6.19.
49. Raoufi M, Ma C, Ormsby A, Vakil H, Brown K, Huang M, Moonka D, Abouljoud M. The Role of Post-Reperfusion Biopsy in the Era of Extended Criteria Donor. Liver Transpl July 2009, 15(7, suppl1): pS266. Impact factor 3.793.
50. *Abou Abbass A, Abouljoud M, Yoshida A, Kim D, *Slater R, Hundley J, Kazimi M, Moonka D. Biliary Complications after Orthotopic Liver Transplantation from Donors after Cardiac Death: Spectrum of Disease. Transplant Proc 42(9):3392-8, 2010 Nov. UI: 21094785. Impact factor 0.984. *Study conception, design, supervise implementation, manuscript writing.*
51. Bajjoka I, Hsaiky L, Brown K, Ma M, Abouljoud M. Thymoglobulin Improves Renal Function Without Accelerating Hepatitis C Virus Recurrence in HCV Positive Liver Transplant Recipients. Am J Transplant May 2009, 9(suppl2): p262. Impact factor 6.19.
52. *Slater R, Mossa-Basha F, *Abou Abbass A, Kapke A, Kim D, Abouljoud M, Yoshida A. The Impact of Surgeon Fatigue on Liver Transplant Outcomes. Am J Transplant May 2009, 9(suppl2): p609. Impact factor 6.19. *Study conception, design, supervise implementation, manuscript writing.*
53. Memon A, Patel A, Goggins M, Kurtz R, Perrine S, Karthikeyan V, Kim D, Abouljoud M. Variables Affecting Predonation Renal Function by Iothalamate GFR in Living Kidney Donors. Am J Transplant May 2009, 9(suppl2): p602. Impact factor 6.19.
54. *Alkortas D, Bajjoka I, Hsaiky L, Abouljoud M. The Quality of Life of Kidney Transplant Recipients Following Transplantation with Expanded Criteria Donor Versus Standard Criteria Donor Organs. Am J Transplant May 2009, 9(suppl2): p565. Impact factor 6.19.

55. *Alkortas D, Bajjoka I, Hsaiky L, Ma M, Abouljoud M. The Quality of Life of Orthotopic Liver Transplant Recipients Following Transplantation with Marginal Organs. *Am J Transplant* May 2009, 9(suppl2): p454. Impact factor 6.19.
56. Eshelman A Abouljoud M. *Meyer T, Fischer D, Moonka D, Brown K. Cognitive Functioning and Quality of Life in End Stage Liver Disease. *Am J Transplant* 2008, 8(Suppl2): p628. Impact factor 6.19. *Study conception, design, supervise implementation, manuscript writing.*
57. Bajjoka I, Hsaiky S, Yoshida A, Abouljoud M. Non-Heart Beating Deceased Liver Donors Have a Negative Impact on Outcomes after Liver Transplantation. *Am J Transplant* 2008, 8(Suppl2): p541. Impact factor 6.19.
58. Hsaiky L, Bajjoka I, Patel D, Abouljoud M. Postoperative Use of Intense Insulin Therapy in Liver Transplant Recipients. *Am J Transplant* 2008, 8(Suppl2): p260. Impact factor 6.19.
59. Parasuraman R, Venkat KK, Patel A, Moonka D, Denny J, Yoshida A, Malinzak L, Brown K, Abouljoud M, Kim D. Renal Allograft Outcome among Recipients of Positive vs. Negative Crossmatch Combined Liver-Kidney Transplantation: UNOS Data Analysis. *Am J Transplant* 2008, 8(Suppl2): p238. Impact factor 6.19. *Study conception, design, supervise implementation, manuscript writing.*
60. Parasuraman R, Nizaar A, Karthikeyan V, Kim D, Denny J, Malinzak L, Abouljoud M, Jacobsen G, Goggins M, Venkat KK. Significant Increase in Infection-Associated Renal Allograft Failure over the Past Decade: UNOS Data Analysis. *Am J Transplant* 2008, 8(Suppl2): p218. Impact factor 6.19. *Study conception, design, supervise implementation, manuscript writing.*
61. *von Riedenauer WB, Shanti C, Abouljoud M. Resection of Giant Liver Adenoma in a 17-Year-Old Adolescent Boy Using Venovenous Bypass, Total Hepatic Vascular Isolation, and In Situ Cooling. *J Pediatr Surg* (August 2007) 42, E23-E27. Impact factor 1.311.
62. Kim D, Lim C, Parasuraman R, Raoufi M, Yoshida A, Arenas J, Denny J, Malinzak L, Almarastani M, Moonka D, Brown K, Sherbondy M, Gordon S, Abouljoud M. Renal Disease Burden Following Liver Transplantation. *Transplant Proc* 38(10):3663-5, 2006 Dec. UI: 17175361. Impact factor 0.984.
63. Malinzak L, Kim D, Abouljoud M, *Almarastani M, Yoshida A, Arenas J. Redo Orthotopic Liver Transplantation For Complications of Hepatic Artery Thrombosis: A High-Risk Arterial Anastomosis. *Am J Transplant* 2006, 6(Suppl2) and *Transplantation* 2006, 82(Issue1)(Suppl3): p724. Impact factor 6.19. *Study conception, design, supervise implementation, manuscript writing.*
64. *Cheaito A, Craig B, Abouljoud M, Arenas J, Yoshida A, Malinzak L, *Almarastani M, Kim D. Sonographic Differences in Venous Return between Piggyback versus Caval Interposition in Adult Liver Transplantation. *Transplant Proc* 38(10):3588-90, 2006 Dec. UI: 17175339. Impact factor 0.984. *Study conception, design, supervise implementation, manuscript writing.*
65. Hsaiky L, Bajjoka I, Hegeman R, Brown K, Abouljoud M. Safety and Efficacy of Enteric-Coated Mycophenolate Sodium in Liver Transplant Recipients. *Am J Transplant* 2006, 6(Suppl2) and *Transplantation* 2006, 82(Issue1)(Suppl3): p718. Impact factor 6.19.
66. Lambing A, Abouljoud M, Kuriakose P. Living Liver Donor Thrombotic Risk: Call for Standardization of Care. *Am J Transplant* 2006, 6(Suppl2) and *Transplantation* 2006, 82(Issue1)(Suppl3): p701. *Study conception, design, supervise implementation, manuscript writing.*

67. Hegeman R, Bajjoka I, Hsaiky L, Parasuraman R, Abouljoud M. A Single Center Comparison between Two Antiviral Cytomegalovirus in Kidney Transplant Mis-Match Patients. *Am J Transplant* 2006, 6(Suppl2) and *Transplantation* 2006, 82(Issue1)(Suppl3): p588.
68. Yoshida A, Zacharias S, Kim D, Arenas J, Hogan K, Brown K, Moonka D, Abouljoud M. Long-Term Efficacy of Endoscopic Management in Post-Liver Transplant Biliary Complications. *Am J Transplant* 2006, 6(Suppl2) and *Transplantation* 2006, 82 (Issue1)(Suppl3): p550.
69. *Meyer T, Eshelman A, Abouljoud M. Preliminary Analyses of Cognitive and Emotional Functioning in Liver Transplant Candidates. *Am J Transplant* 2006, 6(Suppl2) and *Transplantation* 2006, 82 (Issue1)(Suppl3): p467.
70. Asfandiyar S, Abouljoud M, Kim D, Brown K, Yoshida A, Arenas J, Sherbondy M, Divine G, Moonka D. Influence of Hepatitis C on Renal Function after Liver Transplantation. *Transplant Proc* 38(10):3643-5, 2006 Dec. UI: 17175355. Impact factor 0.984. *Study conception, design, supervise implementation, manuscript writing*.
71. Bajjoka I, Hsaiky L, Hegeman R, Brown K, Abouljoud M. Sustained Benefit of Thymoglobulin Induction in Preserving Renal Function in Liver Transplant Recipients. *Am J Transplant* 2006, 6(Suppl2) and *Transplantation* 2006, 82(1)(Suppl3): p208.
72. Lambing A, Kuriakose P, Abouljoud M. Hypercoagulability Risks among Adult Living Liver Donors. *Transplant Proc* 38(10):3579-81, 2006 Dec. UI: 17175336. Impact factor 0.984.
73. Abouljoud M, Bansal A. Rex Shunt – A Treatment Option for Extrahepatic Portal Thrombosis in Adults. *J International Hepato Pancreato Biliary Assoc* Vol. 8 Suppl. 1, 78(P85), March 2006. Impact factor 2.05.
74. Abouljoud M. Laparoscopic Left Lateral Segmentectomy Using Vapor Pulse Coagulation System. *J International Hepato Pancreato Biliary Assoc*. Vol. 8, Suppl. 1, 50(V18), March 2006. Impact factor 2.05.
75. Asfandiyar S, Abouljoud M, Kim D, Brown K, Moonka D. Effect of Hepatitis C Virus on Renal Function after Liver Transplantation. *Hepatology* 42 Suppl. 4, 725(A), 2005. Impact factor 11.19. *Study conception, design, supervise implementation, manuscript writing*.
76. Abouljoud M, Bansal M, Ma C, Moonka D, Sherbondy M, Brown K, Gordon S, Arenas J, Yoshida A, Kim D. Analysis of Hepatocellular Carcinoma (HCC) Histology after Ablation Therapy in Patients Undergoing Liver Transplantation (OLT). *Hepatology* 42 Suppl. 4, 505(A), 2005. Impact factor 11.19.
77. Attallah N, Goggins M, Nori U, Abouljoud M, Zasuwa G, Venkat KK, Parasuraman R. Comparison of Long-Term Actual Renal Allograft Survival in Mycophenolate Mofetil and Azathioprine-Based Triple Drug Immunosuppression Protocols. *Transplant Proc* 37(5):2060-2, 2005 Jun. UI: 15964338. Impact factor 0.984. *Study conception, design, supervise implementation, manuscript writing*.
78. Antaki F, Abouljoud M, Yoshida A, Kim D, Arenas J, Moonka D. Intra-Operative Observations Have a Limited Role in Predicting Arterial and Biliary Complications After Orthotopic Liver Transplantation. *Hepatology* 42 Suppl. 4, 333(A), 2005. Impact factor 11.19. *Study conception, design, supervise implementation, manuscript writing*.
79. Arenas J, Bernbeck M, Kim D, Yoshida A, Madek W, Hayes R, Hall M, Malinzak L, Sherbondy M, Brown K, Moonka D, Abouljoud M. Strategies to Optimize Outcomes on Donor After Cardiac Death (DCD) Liver Transplantation. *Hepatology* 42 Suppl. 4, 294(A), 2005. Impact factor 11.19.

80. Kim D, Bazzi W, Raoufi M, Brown K, Yoshida A, Arenas J, Jerius J, Moonka D, Neece S, Hogan K, Abouljoud M. Impact of Hepatitis C in Resource Utilization Following Orthotopic Liver Transplantation. *Am J Transplant* 5 Suppl. 11, 506(A), 2005.
81. Abouljoud M, Eshelman A, Raoufi M, Bertges-Yost W. Strategies to Reduce Burnout among Transplant Surgeons in North America. *Am J Transplant* 5 Suppl. 11, 492(A), 2005.
82. Shah V, Ahmed J, Malinzak L, Karthikeyan V, Patel A, Ortigosa-Goggins M, Kim D, Arenas J, Yoshida A, Abouljoud M, Jerius J, Parasuraman R, Venkat KK. Change in Donor Serum Creatinine Post Kidney Donation Predicts Allograft Function in Recipients. *Am J Transplant* 5 Suppl. 11, 477(A), 2005. *Study conception, design, supervise implementation, manuscript writing.*
83. Parasuraman R, Ahmed J, Shah V, Malinzak L, Karthikeyan V, Patel A, Ortigosa-Goggins M, Kim D, Arenas J, Jerius J, Yoshida A, Venkat KK, Abouljoud M. Race is not a Deterrent for Living Unrelated Kidney Donation: A Single Center Experience. *Am J Transplant* 5 Suppl. 11, 262(A), 2005. *Study conception, design, supervise implementation, manuscript writing.*
84. Ahmed J, Shah V, Malinzak L, Karthikeyan V, Patel A, Ortigosa-Goggins M, Arenas J, Kim D, Jerius J, Abouljoud M, Yoshida A, Venkat KK, Parasuraman R. Comparison of the Increase in Serum Creatinine Post Kidney Donation between African American and Caucasian Donors. *Am J Transplant* 5 Suppl. 11, 262(A), 2005. *Study conception, design, supervise implementation, manuscript writing.*
85. Hsaiky L, Bajjoka I, Kim D, Dingle R, Yoshida A, Jerius J, Arenas J, Abouljoud M. The Use of Metformin in Liver Transplant Recipients. *Am J Transplant* 5 Suppl. 11, 236(A), 2005. *Study conception, design, supervise implementation, manuscript writing.*
86. Abouljoud M, Yoshida A, Kim D, Jerius J, Moonka D, Ravinuthala R, Brown K. Transjugular Intrahepatic Portosystemic Shunts for Refractory Ascites after Liver Transplantation. *Transplantation (Suppl)* 78:386A, 2004.
87. Abouljoud M, *Bertges-Yost W, Eshelman A, Raoufi M. National Study of Burnout among Transplant Surgeons in North America. *Transplantation (Suppl)* 78:137A, 2004.
88. Abouljoud M, Yoshida A, Kim D, Jerius J. Safety and efficacy of Bioglue in preventing bile leakage after major liver resections. *HPB* 6, suppl. 1, 135(A), 2004. Impact factor 2.05.
89. Abouljoud M, Yoshida A, Moonka D, Croteau D, McVinnie D, Brown K. Favorable outcomes after selective use of Transjugular intrahepatic portosystemic shunts following liver transplantation. *Hepatology* 38 suppl. 1:377A, 2003. Impact factor 11.19.
90. Abouljoud M, Yoshida A, Dagher F, Moonka D, Brown K. Favorable experience with recipient splenic artery inflow in adult liver transplantation. *Liver Transpl* 9(6):C-50, 2003. Impact factor 3.793.
91. Abouljoud M, Yoshida A, Dagher F, Bajjoka I, Moonka D, Brown K. Thrombotic thrombocytopenic purpura after liver transplantation with tacrolimus based immunosuppression. *Liver Transpl* 9(6):C-14, 2003. Impact factor 3.793.
92. Douzdjian V, Kukuruga D, Bajjoka I, Abouljoud M. The impact of duffy blood type on renal allograft survival in African Americans. *Transplantation* 69(8):A-S142, 2000.
93. Abouljoud M, Kumar MSA, Brayman K, Emre S, Bynon S. Conversion to Neoral provides effective rescue therapy for liver and kidney transplant patients intolerant of Prograf. *Transplantation* 69(8):A-S181, 2000.

94. Bajjoka I, Francis K, Douzdjian V, Brown K, Moonka D, Abouljoud M. Peptic ulcer disease in liver transplantation is infrequently due to Helicobacter Pylori. *Transplantation* 69(8):A-S316, 2000.
95. Douzdjian V, Bajjoka I, Abouljoud M. Is it safe to perform the donor and recipient operations sequentially instead of simultaneously in living-donor kidney transplants? *Transplantation* 69(8):A-S332, 2000.
96. Brown K, Thomas M, Nakhleh R, Abouljoud M, Moonka D. Cost-effectiveness and sensitivity of screening strategies for hepatocellular carcinoma and portal vein thrombosis in liver transplant candidates. *Transplantation* 69(8):A-S390, 2000.
97. Deshpande V, Burd E, Aardema K, Ma C, Moonka D, Abouljoud M, Nakhleh R. Relationship of hepatitis C virus RNA levels in the native livers to graft survival and transplant associated cholestatic jaundice. *Mod Pathol* 12(1):161A, 1999. Impact factor 6.364.
98. Kupin W, Venkat KK, Goggins M, Douzdjian V, Escobar F, Mozes M, Abouljoud M. Improved outcome of steroid withdrawal in Mycophenolate Mofetil-treated primary cadaveric renal transplant recipients. *Transplant Proc* 31(1-2):1131-2, 1999 Feb-Mar. UI: 10083505. Impact factor 0.984.
99. Kupin W, Venkat KK, Goggins M, Douzdjian V, Escobar F, Mozes M, Abouljoud M. Transplantation without maintenance corticosteroids in 1-haplotype and 2-haplotype HLA matched living-related renal transplant recipients treated with Mycophenolate Mofetil and Cyclosporine. *Transplant Proc* 31(1-2):744-5, 1999 Feb-Mar. UI: 10083317. Impact factor 0.984.
100. Kupin W, Venkat KK, Goggins M, Douzdjian V, Escobar F, Mozes M, Abouljoud M. Improved outcome of steroid withdrawal in Mycophenolate Mofetil treated primary cadaveric renal transplant recipients. *Transplantation* 65:232, 1998.

ABSTRACTS AND POSTERS:

Podium Presentations (refereed)

1. Nagai S, Takahashi K, Safwan M, Abouljoud M, Jafri S. Delayed Early Lactate Clearance after Liver Transplantation: A Propensity Score Matching Study. Oral presentation. AASLD Liver Disease Meeting, Nov 9-13, 2018, San Francisco, CA.
2. Nagai S, Chau L, Safwan M, Schilke R, Rizzari M, Collins K, Yoshida A, Abouljoud M, Moonka D. Survival Benefit of Liver Transplantation in the MELD-Na Era. Oral presentation. 27th International Congress of the Transplantation Society, Jun 30-Jul 5, 2018, Madrid, Spain.
3. Nagai S, Muszkat Y, Jafri M, Safwan M, Schilke R, Collins K, Yoshida A, Abouljoud M, Sulejmani N, Rizzari M. Comparison of Induction and Maintenance Immunosuppression Regimens in Intestinal and Multivisceral Transplant: An Analysis of the UNOS Registry. Oral presentation. 27th International Congress of the Transplantation Society, Jun 30-Jul 5, 2018, Madrid, Spain.
4. Safwan M, Nagai S, Rizzari M, Collins K, Yoshida A, Skorupski S, Fagoaga O, Abouljoud M. Effect of Preformed Donor-Specific Antibodies in Intestine/Multivisceral Transplantation. Oral presentation. XV International Congress of the Intestinal Rehabilitation & Transplant Association (CIRTA), Jun 28-Jul 1, 2017, New York, NY.
5. Pahari H, Rizzari M, Safwan M, Khan H, Jafri S, Muszkat Y, Collins K, Yoshida A, Abouljoud M, Nagai S. Effect of Donor Vasopressor Requirements on Recipient Outcomes

- for Intestinal and Multivisceral Grafts – Is it Overrated? Oral presentation. XV International Congress of the Intestinal Rehabilitation & Transplant Association (CIRTA), Jun 28-Jul1, 2017.
6. Markmann J, Ghobrial M, Magliocca J, Demetris A, Abouljoud M. Results of the Initial Phase of the Portable Organ Care System (OCS™) Liver PROTECT Pivotal Trial. Oral presentation. American Transplant Congress, Apr 29-May 3, 2017, Chicago, IL.
 7. Magliocca J, Markmann J, Abouljoud M, Ghobrial M, Demetris A. 36 Hours of Ex-Vivo Warm Cellular Perfusion of Swine Liver Using the Organ Care System (OCS™) Liver with Excellent Functional, Metabolic and Histological Outcomes. Oral presentation. American Transplant Congress, Apr 29-May 3, 2017, Chicago, IL.
 8. Safwan M, Rizzari M, Collins K, Yoshida A, Skorupski S, Fagoaga O, Abouljoud M. Effect of Preformed Donor-Specific Antibodies in Intestine/Multivisceral Transplantation. Oral presentation. American Transplant Congress, Apr 29-May 3, 2017, Chicago, IL.
 9. Jesse M, Reghan N, Yoshida A, Moonka D, Eshelman A, Abouljoud M, Rizzari M. Substance Abuse in Acute Liver Failure: Time to Talk about Opiates. Oral presentation, American Transplant Congress, Apr 29-May 3, 2017, Chicago IL.
 10. Abouljoud M, Nagai S. Living Donor Right Hepatectomy Using Mini-Incision in 91 Patients. Oral presentation, 7th Living Donor Abdominal Organ Transplant Conference: State of the Art, Trieste, Italy, September 9-10, 2016.
 11. Abouljoud M, Jesse M. Pre-Organ Donation Psychiatric Characteristics and Post-Donation Pain. Oral presentation, 7th Living Donor Abdominal Organ Transplant Conference: State of the Art, Trieste, Italy, September 9-10, 2016.
 12. Moonka D, Nagai S, Divine G, Abouljoud M, Salgia R. Influence of Donor Age and Cold Ischemia on Recurrence of Hepatocellular Carcinoma after Liver Transplantation. Oral presentation. XXVI International Congress of the Transplantation Society (TTS 2016), Official TTS Biennial Congress, Hong Kong, August 18-23, 2016.
 13. Moonka D, Shah V, Lagnajita D, Gadde R, Divine G, Yoshida A, Jafri SM, Abouljoud M, Salgia R. Degree of Tumor Necrosis from Pre-Transplant Loco-Regional Therapy is Associated with Tumor Free Survival after Liver Transplantation. Oral presentation. XXVI International Congress of the Transplantation Society (TTS 2016) Official TTS Biennial Congress, Hong Kong, August 18-23, 2016.
 14. Kane W, Putchakayala K, Takahashi K, Rizzari M, Yoshida A, Abouljoud M. Left Renal Vein Ligation for Management of Portal Hypoperfusion in Liver Transplantation. Oral presentation, Michigan Chapter, American College of Surgeons, Mackinac Island, MI, May 18-20, 2016.
 15. Jesse M, Eshelman A, Rosetti T, Abouljoud M, Denny J, Patel A, Kim D. Psychiatric Recommendations for Patients Pursuing Kidney Transplantation. Oral Presentation, 2015 American Transplant Congress, Pennsylvania Convention Center, May 2-6, 2015.
 16. Jesse M, Abouljoud M, Hogan K, Eshelman A. Burnout in Transplant Nurses and Nurse Coordinators. Oral Presentation, NATCO's 39th Annual Meeting, Grand Hyatt, San Antonio, TX, August 10-13, 2014.
 17. *Nagai S, Kohno K, Altshuler D, Nakamura M, Brown K, Abouljoud M, Moonka D. Peri-Transplant Absolute Lymphocyte Count as Predictive Factor for Advanced Recurrence of Hepatitis C after Liver Transplantation. Oral Presentation, 13th Congress of the Asian Society of Transplantation Annual Meeting, Kyoto Japan, September 3-9, 2013.

18. Florman S, Rice K, Chan L, Zhang R, Abouljoud M, Steinberg S, Pearson T, Pupim L, Vincenti F. Outcomes at Five Years in Black/African-American Kidney Transplant Recipients from the Long-Term Extension of the Belatacept BENEFIT and BENEFIT-EXT Studies. Oral. ATC 2013 Annual Meeting.
19. *Nagai S, Yoshida A, Kazimi M, Brown K, Moonka D, Abouljoud M. Novel Prognostic Factors in Recurrence of Hepatocellular Carcinoma after Liver Transplantation: Adverse Oncological Impact of Prolonged Ischemia Time and Peri-transplant Lymphopenia. Oral Presentation, 113th Annual Congress of Japan Surgical Society, April 11-13, 2013, Nagoya Japan.
20. *Nagai S, Yoshida A, Kohno K, Altshuler D, Nakamura M, Brown K, Kazimi M, Abouljoud M, Moonka D. Peri-Transplant Absolute Lymphocyte Count is a Reliable Predictive Factor for Advanced Recurrence of Hepatitis C Following Liver Transplantation. Oral Presentation, ATC Annual Meeting, Seattle, WA, May 18-22, 2013.
21. *Nagai S, Yoshida A, *Brown L, Kazimi M, Kim D, Abouljoud M. Clinical Implication of Ischemic Time on Recurrence of Hepatocellular Carcinoma Following Liver Transplantation. Oral Presentation, ATC 2012 Annual Meeting, Boston, MA, June 2-6, 2012.
22. Zanini M, *Abou Abbass A, Kazimi M, Yoshida A, Abouljoud M. Experience with Selective Transarterial Embolization as a Therapeutic Option for Focal Nodular Hyperplasia: A Case Series. Oral Poster Presentation, 12TH Annual AHPBA Meeting 2012, Eden Roc Renaissance Resort, Miami Beach, FL, March 7-11, 2012.
23. Grinyo J, Abouljoud M, Germain M, Manfro R, Morales J, Legendre C, Lin C, Agarwal M, Medina J. Improving or Sustaining Renal Function over Three Years with Belatacept or Cyclosporine A (CsA): Insights from the BENEFIT Study". Oral. ESOT Congress, Glasgow, September 4-7, 2011.
24. *Salami A, Qureshi W, Kuriakose P, Abouljoud M. Frequency and Risk Factors of Venous Thromboembolism in Liver Transplant Recipients – A 15-Year Single Center Experience. Abstract 1372, Oral Presentation. American Transplant Congress 2011, Philadelphia, PA, April 30-May 4, 2011.
25. *Abou Abbass A, Abouljoud M. Experience with Selective Transarterial Embolization as a Therapeutic Option for Focal Nodular Hyperplasia: A Case Series. Oral Presentation. The Detroit Surgical Association Meeting, Comerica Park, Detroit, MI, November 22, 2010.
26. Eshelman A, Abouljoud M, *Meyer T, Fischer D, Moonka D, Paulson D, Brown K. The Influence of Alcohol Abuse History on the Differential, Longitudinal Patterns of Mental and Physical Quality of Life Following Liver Transplant. Oral Presentation, XXIII International Congress of the Transplantation Society, Vancouver, BC, Canada, August 15-19, 2010.
27. Raoufi M, *El-Atrache M, Brown K, Moonka D, Yoshida A, Kim D, Kazimi M, Sharma S, Abouljoud M. Crucial Role of Post-Reperfusion in Allograft Biopsy in Evaluation of Follow-up Biopsies after Liver Transplantation. Oral Presentation, XXIII International Congress of the Transplantation Society, August 15-19, 2010, Vancouver, Canada.
28. Abouljoud M, Axelrod D, Klintmalm G, Merion R. Practice Profiles of Transplant Surgeons in the United States: Results of National Survey by the American Society of transplant Surgeons. Oral Presentation, American Transplant Congress 2010, San Diego, CA, May 1-5, 2010.

29. Abouljoud M, *El-Atrache M, *Cheaito A, Yoshida A, Kim D, Kazimi M, Brown K, Moonka D. Single Center Experience with the Up-do-Seven and Milan Criteria in Patients with 141 Cases of Liver Transplantation for Hepatocellular Carcinoma. Oral presentation. American Transplant Congress 2010, San Diego, CA, May 1-5, 2010.
30. Abouljoud M, *El-Atrache M, Yoshida A, Kim D, Hundley J, Kazimi M. Recurrence of Non-Alcoholic Steato-Hepatitis (NASH) and Cryptogenic Cirrhosis (CC) Following Liver Transplantation (LT) in the Context of Metabolic Syndrome. Oral and Poster Presentation, ASTS 10th Annual State of the Art Winter Symposium, Ft. Lauderdale, Florida, January 15-17, 2010.
31. Abouljoud M, Eshelman A, Yoshida A, Kim D, Brown K, Moonka D. Patient Survival Expectations after Liver Transplantation, Patient Selection, Insurance Contracts, and All That Jazz. Oral and Poster Presentation, Frontiers of Ethics in Transplantation: Dilemmas and Struggles, Chicago, Illinois, April 4-6, 2008.
32. Abouljoud M. Outcomes and Trends in Liver Transplantation as Reported in the SRTR Registry. Oral Presentation, 2008 AHPBA Congress, Ft. Lauderdale, Florida, March 27-30, 2008.
33. *Slater R, Yoshida A, Kim D, Abouljoud M. Surgical Portosystemic Shunts for Portal Hypertension in the Era of Orthotopic Liver Transplantation: The Role of the Splenorenal Interposition H-Graft. Oral Presentation, 2008 AHPBA Congress, Ft. Lauderdale, Florida, March 27-30, 2008.
34. Raoufi M, Ma C, Ormsby A, Shah V, Brown K, Sherbondy M, Moonka D, Abouljoud M. Histologic Findings in Post-Reperfusion and Follow-up Biopsies of Liver Transplant Patients: Is There Any Correlation? Oral and Poster Presentation, 8th American Hepatopancreatobiliary (AHPBA) Congress, Ft. Lauderdale, Florida, March 27-30, 2008.
35. Malinzak L, *Slater R, Kim D, Denny J, Yoshida A, Abouljoud M. Renal Transplantation in Patients with Systolic Dysfunction. Mini-Oral Presentation, ASTS 8th Annual State of the Art Winter Symposium, Marco Island, Florida, January 25-27, 2008.
36. Parasuraman R, Karthikeyan V, Attallah N, Frinak S, Kim D, Denny J, Yoshida A, Abouljoud M, Venkat KK. Significant Decrease in Estimated GFR (eGFR) Among African American Kidney Donors Compared to Caucasians – A Single Center Experience. Oral Presentation. ATC, San Francisco, California, May 5-9, 2007.
37. Bajjoka I, Hsaiky L, Brown K, Abouljoud M. Safety of Thymoglobulin Induction in HCV Liver Transplant Recipients. Oral Presentation. ATC, San Francisco, California, May 5-9, 2007.
38. Bajjoka I, Hsaiky L, Brown K, Abouljoud M. Comparing Thymoglobulin Induction and Delayed Calcineurin Inhibitor Initiation with no Antibody Induction and Early Calcineurin Inhibitor Initiation in Liver Transplantation. Oral Presentation. ATC, San Francisco, California, May 5-9, 2007.
39. Hsaiky L, Bajjoka I, Abouljoud M. Postoperative Use of Intense Insulin Therapy in Liver Transplant Recipients. Oral Presentation. ATC, San Francisco, California, May 5-9, 2007.
40. *Almarastani M, Arenas J, Kim D, Yoshida A, *Al Harakeh A, *Bansal M, Raoufi M, Abouljoud M. Clinical Outcomes After Liver Transplantation (OLT) From Extended Criteria Donors (ECD) Are Comparable to Those From Standard Criteria Donors (SCD). Oral Presentation. ATC, San Francisco, California, May 5-9, 2007.

41. Bajjoka I, Hsaiky L, Brown K, Abouljoud M. Safety of Thymoglobulin Induction in HCV Liver Transplant Recipients. Oral Presentation. ATC, San Francisco, California, May 5-9, 2007.
42. Bajjoka I, Hsaiky L, Brown K, Abouljoud M. Comparing Thymoglobulin Induction and Delayed Calcineurin Inhibitor Initiation With No Antibody Induction and Early Calcineurin Inhibitor Initiation in Liver Transplantation. Oral Presentation. ATC, San Francisco, California, May 5-9, 2007.
43. Hsaiky L, Bajjoka I, Abouljoud M. Postoperative Use of Intense Insulin Therapy in Liver Transplant Recipients. Oral Presentation. ATC, San Francisco, California, May 5-9, 2007.
44. Parasuraman R, Venkat KK, Patel A, Attallah N, Karthikeyan V, Goggins M, Denny J, Yoshida A, Malinzak L, Brown K, Abouljoud M, Kim D. Comparison of Renal Allograft Rejection Rates among Positive versus Negative Crossmatch Recipients of Combined Liver-Kidney Transplantation: Analysis of UNOS Data Base. Oral presentation. ATC 2007.
45. Bajjoka I, Hsaiky L, Hegeman R, Brown K, Abouljoud M. Sustained Benefit of Thymoglobulin Induction in Preserving Renal Function in Liver Transplant Recipients. Oral Presentation, World Transplant Congress, Boston, Massachusetts, July 22-27, 2006.
46. Asfandiyar S, Abouljoud M, Kim D, Brown K, Havstead S, Moonka D. Effect of Hepatitis C Virus on Renal Function after Liver Transplantation. Oral Presentation, World Transplant Congress, Boston, Massachusetts, July 22-27, 2006.
47. *Meyer T, Eshelman A, Abouljoud M. Preliminary Analysis of Cognitive and Emotional Functioning in Liver Transplant Candidates. Oral Presentation, World Transplant Congress, Boston, Massachusetts, July 22-27, 2006.
48. Asfandiyar S, Abouljoud M, Kim D, Brown K, Sherbondy M, Havstad S, Moonka D. Influence of Hepatitis C on Renal Function after Liver Transplantation. Oral presentation at the 2006 World Transplant Congress, Boston, MA, July 22-27, 2006.
49. Lambing A., Kuriakose P., Abouljoud M. Hypercoagulable Risks of Living Liver Donors. Oral Presentation, World Transplant Congress, Boston, Massachusetts, July 22-27, 2006.
50. *B-Yost W, Eshelman A, Abouljoud M, Raoufi M. A National Study of Burnout among Transplant Surgeons in North America and Spousal Perceptions. Oral Presentation at the Society of Behavioral Medicine's 27th Annual Meeting and Scientific Sessions, San Francisco, CA, March 22-25, 2006.
51. Tedesco Silva Jr H, Yang H, Abouljoud M, Kuo P, Wisemandle K, Bhattacharya P, Dhadda S, Holman J, Fitzsimmons W, First MR. One Year Results of a Comparative Trial of Tacrolimus/MMF, Modified-Release Tacrolimus/MMF and Cyclosporine/MMF in De Novo Kidney Transplant Recipients. Oral presentation, March 2006.
52. Malinzak L, Kim D, Madek W, Hayes R, Philip S, Abouljoud M, Yoshida A, Arenas J. Donation After Cardiac Death Adds to Organ Donor Pool in Michigan. Oral Presentation at Genzyme Fellows Conference, Boston, MA, June, 2005.
53. Malinzak L, Kim D, Abouljoud M, Arenas J, Yoshida A. Kidney Transplant Outcomes after Simultaneous or Sequential Transplant into Recipients of Liver or Heart Transplant. Oral Presentation at the Michigan Chapter American College of Surgeons, Grand Rapids, MI, May, 2005.
54. Malinzak L, Kim D, Abouljoud M, Arenas J, Jerius J, Yoshida A. Comparison of simultaneous vs sequential kidney transplant with heart and liver transplant recipients.

- Oral presentation at the American Transplant Congress 2005, Seattle, WA, May 21-25, 2005.
55. Abouljoud M, *Bertges-Yost W, Eshelman A, Raoufi M. National Study of Burnout among Transplant Surgeons in North America. Oral presentation. American Hepato-Pancreato-Biliary Association National Meeting, April 14-17, 2005, Fort Lauderdale, Florida.
 56. Bajjoka I, Dingle R, Yoshida A, Kim D, Jerius J, Odell K, Abouljoud M. Thymoglobulin induction therapy allows delay of calcineurin inhibitors in liver transplant recipients with renal insufficiency. Oral presentation. American Transplant Congress 2004, Boston, Massachusetts May 2004.
 57. Lam P, Yoshida A, Brown K, Abouljoud B, Dagher F, Bajjoka I, Moonka D. The efficacy of Sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors. Oral presentation. American Transplant Congress 2003, Washington DC, May 2003.
 58. Abouljoud M. Update on Split and Living Donor Liver Transplantation. The VIII International Congress of the Middle East Society for Organ Transplantation, Muscat, Oman, October 2002.
 59. Abouljoud M, Escobar F, Douzjdjian V. More Organs Everyone! The Dilemma Continues. The VII International Congress of the Middle East Society for Organ Transplantation, Beirut, Lebanon, October 2000.
 60. Abouljoud M, Escobar F, Douzjdjian V. Split and Living Donor Liver Transplantation. The VII International Congress of the Middle East Society for Organ Transplantation, Beirut, Lebanon, October 2000.
 61. Abouljoud M, Escobar F, Douzjdjian V, Bajjoka I, Moonka D, Shick L, Brown K. Recurrent disease after liver transplantation. The VII International Congress of the Middle East Society for Organ Transplantation, Beirut, Lebanon, October 2000.
 62. Abouljoud M, Escobar F, Douzjdjian V, Moonka D, Shick L, Brown K. Successful strategy for reducing biliary complications after liver transplantation. The VII International Congress of the Middle East Society for Organ Transplantation, Beirut, Lebanon, October 2000.
 63. Abouljoud M. for the OLN-452 Study Group. Conversion to Neoral provides effective rescue therapy for liver and kidney transplant patients intolerant of Prograf. Oral presentation. The 18th International Congress of the Transplantation Society. Rome, August, 2000.
 64. Douzjdjian V, Bajjoka I, Abouljoud M. Is it safe to perform the donor and recipient operations sequentially instead of simultaneously in living-donor kidney transplants? Oral presentation. The 19th Annual Meeting of the American Society of Transplantation. Chicago, May, 2000.
 65. Abouljoud M, Kumar MSA, Brayman K, Emre S, Bynon S. Conversion to Neoral provides effective rescue therapy for liver and kidney transplant patients intolerant of Prograf. Oral presentation. The 19th Annual Meeting of the American Society of Transplantation. Chicago, May, 2000.
 66. Douzjdjian V, Bajjoka I, Kupin W, Venkat KK, Escobar F, Abouljoud M. The impact of zero mismatched renal graft sharing: a single center experience. Oral presentation. The 32nd Annual Meeting of the American Society of Nephrology. November, 1999.

67. Douzjdjian V, Bajjoka I, Escobar F, Kupin W, Venkat KK, Abouljoud M. Effect of race on early renal graft function. Oral presentation. The 32nd Annual Meeting of the American Society of Nephrology. November, 1999.
68. Abouljoud M, Douzjdjian V. Strategies to increase living kidney donation. Oral presentation. The 3rd international meeting of the Arab American Medical Association. Beirut, Lebanon, June 1999.
69. Emre S, Abouljoud M for the OLN-452 Study Group. Conversion to Neoral provides effective rescue therapy for liver transplant patients intolerant of Prograf. An interim analysis of an ongoing prospective study. Oral presentation. The 18th Annual Meeting of the American Society of Transplantation. Chicago, May, 1999.
70. Douzjdjian V, Kupin W, Venkat KK, Goggins M, Escobar F, Abouljoud M. A comparison of risk factors for renal graft failure in Caucasians and African-Americans. Oral presentation. The 18th Annual Meeting of the American Society of Transplantation. Chicago, May, 1999.
71. Deshpande V, Burd E, Aardema K, Ma C, Moonka D, Brown K, Abouljoud M, Nakhleh R. Cholestatic hepatitis (CH) in liver allografts of hepatitis C (HCV) patients: histopathologic progression and correlation with HCV-RNA levels. Oral. The 18th Annual Meeting of the American Society of Transplantation. Chicago, May, 1999.
72. Gottschlich M, Aardema K, Burd E, Nakhleh R, Brown K, Abouljoud M, Moonka D. The use of hepatitis C viral RNA levels in liver tissue to distinguish rejection from recurrent hepatitis C. Oral presentation. The 18th Annual Meeting of the American Society of Transplantation. Chicago, May, 1999. Recipient of the Young Investigator Award. *Recipient of the Young Investigator Award.*
73. Bajjoka I, Douzjdjian V, Seng B, Habowski S, Abouljoud M. Low-dose OKT3 with Mycophenolate Mofetil versus Standard-Dose OKT3 without Mycophenolate Induction in High Risk Kidney Transplant Recipients. Oral presentation. American College of Clinical Pharmacy Annual Meeting. Cincinnati, Ohio, November 8-11, 1998.
74. Kupin W, Venkat KK, Goggins M, Douzjdjian V, Escobar F, Mozes M, Abouljoud M. Improved Outcome of Steroid Withdrawal in Mycophenolate Mofetil Treated Primary Cadaveric Renal Transplant Recipients. Oral presentation. The 17th World Congress of the Transplantation Society. Montreal, Canada, July 12-17, 1998.
75. Douzjdjian V, Escobar F, Kupin W, Venkat KK, Abouljoud M. Should a Living-Donor Kidney Transplant Take Priority Over Simultaneous Pancreas-Kidney Transplant? A Cost-Effectiveness Analysis. Oral presentation. The 24th Annual Meeting of the American Society of Transplant Surgeons. Chicago, May, 1998.
76. Kupin W, Venkat KK, Goggins M, Douzjdjian V, Escobar F, Mozes M, Abouljoud M. Transplantation without Steroids in 1-Haplotype and 2-Haplotype matched Living related Renal Transplant Recipients Treated with Mycophenolate Mofetil. Oral. The 17th Annual Meeting of the American Society of Transplant Physicians. Chicago, May, 1998.
77. Kupin W, Venkat KK, Goggins M, Douzjdjian V, Escobar F, Mozes M, Abouljoud M. Improved Outcome of Steroid Withdrawal in Mycophenolate Mofetil Treated Primary Cadaveric Renal Transplant Recipients. Oral presentation. The 17th Annual Meeting of the American Society of Transplant Physicians. Chicago, May, 1998.
78. Escobar F, Schwartz S, Elliott J, Abouljoud M. A Preliminary Study Comparing a New, "Hooded" vs. Conventional ePTFE Graft in Hemodialysis Patients. Oral. Vascular Access for Hemodialysis VI Symposium, May 7-8, 1998, Miami, Florida.

79. Kupin W, Venkat KK, Goggins M, Douzdjian V, Escobar F, Mozes M, Abouljoud M. Transplantation without Steroids in 1-Haplotype and 2-Haplotype matched Living related Renal Transplant Recipients Treated with Mycophenolate Mofetil. Oral presentation. The 17th World Congress of the Transplantation Society. Montreal, Canada, July 12-17, 1998.
80. Kupin W, Nakhleh R, Lee M, Venkat KK, Goggins M, Mozes M, Escobar F, Abouljoud M. Separate risk factors for the development of transplant glomerulopathy vs chronic tubulo-interstitial rejection. Oral presentation. Fifteenth annual meeting of the American Society of Transplant Physicians, Dallas, Texas, May 1996.
81. Abouljoud M, Brown K, May E, Baliad P, Escobar F, Mozes M. Cost-effective management of acute rejection in liver transplant recipients: a managed care perspective. Oral presentation. Fifteenth annual meeting of the American Society of Transplant Physicians, Dallas, Texas, May 1996.
82. Kupin W, Goggins M, Kim S, Venkat KK, Schoeppner H, Mozes M, Escobar F, Abouljoud M, Johnson C. Cholestatic hepatitis as a presenting feature of hepatitis C virus (HCV) infection in renal transplant recipients. Oral presentation. XIIIth International Congress of Nephrology, July 1995, Madrid, Spain.
83. Mulligan D, Goldstein R, Crippin J, Abouljoud M, Levy M, Husberg B, Gonwa T, Foster B, Klintmalm G. The use of anti-hepatitis C virus seropositive organs in liver transplantation. Oral presentation. Transplantation Society Meeting, August 28, 1994, Kyoto, Japan.
84. Abouljoud M, Levy M, Klintmalm G and the FK-506 U.S. Multicenter Study Group. Hyperlipidemia after liver transplantation: Long term Results of the FK-506/Cyclosporine a U.S. Multicenter Trial. Oral presentation. Transplantation Society Meeting, August 28, 1994, Kyoto, Japan.
85. Levy M, Jennings L, Abouljoud M, Mulligan D, Goldstein R, Husberg B, Gonwa T, Klintmalm G. Quality of life improvements one, two, and five years after liver transplantation. Oral presentation at the 13th annual meeting of the American Society of Transplant Physicians, May 16-18, 1994, Chicago.
86. Abouljoud M, Levy M, Mulligan D, Goldstein R, Husberg B, Gonwa T, Klintmalm G. Is transjugular intrahepatic portosystemic shunt preferable to distal splenorenal shunt in the management of refractory variceal bleeding prior to liver transplantation? Oral presentation at the 20th annual meeting of the American Society of Transplant Surgeons, May 18-20, 1994, Chicago.
87. Ranjan D, Abouljoud M, Poplawski S, Tennyson G, Hutton T. Analysis of liver biopsies in patients with hepatic allograft dysfunction in the absence of acute cellular rejection. Oral presentation. Congress of the International Liver Transplantation Society, October 1993, Toronto, Canada.
88. Abouljoud M, Deierhoi M, Hudson S, Diethelm A. Nephrectomy of primary renal allografts as a risk factor in re-transplant outcome. Oral presentation. Transplant Fellows meeting, New Orleans, April 1993.
89. Venkat KK, Abouljoud M, Kupin W, Mozes M. Longterm results and factors affecting success of corticosteroid withdrawal in cyclosporine and azathioprine treated primary cadaveric kidney transplant recipients. Oral presentation. The American Society of Transplant Physicians, May 1991.

90. Abouljoud M, Venkat KK, Kupin W, Mozes M. Longterm results after corticosteroid withdrawal in primary cadaveric renal transplant recipients. Oral presentation. NKF-ASN joint session, December 1990, Washington, DC. Detroit Surgical Society May 1991.

Poster Presentations (refereed)

1. Safwan M, Acho C, Morita Y, Fernandez V, Abouljoud M, Nagai S. Immediate Post-Operative Extubation Decreases Pulmonary Complications in Liver Transplantation Recipients. Poster presentation. AASLD Liver Disease Meeting Nov 9-13, 2018, San Francisco, CA.
2. Mohamed A, Safwan M, Abouljoud M, Nagai S. Recovery of Bowel Function after Liver Transplantation. Poster presentation. AASLD Liver Disease Meeting Nov 9-13, 2018, San Francisco, CA.
3. Nagai S, Safwan M, Rizzari M, Abouljoud M, Raoufi M, Sulejmani N, Ramesh M. Brincidofovir for Adenovirus Disease in Intestinal Transplant Patients. Poster presentation. XV International Congress of the Intestinal Rehabilitation & Transplant Association (CIRTA), Jun 28-Jul 1, 2017, New York, NY.
4. Nagai S, Rizzari M, Collins K, Yoshida A, Beltran N, Safwan M, Abouljoud M, Muszkat Y, Jafri S. Center Experience and Outcome of Intestinal Transplantation. Poster presentation. XV International Congress of the Intestinal Rehabilitation & Transplant Association (CIRTA), Jun 28-Jul 1, 2017, New York, NY.
5. Bajjoka-Francis I, Yaldo A, Crombez C, Abouljoud M. Long-Term Outcomes Among Slow Versus Delayed or Immediate Graft Function Kidney Transplant Recipients: A Single-Center Experience. Poster presentation. American Transplant Congress, Apr 29-May 3, 2017, Chicago, IL.
6. Bajjoka-Francis I, Yaldo A, Crombez C, Brown K, Abouljoud M. Long-Term Preservation of Renal Function in Liver Transplant Recipients with Rabbit Anti-Thymocyte Globulin Induction and Delayed Initiation of Calcineurin Inhibitors. Poster presentation. American Transplant Congress, Apr 29-May 3, 2017, Chicago, IL.
7. Puchakayala K, Skorupski S, Farhan S, Chaffins M, Safwan M, Pahari H, Collins K, Nagai S, Abouljoud M. Graft-Versus-Host Disease Following Deceased Donor Orthotopic Liver Transplant. Poster presentation. American Transplant Congress, Apr 29-May 3, 2017, Chicago, IL.
8. Safwan M, Abouljoud M, Salgia R. Outcome of Liver Transplantation in Patients with Prior Bariatric Surgery. Poster presentation. American Transplant Congress, Apr 29-May 3, 2017, Chicago, IL.
9. Safwan M, Nagai S, Takahashi K, Collins K, Puchakayala K, Rizzari M, Yoshida A, Abouljoud M. Is it Safe to use Older Donor Liver Grafts for Older Recipients? Poster presentation. American Transplant Congress, April 29-May 3, 2017, Chicago, IL.
10. Jesse M, Kulas M, Uritis J, Beltran N, Abouljoud M. Pilot Study on Acupuncture in Living Liver and Kidney Donors. Poster. American Transplant Congress, Apr 29-May 3, 2017, Chicago, IL.
11. Nagai S, Safwan M, Collins K, Rizzari M, Moonka D, Brown K, Patel A, Yoshida A, Abouljoud M. An Argument for Expanding the Simultaneous Liver and Kidney Transplant Criteria: Validity of the New UNOS Allocation Policy. Poster presentation. American Transplant Congress, Apr 29-May 3, 2017, Chicago, IL.

12. Nagai S, Safwan M, Collins K, Rizzari M, Moonka D, Patel A, Brown K, Abouljoud M. Rapid Deterioration of Pre-Transplant Kidney Function Requiring Dialysis is a Prognostic Factor in Liver Transplant Alone. Poster presentation. American Transplant Congress, Apr 29-May 3, 2017, Chicago, IL.
13. Nagai S, Safwan M, Collins K, Rizzari M, Yoshida A, Abouljoud M. Incidence of Outcomes of Immediate Post-Operative Dialysis in Liver Transplantation. Poster presentation. American Transplant Congress, Apr 29-May 3, 2017, Chicago, IL.
14. Takahashi K, Nagai S, Safwan M, Puchakayala K, Rizzari M, Collins K, Yoshida A, Schnickel G, Abouljoud M. Prolonged Cold Ischemia Time as a Risk for Low Regeneration at the Early Phase After Living Donor Liver Transplantation. Poster presentation. American Transplant Congress, Apr 29-May 3, 2017, Chicago, IL.
15. Takahashi K, Nagai S, Safwan M, Puchakayala K, Collins K, Rizzari M, Yoshida A, Abouljoud M, Jafri S. Lactate Level Immediate Post-Liver Transplantation is Predictor of Early Allograft Dysfunction. Poster presentation. American Transplant Congress, Apr 29-May 3, 2017, Chicago, IL.
16. Collins K, Thompson R, Puchakayala K, Malinzak L, Denny J, Rizzari M, Yoshida A, Nagai S, Kim D, Abouljoud M. Public Health Service Increased Risk (PHSIR) Kidneys: Outcomes and Establishing Best Practices. Poster. 17th Annual ASTS State of the Art Winter Symposium, Jan 26-29, 2017, Miami, FL.
17. Pahari H, Nagai S, Takahashi K, Tinney F, Puchakayala K, Malinzak L, Denny J, Rizzari M, Yoshida A, Collins K, Abouljoud M, Kim D. Risk Factors and 2 Year Outcomes of Low Estimated Glomerular Filtration Rate in the Immediate Post-Operative Period for Living Kidney Donors. Poster. 17th Annual ASTS State of the Art Winter Symposium, Jan 26-29, 2017, Miami, FL.
18. Tinney F, Yessayan L, Williamson S, Abouljoud M, Patel A. Characterization of Vascular Lesions in Living Donor Renal Transplant Implant Biopsies. Poster. 17th Annual ASTS State of the Art Winter Symposium, Jan 26-29, 2017, Miami, FL.
19. Takahashi K, Nagai S, Puchakayala K, Kane W, Safwan M, Rizzari M, Collins K, Yoshida A, Schnickel G, Abouljoud M. Multifactorial Risks for Low Regeneration of the Early Phase After Living Donor Liver Transplantation. Poster. 17th Annual ASTS State of the Art Winter Symposium, Jan 26-29, 2017, Miami, FL.
20. Nagai S, Takahashi K, Collins K, Puchakayala K, Safwan M, Rizzari M, Yoshida A, Abouljoud M. Is it Safe to Use Older Donor Liver Grafts for Older Recipients? 17th Annual ASTS State of the Art Winter Symposium, Jan 26-29, 2017, Miami, FL.
21. Safwan M, Yoshida A, Collins K, Rizzari M, Moonka D, Brown K, Patel A, Abouljoud M, Nagai S. An Argument for Expanding the Criteria for Simultaneous Liver and Kidney Transplant: Pre-Liver Transplant Glomerular Filtration Rate Less Than 30 mL/min for Greater Than 2 Weeks Has Worse Outcomes. Poster. 17th Annual ASTS State of the Art Winter Symposium, Jan 26-29, 2017, Miami, FL.
22. Safwan M, Abouljoud M, Salgia R. Outcome of Liver Transplantation in Patients with Prior Bariatric Surgery. Poster. 17th Annual ASTS State of the Art Winter Symposium, Jan 26-29, 2017, Miami, FL.
23. Puchakayala K, Nagai S, Safwan M, Takahashi K, Abouljoud M. Implementation of Operative Bundles May Decrease Complications. Poster. 17th Annual ASTS State of the Art Winter Symposium, Jan 26-29, 2017, Miami, FL.

24. Putchakayala K, Nagai S, Safwan M, Takahashi K, Abouljoud M. Implementation of Operative Bundles May Decrease Complications. Poster. 17th Annual ASTS State of the Art Winter Symposium, Jan 26-29, 2017, Miami, FL.
25. Putchakayala K, Zanini M, Takahashi K, Francis I, Abouljoud M. Hypercoagulability Persists up to 3 Months After Partial Hepatectomy. Poster. 17th Annual ASTS State of the Art Winter Symposium, Jan 26-29, 2017, Miami, FL.
26. Safwan M, Rizzari M, Collins K, Yoshida A, Skorupski S, Fagoaga O, Abouljoud M, Nagai S. Effect of Preformed Donor-Specific Antibodies in Intestine/Multivisceral Transplantation. Poster. 17th Annual ASTS State of the Art Winter Symposium, Jan 26-29, 2017, Miami, FL.
27. Safwan M, Ramesh M, Rizzari M, Collins K, Yoshida A, Sulejmani N, Abouljoud M, Nagai S. Brincidofovir for Adenovirus Disease in an Intestinal Transplant Patient. Poster. 17th Annual ASTS State of the Art Winter Symposium, Jan 26-29, 2017, Miami, FL.
28. Jesse M, Goldstein E, Rebhan N, Ho CX, Macaulay T, Bebanic M, Shkokani L, Moonka D, Abouljoud M, Yoshida A. Predicting Survival to Listing for Liver Transplantation: Do MELD and Race Interact? Poster. 2016 American Transplant Congress, June 11-15, 2016, Boston, MA.
29. Nagai S, Yoshida A, Rizzari M, Collins K, Kim D, Abouljoud M. Center and Surgeons' Experience Improves Outcome in Adult-to-Adult Living Donor Liver Transplantation: Validation of the Report of the A2ALL Consortium. Poster. 2016 American Transplant Congress, June 11-15, 2016, Boston, MA.
30. Takahashi K, Putchakayala K, Rizzari M, Collins K, Nagai S, Yoshida A, Abouljoud M, Schnickel G. Multifactorial Prediction of Biliary Stricture after Liver Transplantation: The Impact of Platelet Counts. Poster. 2016 American Transplant Congress. Poster. June 11-15, 2016, Boston, MA.
31. Jesse M, Abouljoud M, Eshelman A, DeReyck C, Leru J. American and European Transplant Surgeons: Research, Teaching, and Burnout. Poster. 2016 American Transplant Congress, June 11-15, 2016, Boston, MA.
32. Nagai S, Yoshida A, Rizzari M, Collins K, Kim D, Abouljoud M. Updated Experience of Living Donor Right Hepatectomy Using Mini-Incision Technique. Poster. 2016 American Transplant Congress, June 11-15, 2016, Boston, MA.
33. Takahashi K, Putchakayala K, Malinzak L, Denny J, Abouljoud M, Kim D. Is Ketorolac Really Safe for Donor Nephrectomy? Poster. 2016 American Transplant Congress, June 11-15, 2016, Boston, MA.
34. Putchakayala K, Kane W, Takahashi K, Rizzari M, Yoshida A, Abouljoud M. Left Renal Vein Ligation for Management of Portal Hypoperfusion in Liver Transplantation. Poster. 2016 American Transplant Congress, June 11-15, 2016, Boston, MA.
35. Jesse M, Goldstein E, Macaulay T, Rebhan N, Ho CX, Bebanic M, Shkokani L, Abouljoud M, Eshelman A, Yoshida A. Racial Disparities in Cognitive and Social Requirements Prior to Listing for Liver Transplant. Poster of Distinction. 2016 American Transplant Congress, June 11-15, 2016, Boston, MA.
36. Jesse M, Goldstein E, Rebhan N, Ho CX, Macaulay T, Bebanic M, Shkokani L, Moonka D, Abouljoud M, Yoshida A. Racial Disparities in the Evaluation for Liver Transplantation. Poster. 2016 American Transplant Congress, June 11-15, 2016, Boston, MA.
37. Tinney F, Yessayan L, Abouljoud M, Patel A. Characterization of Vascular Lesions in Living Donor Renal Transplant Implant Biopsies. Poster. 2016 American Transplant Congress, June 11-15, 2016, Boston, MA.

38. Vincenti F, Medina Pestana J, Abouljoud M, Bresnahan B, Duro Garcia V, Mulloy L, Rice K, Rostaing L, Zayas C, Calderon K, Meier-Kriesche U, Polinsky M, Zhao H, Larsen CP. Outcomes in Black vs. Non-Black Patients Administered Belatacept or Cyclosporine in BENEFIT. Poster. 2016 American Transplant Congress, June 11-15, 2016, Boston, MA.
39. Takahashi K, Putschakayala K, Malinzak L, Denny J, Yoshida A, Abouljoud M, Kim D. Is Ketorolac Really Safe for Living Donor Nephrectomy? Poster. 16th ASTS Annual State of the Art Winter Symposium. Jan 14-17, 2016, Miami Beach, FL.
40. Jesse M, Habra R, Mekaru S, Goldstein E, Eshelman A, Abouljoud M. Living Liver Donors: Disparity, Distress, and Sleep. Poster. The Liver Meeting®, American Association for the Study of Liver Diseases (AASLD), Nov 13-17, 2015, San Francisco, CA.
41. Takahashi K, Bruno D, Kazimi M, Yoshida A, Abouljoud M. Intrahepatic Cholangiocarcinoma in the Liver Explant after Liver Transplantation: What to do next? Poster. American Association for the Study of Liver Diseases (AASLD), Nov 13-17, 2015, San Francisco, CA.
42. Abouljoud M, Helderman J, Zhang R, Calderon K, Chen S, Rizk S, Gerber D. Home Infusion of Belatacept in Kidney Transplant Recipients. Vincenti F, Poster. ASN 2015 Kidney Week, November 3-8, 2015, San Diego, CA.
43. Jesse M, Abouljoud M, Eshelman A, Lerut J. Burnout in ESOT Surgeons. 17th Congress of the European Society for Organ Transplantation, ePoster. September 13-16, 2015, Brussels, Belgium.
44. Bhatti F, Jesse M, George K, Centala J, Ehrman J, Eshelman A, Abouljoud M, Brown K. Pilot Study on Safety and Feasibility of Complete Meal Replacement in Liver Transplant Recipients and Potential Donors. Poster. American Transplant Congress. May 2-6, 2015, Philadelphia, PA.
45. *Yip J, Bruno D, Burmeister C, Kazimi M, Yoshida A, Abouljoud M, Schnickel G. Deep Vein Thrombosis and Pulmonary Embolism in Liver Transplant Patients: Risks and Prevention. Poster Presentation, 15th Annual State of the Art Winter Symposium, American Society of Transplant Surgeons, Jan 15-18, 2015, Miami, FL.
46. *Takahashi K, Bruno D, *Tabbal M, Kazimi M, Yoshida A, Abouljoud M, Schnickel G. Platelet Count and Risk of Biliary Stricture after Liver Transplant. Poster Presentation, 15th Annual State of the Art Winter Symposium, American Society of Transplant Surgeons, Jan 15-18, 2015, Miami, FL.
47. Jesse M, Rubinstein E, Eshelman A, *Wee C, Tankasala M, Abouljoud M. Platelet Count and Risk of Biliary Stricture after Liver Transplant. Lifestyle & Self-Management by Those Who Live It: Patients Engaging Patients in a Chronic Disease Model. Poster Presentation, Institute for Healthcare Improvement 27th Annual National Forum, December 7-10, 2014, Orlando, FL.
48. Rubinstein E, Eshelman A, Tankasala M, Abouljoud M, Jesse M. Lifestyle & Self-Management by Those Who Live It: Patients Engaging Patients in a Chronic Disease Model. Poster Presentation, 5th Annual International Patient Safety Symposium, “The Patient Voice: Are We Listening”, Friday, November 21, 2014, Windsor, Ontario.
49. Rubinstein E, Eshelman A, Tankasala M, Abouljoud M, Jesse M. Lifestyle & Self-Management by Those Who Live It: Patients Engaging Patients in a Chronic Disease Model. Poster Presentation for Leadership Tour, Henry Ford Hospital Quality Exposition Forum, October 22-23, 2014, Henry Ford Hospital, Detroit, MI.

50. *Nagai S, Kohno K, Altshuler D, Nakamura M, Brown K, Abouljoud M, Moonka D. Peri-Transplant Absolute Lymphocyte Count as a Predictive Factor for Advanced Recurrence of Hepatitis C after Liver Transplantation. ASTS 2014 Vanguard Prize. Recognition Award Ceremony, ASTS 14th Annual State of the Art Winter Symposium. Poster of distinction. *Meeting the Challenges of Innovation*, January 23-26, 2014, Loews Miami Beach, Miami, FL.
51. *Theodoropoulos I, Schnickel G, *Nagai S, Bruno D, Kazimi M, Yoshida A, Abouljoud M. Sinusoidal Dilatation after Liver Transplant, a Predictor of HCV Recurrence? Poster (P-103) Presentation, ASTS 14th Annual State of the Art Winter Symposium *Meeting the Challenges of Innovation*, January 23-26, 2014, Loews Miami Beach, Miami, FL.
52. Zalawadia C, *Nagai S, *Salami A, Parekh R, Kuchipudi A, *Tabbal M, Nakamura M, Altshuler D, Peterson E, Raoufi M, Abouljoud M, Schnickel G, Brown K, Moonka D. Jafri S. Incidence, Outcome and Factors Affecting Post Liver Transplant Cholestatic Hepatitis. Digestive Disease Week 2014 December 3, 2013. Control ID 1902953.
53. *Theodoropoulos I, Schnickel G, *Nagai S, Bruno D, Kazimi M, Yoshida A, Abouljoud M. Sinusoidal Dilatation after Liver Transplant. A Predictor of Early HCV Recurrence? Poster presentation. AASLD 2013 Annual Meeting, November 1-5, Washington, DC.
54. *Nagai S, Schnickel G, *Theodoropoulos I, Bruno D, Kazimi M, Brown K, Yoshida A, Abouljoud M. Liver Transplantation for Patients with Pretransplant Undetectable Hepatitis C RNA: Can Eradication of Virus Guarantee Superior Outcome? Poster presentation. AASLD 2013, Control ID 1719020.
55. Patel A, Goggins M, Malinzak L, Karthikeyan V, Venkat KK, Denny J, Kim D, Abouljoud M. SCD Kidneys Defined by Age, But Associated with ECD-Defining Comorbidities Result in Inferior Recipient Outcomes. Poster Presentation, ATC Annual Meeting, Seattle, WA, May 18-22, 2013.
56. Patel A, Malinzak L, Goggins M, Karthikeyan V, Venkat KK, Abouljoud M. Effect of Donor Comorbidities on Patient Survival – Standard Criteria Donor Kidney Compared to Expanded Criteria Donor Kidney Transplantation. Poster Presentation, ATC Annual Meeting, Seattle, WA, May 18-22, 2013.
57. Sander Florman¹, Kim Rice², Larry Chan³, Rubin Zhang⁴, MarwanAbouljoud⁵, Steven Steinberg⁶, Thomas Pearson⁷, Lara Pupim⁸, FlavioVincenti⁹. 1Mt Sinai Medical Center, US; 2Baylor University Medical Center, US; 3University of Colorado, US; 4Tulane University, US; 5Henry Ford Hospital, US; 6Balboa Institute of Transplantation, US; 7Emory University, US; 8Bristol-Myers Squibb, US; 9University of California San Francisco Kidney Transplant Service, US. Outcomes at Five Years in Black/African-American Kidney Transplant Recipients from the Long-Term Extension of the Belatacept BENEFIT and BENEFIT-EXT Studies. Poster Presentation, ATC Annual Meeting, Seattle, WA, May 18-22, 2013.
58. Patel A, Goggins M, Malinzak L, Karthikeyan V, Venkat KK, Kim D, Denny J, Abouljoud M. Donor Comorbidities Rather Than Age Alone Determine Recipient Outcomes in “SCD” Kidney Transplants. Poster Presentation, ATC Annual Meeting, Seattle, WA, May 18-22, 2013.
59. *Nagai S, *Brown L, Kazimi M, Moonka D, Abouljoud M, Yoshida A. Peri-Transplant Lymphopenia is a Novel Prognostic Factor in Recurrence of Hepatocellular Carcinoma after Liver Transplantation. Poster Presentation, 63rd Annual AASLD Meeting, Boston, MA, November 9-13, 2012.

60. *Patil V, *Brown L, Kazimi M, Yoshida A, Abouljoud M. Trends in Postoperative Liver Function Recovery: A Comparison of Right Hepatectomy in Living Donor Liver Resections (LDLR) and Hepatobiliary Diseases (HPB). Poster Presentation, 24th International Congress of the Transplantation Society, Berlin, Germany, July 15-19, 2012.
61. Ramesh M, Bajjoka I, Abouljoud M, Goggins M, del Busto R, Patel A. Higher Incidence Rate of Clostridium Difficile Associated Diarrhea (CDAD) in Liver Transplant Recipients (LTR) Compared to General Surgery Patients (GS). Poster Presentation, ATC 2012 Annual Meeting, Boston, MA, June 2-6, 2012.
62. Abouljoud M, *El-Atrache M, Yoshida A, Kim D, Kazimi M, Moonka D, Brown K. Outcomes and Patterns of Recurrence of Hepatocellular Carcinoma after Liver Transplantation: A Single Center Experience. Poster Presentation, ASTS 12th Annual State of the Art Winter Symposium, Miami, Florida, January 12-15, 2012.
63. Patel H, Parekh R, Divine G, Abouljoud M, Batra S. Adult Living Donor Liver Transplantation – 10 Year Donor Safety Experience. Poster Presentation Named “AASLD Presidential Poster of Distinction”; 62nd Annual American Association for the Study of Liver Diseases, San Francisco, CA, November 4-8, 2011.
64. Denny J, Bajjoka I, Williams J, Miller J, Churchill D, Brown L, Patil V, Kim D, Malinzak L, Abouljoud M. Analysis of Young vs. Elderly Recipients of SCD Kidney transplants. Poster. Abstract 251917, ATC 2011 Meeting.
65. Bajjoka I, Abouljoud M, Williams J, Miller J, *Churchill D, *Brown L, *Patil V, Kim D, Malinzak L, Denny J. Analysis of Young vs. Elderly Recipients of a LRD/LURD Kidney Transplant. Poster. Abstract 251932, ATC 2011 Meeting.
66. Bajjoka I, Abouljoud M, Williams J, Miller J, *Churchill D, *Brown L, *Patil V, Kim D, Malinzak L, Denny J. Analysis of Young vs. Elderly Kidney Transplant Recipients. Poster. Abstract 251922, ATC 2011 Meeting.
67. Denny J, Bajjoka I, Williams J, Miller J, *Churchill D, *Brown L, *Patil V, Kim D, Malinzak L, Abouljoud M. Analysis of Young vs. Elderly White and Black Kidney Transplant Patients. Poster. Abstract 251925, ATC 2011 Meeting.
68. Smolinski S, Sturza S, Getzen T, Bernreuter K, Croteau D, Schwartz S, Abouljoud M, *El-Atrache M. Considerations in TIPS Post-Orthotopic Liver Transplant: Don't Forget the Hepatic Artery. Poster Presentation, The Society of Interventional Radiology, 36th Annual Scientific Meeting, Chicago, IL, March 26-31, 2011.
69. Eshelman A, Abouljoud M. Suicide in a Living Kidney Donor: Protocol Changes to Minimize Risk and Prevent a “Perfect Storm”. Abstract 2242, Poster Presentation, American Transplant Congress 2011, Philadelphia, PA, April 30-May 4, 2011.
70. Fleming J, Davis S, Chambers R, Hetterman B, Wang L, Hagopian J, Abouljoud M. Risk Factors of Hospital-Acquired and Multi-Drug Resistant Infections in Early Post-Liver Transplant. Abstract 251569, Poster Presentation, American Transplant Congress 2011, Philadelphia, PA, April 30-May 4, 2011.
71. Abouljoud M, Slater R. Reduction in Hypersplenism after Liver Transplantation is Independent of Caval Implantation Technique. ASTS 11th Annual State-of-the-Art Winter Symposium, Hollywood, Florida, Poster Presentation, January 13-16, 2011.
72. Eshelman A, Abouljoud M, *Meyer T, Fischer D, Moonka D, Paulson D, Brown K. Depression Level at Baseline Predicts Recovery Following Liver Transplantation. Poster Presentation, 57th Annual Meeting of the Academy of Psychosomatic Medicine, “Advancing

Psychosomatic Medicine Through Excellence in Education”, Marco Island, Florida, November 10-13, 2010.

73. Eshelman A, Abouljoud M, *Meyer T, Fischer D, Moonka D, Paulson D, Brown K. Emotional Closeness Predicts Improvement in Depression and Anxiety Following Liver Transplantation. Poster presentation. 11th International Congress of Behavioral Medicine, August 4-7, 2010, Washington, DC.
74. Rech M, Fleming J, Moore C, Patel A, Abouljoud M. Vitamin D Status at the Time of Transplant and with a 1 Year Follow-up. Poster Presentation, XXIII International Congress of the Transplantation Society, Vancouver, BC, Canada, August 15-19, 2010.
75. *Cheaito A, Abouljoud M, *El-Atrache M, Yoshida A, Kim D, Kazimi M, *Slater R, Brown K, Moonka D. Significance of Pre-Transplant Tumor Volume on Outcomes after Transplantation for Hepatocellular Carcinoma: Experience with 141 Patients. Poster Presentation, XXIII International Congress of the Transplantation Society, August 15-19, 2010, Vancouver, Canada.
76. Abouljoud M, *Cheaito A, *El-Atrache M, Yoshida A, Kim D, Kazimi M, *Slater R, Brown K, Moonka D. Effect of Preoperative RFA and TACE on Recurrence of Hepatocellular Carcinoma after Liver Transplantation. Poster Presentation, XXIII International Congress of the Transplantation Society, August 15-19, 2010, Vancouver, Canada.
77. Abouljoud M, *El-Atrache M, Yoshida A, Kim D, Kazimi M, *Slater R, Brown K, Moonka D. Patient Survival after Liver Transplantation for Hepatocellular Carcinoma: Single Center Experience with the Milan and Up-to-Seven Criteria. Poster Presentation, XXIII International Congress of the Transplantation Society, August 15-19, 2010, Vancouver, Canada.
78. Abouljoud M, *El-Atrache M, Yoshida A, Kim D, Kazimi M, *Slater R, Brown K, Moonka D. Validation of the Donor Risk Index in Predicting Long-Term Graft Survival after Liver Transplantation: A Single Center Experience. Poster Presentation, XXIII International Congress of the Transplantation Society, August 15-19, 2010, Vancouver, Canada.
79. Abouljoud M, *El-Atrache M, Yoshida A, Kim D, Kazimi M, *Slater R, Brown K, Moonka D, *Abou Abbass A, *Patil V. Significance of the Metabolic Syndrome after Orthotopic Liver Transplantation among Patients with NASH and Cryptogenic Cirrhosis. Poster Presentation, XXIII International Congress of the Transplantation Society, August 15-19, 2010, Vancouver, Canada.
80. *El-Atrache M, Abouljoud M, Sharma S, Yoshida A, Kim D, Kazimi M, *Slater R, Brown K, Moonka D, *Abou Abbass A, *Patil V. Transjugular Intrahepatic Portosystemic Shunt in Liver Transplant Recipients: Single Center Experience with 13 Patients. Poster Presentation, XXIII International Congress of the Transplantation Society, August 15-19, 2010, Vancouver, Canada.
81. *El-Atrache, M, Sharma S, Yoshida A, Kim D, Hundley J, Kazimi M, Brown K, Moonka D, Abouljoud, M. Transjugular Intrahepatic Portosystemic Shunt Following Liver Transplantation: Experience with 13 Patients. Poster Presentation, 9th World Congress of the IHPBA Meeting, Buenos Aires, Argentina, April 18-22, 2010.
82. Abouljoud M, *El-Atrache M, Yoshida A, Kim D, Hundley J, Kazimi M. Recurrence of Non-Alcoholic Steato-Hepatitis (NASH) and Cryptogenic Cirrhosis (CC) Following Liver Transplantation (LT) in the Context of Metabolic Syndrome. Oral and Poster Presentation, ASTS 10th Annual State of the Art Winter Symposium, Ft. Lauderdale, Florida, January 15-17, 2010.

83. *Cheaito A, Yoshida A, Brown K, Moonka D, Abouljoud M. Effect of RFA and Tace on Recurrence of Hepatocellular Carcinoma After Liver Transplantation: 8 Year Experience with 145 Patients. Poster Presentation, 60th Annual Meeting of the AASLD, Boston, MA, October 30-November 3, 2009.
84. *Cheaito A, Yoshida A, Brown K, Moonka D, Abouljoud M. Impact of Pre-Operative Tumor Volume and Staging of HCC on Transplant Outcomes: A Single Center Experience. Poster Presentation, 60th Annual Meeting of the AASLD, Boston, MA, October 30-November 3, 2009.
85. Raoufi M, Ma C, Ormsby A, Vakil H, Brown K, Huang M, Moonka D, Abouljoud M. The Role of Post-Reperfusion Biopsy in the Era of Extended Criteria Donor. Poster Presentation, International Liver Transplant Society, 15th Annual International Congress, New York, July 8-11, 2009.
86. *Abou Abbass A, Yoshida A, Kim D, *Slater R, Hundley J, Kazimi M, Moonka D, Abouljoud M. Biliary Complications after Orthotopic Liver Transplantation from Donors after Cardiac Death: Spectrum of Disease. Poster. ILTS 15th Annual International Congress, New York, NY, July 8-11, 2009.
87. *Slater R, Mossa-Basha F, *Abou Abbass A, Kapke A, Kim D, Abouljoud M, Yoshida A. The Impact of Surgeon Fatigue on Liver Transplant Outcomes. Poster Presentation, American Transplant Congress, Boston, MA, May 30-June 3, 2009.
88. Raoufi M, Ma C, Ormsby A, Vakil H, Brown K, Huang M, Moonka D, Abouljoud M. The Role of Post-Reperfusion Biopsy in the Era of Extended Criteria Donor: Clinicopathologic Correlation and Follow-up Analysis of 50 Liver Transplant Patients. Poster Presentation, United States and Canadian Association of Pathologists (USCAP), Boston, MA, March 7-13, 2009.
89. Raoufi M, Ma C, Ormsby A, Shah V, Brown K, Sherbondy M, Moonka D, Abouljoud M. Histologic Findings in Post-Reperfusion and Follow-up Biopsies in Liver Transplant Patients: Is There Any Correlation? Poster Presentation, The 2008 Joint International Congress of ILTS, ELITA and LICAGE, Paris, France, July 9-12, 2008.
90. Abouljoud M, Eshelman A, Yoshida A, Kim D, Brown K, Moonka D. Patient Survival Expectations after Liver Transplantation, Patient Selection, Insurance Contracts, and All That Jazz. Oral and Poster Presentation, Frontiers of Ethics in Transplantation: Dilemmas and Struggles, Chicago, Illinois, April 4-6, 2008.
91. Raoufi M, Ma C, Ormsby A, Shah V, Brown K, Sherbondy M, Moonka D, Abouljoud M. Histologic Findings in Post-Reperfusion and Follow-up Biopsies of Liver Transplant Patients: Is There Any Correlation? Oral and Poster Presentation, 8th American Hepatopancreatobiliary (AHPBA) Congress, Ft. Lauderdale, Florida, March 27-30, 2008.
92. Eshelman A, Abouljoud M, *Meyer T, Fischer D, Moonka D, Brown K. Cognitive Functioning and Quality of Life in End Stage Liver Disease. Poster Presentation, 2008 Annual Meeting and Scientific Session, Society of Behavioral Medicine, San Diego, California, March 26-29, 2008.
93. Raoufi M, Ma C, Ormsby A, Shah V, Brown K, Sherbondy M, Moonka D, Abouljoud M. Histologic Findings in Post-Reperfusion and Follow-up Biopsies of Liver Transplant Patients: Is There Any Correlation? Poster Presentation, 97th Annual Meeting of the United States and Canadian Academy of Pathology, Denver, Colorado, March 1-7, 2008.

94. *Al Harakeh A, Abouljoud M. Clinical Outcomes and Kidney Graft Survival after Combined Liver and Kidney Transplantation. Poster Presentation, ASTS Winter Symposium, Marco Island, Florida, January 25-27, 2008.
95. Kim D, Arun M, Parasuraman R, Yoshida A, Denny J, Malinzak L, *Al Harakeh A, *Slater R, Abouljoud M. Living Donor Older than 50 Years: Should They be Considered ECD? Poster presented at the ASTS 8th Annual State of the Art Winter Symposium, Marco Island, Florida, January 25-26, 2008.
96. Abouljoud M, Kaseb A. A 10-Year Retrospective Analysis of Risk Factors, Patterns of Cancer Recurrence, and Survival Post Liver Transplant for Cirrhosis and Hepatocellular Carcinoma. Poster Presentation, International Liver Cancer Association, Barcelona, Spain, October 5-7, 2007.
97. Parasuraman R, Gonik N, Kim D, Abouljoud M, Venkat KK. Role of Microscopic Hematuria in the Evaluation of Urological Malignancy in Renal Transplant Recipients – A Single Center Experience. Poster presented at the 13th Annual ESOT Meeting, September 2007, Prague.
98. Kaseb A, Abouljoud M. A 10-Year Retrospective Analysis of Risk Factors, Patterns of Cancer Recurrence, and Survival after Liver Transplant for Cirrhosis and Hepatocellular Carcinoma. Poster Presentation. 2007 ASCO Annual Meeting, Chicago, Illinois, June 1-5, 2007.
99. Kaseb A, Abouljoud M. A 10-Year Retrospective Analysis of Cancer Recurrence after Incidental Diagnosis of Hepatocellular Carcinoma at the Time of Liver Transplant for Cirrhosis. Poster Presentation. ASCO GI Cancer Symposium, Orlando, Florida, January 19-21, 2007.
100. *Kwon D, *Almarastani M, *Al Harakeh A, Yoshida A, Arenas J, Denny J, Parasuraman R, Abouljoud M, Kim D. Does Increasing Cold Ischemia Time Affect Kidney Function After Laparoscopic Live Donor Nephrectomy? Poster Presentation. ASTS Winter Symposium, Marco Island, Florida, January 11-14, 2007.
101. *Almarastani M, Arenas J, Kim D, Yoshida A, Al Harakeh A, Raoufi R, Abouljoud M. Clinical Outcomes After Liver Transplantation (OLT) from Extended Criteria Donors (ECD) Are Comparable to Those From Standard Criteria Donors (SCD). Poster Presentation. ASTS Winter Symposium, Marco Island, Florida, January 11-14, 2007.
102. *Almarastani M, Sherbondy M, Brown K, Moonka D, Gordon S, Arenas J, Kim D, Yoshida A, Malinzak L, Raoufi M, Abouljoud M. Recurrent Disease after Liver Transplantation (OLT) for Non-alcoholic Steato-hepatitis (NASH) AND Cryptogenic Cirrhosis (CC): A Cause for Concern. Poster Presentation, 57th Annual AASLD Meeting, Boston, Massachusetts, October 27-31, 2006.
103. Hegeman R, Bajjoka I, Hsaiky L, Parasuraman R, Abouljoud M. A Single Center Comparison between Two Antiviral Prophylaxis Regimens for the Prevention of Cytomegalovirus in Kidney Transplant Mis-Match Patients. Poster Presentation, World Transplant Congress, Boston, Massachusetts, July 22-27, 2006.
104. *Cheaito A, Abouljoud M, Arenas J, Yoshida A, Craig B, Malinzak L, *Almarastani M, Kim D. Sonographic Differences in Venous Return Between Piggyback versus Caval Interposition after Adult Liver Transplantations. Poster Presentation, World Transplant Congreso, Boston, Massachusetts, July 22-27, 2006.
105. Kim D, Lim C, Parasuraman R, Raoufi M, Arenas J, Yoshida A, Denny J, Malinzak L, *Almarastani M, Moonka D, Brown K, Sherbondy M, Gordon S, Abouljoud M. Renal

- Disease Burden Following Liver Transplantation. Poster Presentation, World Transplant Congress, Boston, Massachusetts, July 22-27, 2006.
106. Malinzak L, Kim D, Abouljoud M, *Almarastani M, Yoshida A, Arenas J. Redo Orthotopic Liver Transplantation for Complications of Hepatic Artery Thrombosis: A High Risk Arterial Anastomosis. Poster Presentation, World Transplant Congress, Boston, Massachusetts, July 22-27, 2006.
 107. Hsaiky L, Bajjoka I, Hegeman R, Brown K, Abouljoud M. Safety and Efficacy of Enteric-Coated Mycophenolate Sodium in Liver Transplant Recipients. Poster presentation, World Transplant Congress, July 22-27, 2006.
 108. Lambing A., Abouljoud M., Kuriakose P. Living Liver Donor Thrombotic Risk. Poster Presentation, World Transplant Congress, Boston, Massachusetts, July 22-27, 2006.
 109. *Meyer T, Abouljoud M. Impaired Cognitive Functioning in a Large Sample of Liver Transplant Candidates. Poster of Distinction Presentation at the Digestive Disease Week (AASLD), Los Angeles, CA, May 20-25, 2006
 110. Abouljoud M, *Bansal A, Arenas J, Yoshida A, Kim D. Rex Shunt – A Treatment Option for Extrahepatic Portal Thrombosis in Adults. Poster Presentation at the 2006 AHPBA Annual Meeting, Miami, FL, March 9-12, 2006.
 111. Abouljoud M, Arenas J, Yoshida A, Kim D. Laparoscopic Major Liver Resections using a Bipolar Vapor Pulse Coagulation System. Poster Presentation at the 2006 AHPBA Annual Meeting, Miami, FL, March 9-12, 2006.
 112. *Meyer T, Crittenden K, Eshelman A, Abouljoud M. Preliminary Analysis of Cognitive Functioning in a Large Sample of Liver Transplant Candidates. Poster Presentation at the American Psychosomatic Society, Denver, CO, March 1-4, 2006
 113. Abouljoud M, Eshelman A, Raoufi M, Bertges-Yost W. Strategies to Reduce Burnout among Transplant Surgeons in North America. Poster. The American Transplant Congress 2005, Seattle, WA, May 21-25, 2005.
 114. Kim D, Bazzi W, Raoufi M, Brown K, Yoshida A, Arenas J, Jerius J, Moonka D, Neece S, Hogan K, Abouljoud M. Impact of Hepatitis C in Resource Utilization following Orthotopic Liver Transplantation. Poster. The American Transplant Congress 2005, Seattle, WA, May 21-25, 2005.
 115. Parasuraman R, Ahmed J, Shah V, Malinzak L, Karthikeyan V, Patel A, Ortigosa-Goggins M, Kim D, Arenas J, Jerius J, Yoshida A, Venkat KK, Abouljoud M. Race is not a Deterrent for Living Unrelated Kidney Donation: A Single Center Experience. Poster presented at the American Transplant Congress 2005, Seattle, WA, May 21-25, 2005
 116. Ahmed J, Shah V, Malinzak L, Karthikeyan V, Patel A, Ortigosa-Goggins M, Arenas J, Kim D, Jerius J, Abouljoud M, Yoshida A, Venkat KK, Parasuraman R. Comparison of the Increase in Serum Creatinine Post Kidney Donation between African American and Caucasian Donors. Poster presented at the American Transplant Congress 2005, Seattle, WA, May 21-25, 2005
 117. Hsaiky L, Bajjoka I, Kim D, Dingle R, Yoshida A, Jerius J, Arenas J, Abouljoud M. The Use of Metformin in Liver Transplant Recipients. Poster presented at the American Transplant Congress 2005, Seattle, WA, May 21-25, 2005
 118. Abouljoud M, Yoshida A, Kim D, Jerius J. Safety and Efficacy of Bioglue in Preventing Bile Leakage after Major Liver Resections. Poster presentation. 6th World Congress of the International Hepato-Pancreato-Biliary Association, June 2-6, 2004, Washington, DC.

119. Abouljoud M, Yoshida A, Kim D, Moonka D, Brown K. Patterns of recurrence after radiofrequency ablation therapy for hepatocellular carcinoma. Poster. AASLD Clinical Research Single Topic Symposium, Atlanta, Georgia, September 19-21, 2003.
120. Abouljoud M, Yoshida A, Moonka D, Croteau, McVinnie D, Sharma R, Brown K. Favorable outcomes after selective use of transjugular intrahepatic portosystemic shunts following liver transplantation. Poster. 54th Annual Meeting of the AASLD, Boston, Massachusetts October 24 - 28, 2003.
121. Abiodum O, Yoshida A, Brown K, Abouljoud M, Ma C, Dagher F, Moonka D. Sensitivity and specificity of liver biopsy in the diagnosis of hepatic artery ischemia in liver transplant patients. Poster presentation. American Transplant Congress 2003, Washington DC, May 2003.
122. Dagher F, Berri R, Yoshida A, Brown K, Moonka D, Bajjoka I, Abouljoud M. Detection of multifocal hepatocellular carcinoma in patients undergoing liver transplantation: are current screening studies reliable? Poster. American Transplant Congress 2003, Washington DC, May 2003.
123. Abouljoud M, Yoshida A, Dagher F, Moonka D, Brown K. Experience with recipient splenic artery inflow in adult liver transplantation. Poster. Seventh Congress of the International Liver Transplantation Society, Barcelona, July, 2003.
124. Abouljoud M, Yoshida A, Dagher F, Bajjoka I, Moonka D, Brown K. Thrombotic thrombocytopenic purpura after liver transplantation with tacrolimus based immunosuppression. Poster. Seventh Congress of the International Liver Transplantation Society, Barcelona, July, 2003.
125. Abouljoud M, Raoufi M, Yoshida A, Dagher F, Moonka D, Brown K. Aberrant arterial anatomy is not associated with higher arterial complications in liver transplantation. Poster. 2003 America's Hepato-Pancreato-Biliary Congress (AHPBA). Miami, 2003.
126. *Rabinovich A, Abouljoud M, Yoshida A, Bajjoka I, Moonka D, Brown L, Dagher F. Role of percutaneous transluminal angioplasty in the treatment of hepatic artery stenosis after liver transplantation. Poster. The 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November, 2002.
127. Cochrane A, Bajjoka I, Dagher F, Yoshida A, Abouljoud A. Changing patterns of infection after liver transplantation. Poster. Eighth Congress of the International Liver Transplantation Society, Chicago, June 13, 2002.
128. Karthikeyan V, Goggins M, Jasti J, Venkat KK, Abouljoud M, Zasuwa G, Yoshida A. Steroid Avoidance in two haplotype matched renal transplant recipients: analysis of long-term graft survival. Poster. American Transplant Congress 2002, Washington, DC, April 2002.
129. Karthikeyan V, Vera E, Parasuraman R, Abouljoud M, Goggins M, Venkat KK. Outcome of plasma exchange therapy in calcineurin inhibitor associated thrombotic microangiopathy in renal transplant recipients. Poster. American Transplant Congress 2002, Washington, DC, April 2002.
130. Bajjoka I, Truong K, Francis K, Hogan K, Cochrane A, Dagher F, Yoshida A, Abouljoud M. Common equations used for estimating creatinine clearance do not accurately predict renal function following liver transplantation. Poster. Transplant Congress 2002, Washington, DC, April 2002.

131. Yoshida A, Hogan K, Dagher F, Moonka D, Brown K, Wong D, Abouljoud M. Endoscopic intervention for biliary complications post-transplant, is it effective. Poster. American Transplant Congress 2002, Washington, DC, April 2002.
132. Quereshi H, Ma C, Brown K, Moonka D, Abouljoud M, Nakhleh R. Fulminant hepatic failure (FHF): clinical pathologic Study of eleven cases treated with orthotopic liver transplantation. Poster. 91st Annual Meeting of the United States and Canadian Academy of Pathology, Chicago, March 2002.
133. Perveen N, Ma C, Brown K, Moonka D, Abouljoud M, Nakhleh R. Clinical pathologic study of 22 patients with cirrhosis and hepatocellular carcinoma treated with orthotopic liver transplantation. Poster. 91st Annual Meeting of the United States and Canadian Academy of Pathology, Chicago, March 2002.
134. *Morris D, *Anagnostopoulos P, *Pipinos I, Escobar F, Abouljoud M. Veno-venous bypass of central occlusions for salvaging hemodialysis grafts and fistulae: Long-term results. Poster. Vascular Access VII Symposium, San Antonio, May, 2000.
135. *Lacka E, *Feczko P, Abouljoud M. Radiofrequency ablation of liver tumors: use of MRI to evaluate efficacy. Poster. Society of Abdominal Radiologists Meeting, Phoenix, AZ, March, 2001.
136. Brown K, Thomas M, Nakhleh R, Abouljoud M, Moonka D. Cost-effectiveness and sensitivity of screening strategies for hepatocellular carcinoma and portal vein thrombosis in liver transplant candidates. Poster. First Joint Meeting of the AST and ASTS, Chicago, May 2000.
137. Bajjoka I, Francis K, Douzdjian V, Brown K, Moonka D, Abouljoud M. Peptic ulcer disease in liver transplantation is infrequently due to Helicobacter Pylori. Poster. First Joint Meeting of the AST and ASTS, Chicago, May 2000.
138. Douzdjian V, Kukuruga D, Bajjoka I, Abouljoud MS. The impact of duffy blood type on renal allograft survival in African Americans. Poster. The 19th Annual Meeting of the American Society of Transplantation. Chicago, May, 2000.
139. Garnick J, Bajjoka I, Douzdjian V, Kupin W, Abouljoud M. The pharmacokinetic effects of sildenafil (Viagra) on tacrolimus (Prograf) blood concentrations. The 19th Annual Meeting of the American Society of Transplantation. Chicago, May, 2000.
140. *Morris D, Velanovich V, Abouljoud MS. Radiofrequency ablation of liver neoplasms: early experience. Poster. SAGES 2000 meeting, Atlanta, March-April, 2000.
141. Douzdjian V, Kupin W, Venkat KK, Escobar F, Abouljoud M. Simultaneous vs sequential donor-recipient operations in living donor kidney transplants. Poster. The 32nd Annual Meeting of the American Society of Nephrology. November, 1999.
142. Bajjoka I, Douzdjian V, *Gottschlich M, Porter W, Amin N, May E, Brown K, Moonka D, Escobar F, Abouljoud M. Erythromycin breath test as an indicator of Tacrolimus safety and efficacy. Poster. The 50th Annual Meeting of the American Association for the Study of Liver Diseases. Dallas, November, 1999.
143. Abouljoud M, *Kabbani L, Douzdjian V, Escobar F, Moonka D, Brown K. Impact of the current liver allocation system on outcome parameters: a single center perspective. Poster. The 50th Annual Meeting of the American Association for the Study of Liver Diseases. Dallas, November, 1999.
144. Bajjoka I, Douzdjian V, Amin N, May E, Brown K, Moonka D, Escobar F, Abouljoud M. Tacrolimus pharmacokinetic and pharmacodynamic changes in liver transplant recipients.

- Poster. The 18th Annual Meeting of the American Society of Transplantation. Chicago, May, 1999.
145. Douzajian V, Kupin W, Venkat KK, Goggins M, Escobar F, Abouljoud M. Race effect in living-related donor kidney transplants. Poster. The 18th Annual Meeting of the American Society of Transplantation. Chicago, May, 1999.
 146. Kupin W, Venkat KK, Douzajian V, Escobar F, Abouljoud M. Socioeconomic and racial risk factors influencing early listing for renal transplantation. Poster. The 18th Annual Meeting of the American Society of Transplantation. Chicago, May, 1999.
 147. Ardema K, Nakhleh R, Terry L, Burd E, Ma C, Moonka D, Brown K, Abouljoud M. Quantitation of Hepatitis C Virus RNA in Liver Tissue of Allografts: Correlation with Histologic Features and Liver Function Tests. Poster. The 17th World Congress of the Transplantation Society. Montreal, Canada, July 12-17, 1998.
 148. Douzajian V, Escobar F, Kupin W, Venkat KK, Abouljoud M. Should a Living-Donor Kidney Transplant Take Priority over Simultaneous Pancreas-Kidney Transplant? A Cost-Effectiveness Analysis. Poster. The 17th World Congress of the Transplantation Society. Montreal, Canada, July 12-17, 1998.
 149. Ardema K, Nakhleh R, Terry L, Burd E, Ma C, Moonka D, Brown K, Abouljoud M. Quantitation of Hepatitis C Virus RNA in Liver Tissue of Allografts: Correlation with Histologic Features and Liver Function Tests. Poster. The 17th Annual Meeting of the American Society of Transplant Physicians. Chicago, May, 1998.
 150. Bajjoka I, Baliad P, Brown K, May E, Escobar F, Mozes M, Abouljoud M. Intravenous versus oral ganciclovir in the prevention of CMV infection and disease in liver transplant recipients. Poster. The 48th Annual Meeting of the American Association for the Study of Liver Diseases. Chicago, November, 1997.
 151. Abouljoud M, Nakhleh R, Escobar F, Mozes M. The fate of arterial vascular conduits preserved in viral culture media: an anatomic study. Poster. Fourth Congress of the International Liver Transplantation Society, Seattle, October, 1997.
 152. Kupin W, Venkat KK, Goggins M, Mozes M, Escobar F, Abouljoud M. Incidence and Risk Factors for Renal Allograft Nephrectomy Prior to and After 6 Months Post-transplant. Poster. Sixteenth Annual Meeting of the American Society of Transplant Physicians, Chicago, May, 1997.
 153. Kupin W, Venkat KK, Goggins M, Mozes M, Abouljoud M, Escobar F. Elective Conversion of Sandimmune to Neoral in Stable Renal Transplant Recipients. Poster. Sixteenth Annual Meeting of the American Society of Transplant Physicians, Chicago, May, 1997.
 154. Kupin W, Parasuraman R, Venkat KK, Goggins M, Mozes M, Escobar F, Abouljoud M. Colchicine-Cyclosporine Interaction in Renal Transplant Recipients. Poster. Sixteenth Annual Meeting of the American Society of Transplant Physicians, Chicago, May, 1997.
 155. May E, Brown K, Hocking N, Mozes M, Abouljoud M. Successful long-term cholesterol reduction using HMG CoA reductase inhibitors in liver transplant recipients. Poster. Forty-seventh Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, November, 1996.
 156. Abouljoud M, Baliad P, Hocking N, Brown K, May E, Escobar F, Mozes MF. Managed care strategies in liver transplantation: is there a clinical benefit? Poster. Forty-seventh Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, November, 1996.

157. Kupin W, Venkat KK, Goggins M, Mozes M, Escobar F, Abouljoud M. Benefit of angiotensin II receptor blockade in the treatment of post-transplant polycythemia in renal transplant recipients. Poster. Sixteenth International Congress of the Transplantation Society, Barcelona, Spain, August, 1996.
158. Kupin W, Nakhleh R, Lee M, Venkat KK, Goggins M, Mozes M, Escobar F, Abouljoud M. Separate risk factors for the development of transplant glomerulopathy vs chronic tubulo-interstitial rejection. Poster. Sixteenth International Congress of the Transplantation Society, Barcelona, Spain, August, 1996.
159. Abouljoud M, Brown K, May E, Baliad P, Escobar F, Mozes M. Cost-effective management of acute rejection in liver transplant recipients: a managed care perspective. Poster. Sixteenth International Congress of the Transplantation Society, Barcelona, Spain, August, 1996.
160. Podila P, Abouljoud M, Peterson C, Batra S, Brown K. Focal nodular hyperplasia and nodular transformation of the liver associated with congenital porto-caval shunt and progression to hepatocellular carcinoma. Poster. Sixty first Annual Scientific Meeting of the American College of Gastroenterology, Seattle, Washington, October, 1996.
161. Podila P, Nattakom T, Abouljoud M, Brown K. FK 506 associated thrombotic thrombocytopenic purpura following liver transplantation. Poster. Sixty first Annual Scientific Meeting of the American College of Gastroenterology, Seattle, Washington, October, 1996.
162. Kupin W, Venkat KK, Goggins M, Mozes M, Escobar F, Abouljoud M. Benefit of angiotensin II receptor blockade in the treatment of post-transplant polycythemia in renal transplant recipients. Poster. Fifteenth annual meeting of the American Society of Transplant Physicians, Dallas, Texas, May 1996.
163. Podila P, Abouljoud M, Peterson C, Brown K. Focal nodular hyperplasia and nodular transformation of the liver associated with congenital porto-caval shunt and progression to hepatocellular carcinoma. Poster presentation. American College of Gastroenterology Forum, Scottsdale, Arizona, April 1996.
164. Kupin W, Goggins M, Kim S, Venkat KK, Schoeppner H, Mozes M, Escobar F, Abouljoud M, Johnson C. Cholestatic hepatitis as a presenting feature of hepatitis C virus (HCV) infection in renal transplant recipients. Poster presentation. Fourteenth annual meeting of the American Society of Transplant Physicians, Chicago, May 1995.
165. Abouljoud M, Levy M, Goldstein R, Mulligan D, Husberg B, Gonwa T, Crippin J, Klintmalm G. Hyperlipidemia after liver transplantation: A randomized study of FK-506 versus Cyclosporine A. Poster presented at the 13th annual meeting of the American Society of Transplant Physicians, May 16-18, 1994, Chicago.
166. Mulligan D, Goldstein R, Levy M, Abouljoud M, Husberg B, Gonwa T, Stone M, Klintmalm G. Liver transplantation for hepatocellular carcinoma: A comparison of outcomes between patients treated with neoadjuvant chemotherapy pre-OLTx and those with incidental hepatomas. Poster at the 45th annual meeting of the AASLD, November 11-15, Chicago, Illinois.
167. Mulligan D, Levy M, Schreimann K, Morphew C, Abouljoud M, Goldstein R, Husberg B, Gonwa T, Klintmalm G. The fate of liver offers declined by a single transplant center: A case study of 543 cases. Poster at the 45th annual meeting of the AASLD, November 11-15, Chicago, Illinois.

168. Mulligan D, Goldstein R, Crippin J, Abouljoud M, Levy M, Husberg B, Gonwa T, Foster B, Klintmalm G. The use of anti-hepatitis C virus seropositive organs in liver transplantation. Poster at the 45th annual meeting of the AASLD, November 11-15, Chicago, Illinois.

Other (Videos)

1. Abouljoud M. Resection of Portal and Superior Mesenteric Vein Aneurysm with Reconstruction Using PTFE. Video Presentation at 9th World Congress of the International Hepato-Pancreato-Biliary Association Meeting, Buenos Aires, Argentina, April 18-22, 2010.
2. Abouljoud M. Laparoscopic Living Donor Liver Transplantation. Video Presentation at the American Hepato-Pancreato-Biliary Association 2009 Annual Meeting, Miami Beach, Florida, March 12-15, 2009.
3. Abouljoud M. Robot Assisted Left Hepatic Sarterectomy. Video Presentation at the American Hepato-Pancreato-Biliary Association 2008 Annual Meeting, Ft. Lauderdale, Florida, March 27-30, 2008.
4. Abouljoud M. Laparoscopic Left Lateral Segmentectomy using Vapor Pulse Coagulation System. Video Presentation at the 2006 AHPBA Annual Meeting, Miami, FL, March 9-12, 2006.

PRESENTATIONS:

Invited and/or Refereed International or National Meetings:

1. Master Class in Liver Disease (MCLD), 10th Annual Symposium. Invited Speaker. Dr. Rela Institute & Medical Centre, Chennai, India, Mar 1-2, 2019.
2. 12th Annual ASTS Fellows Symposium. "Resilience and Work-Life Interactions: A Primer". Oct 5-7, 2018, Grapevine, TX.
3. 24th Annual Practice of Transplant Administration: Organ Transplantation: The Physician Leadership Imperative, Transplant Management Group. "Leadership Redux: Experiential Reflections in Transplantation". September 6-7, 2018, San Diego, CA
4. ASTS 2017 Program Director Meeting. "Transplant Accreditation & Certification". Nov 3, 2017, Chicago, IL.
5. ASTS 2017 Program Director Meeting. "Managed Time Policy". Nov 3, 2017, Chicago, IL.
6. ASTS 2017 Program Director Meeting. "Panel Q&A". Nov 3, 2017, Chicago, IL.
7. Association of Psychologists in Academic Health Centers 8th Annual National Conference, Promoting Psychology in the Evolving Healthcare Landscape: Enhancing the Well-Being of Patients, Providers, and Populations. "Leadership Perspectives on Integrating Psychologists in Clinical Departments: Evolving Paradigm". March 9-11, 2017, Detroit, MI.
8. Association of Psychologists in Academic Health Centers 8th Annual National Conference, Promoting Psychology in the Evolving Healthcare Landscape: Enhancing the Well-Being of Patients, Providers, and Populations. "Perspectives on Healthcare Provider Wellbeing: A Call to Action". March 9-11, 2017, Detroit, MI.
9. ASTS 17th Annual State of the Art Winter Symposium, Organ Donation 2.0: Turning Ideas into Action. "Career Mentorship for All Ages". January 26-29, 2017, Loews, Miami Beach, Florida.

10. 11th Annual Academic Surgical Congress. Invited Speaker, Hot Topic Session #1 “Departments, Centers, Institutes, and Service Lines: What does it all mean?” February 2-4, 2016, Jacksonville, FL.
11. ASTS 16th Annual State of the Art Winter Symposium: Limited Supply, Increasing Demand: Expanding Organ Donation. Invited Speaker, “Transplant Techniques in HPB Surgery”. January 14-17, 2016, Loews, Miami Beach, Florida.
12. Frontiers in Organ Failure and Transplant Management, Invited Faculty/Speaker, “Resilience in Medicine: Transplant Provider Experience”. November 19-21, 2015, Houston Methodist, Houston, TX.
13. TMG 21st “The Practice of Transplant Administration” Workshop. Invited Speaker, “Transplant Physician Compensation: How to Account for Non-Billable Work”. Oct 1-2, 2015, San Diego, CA.
14. National Medical Association, “Perspectives in Living Liver Transplantation”, August 1-5, 2015, Cobo Center, Detroit, MI.
15. Houston Surgical Society, “Resilience in Surgical Practice”, May 12, 2015, Houston, TX.
16. 7th International Conference on Health Issues in Arab Communities. Invited Speaker and Session Co-Chair, “Organ Donation and Allocation in the United States”. March 1-7, 2015, Al Bustan Palace, Muscat, the Sultanate of Oman.
17. ASTS 15th Annual State of the Art Winter Symposium, “Transplant: The Ultimate Team Sport”. Invited Expert Panelist and Speaker, “Career Development Seminar”, “Transplant Surgeon Pay”. January 15-18, 2015, Loews, Miami Beach, Florida.
18. ASTS 15th Annual State of the Art Winter Symposium, “Transplant: The Ultimate Team Sport”. Invited Speaker, “Creating the Home Field Advantage – Teamwork in the OR”. January 15-18, 2015, Loews, Miami Beach, Florida.
19. ASTS Advanced Leadership Development Program, Part III. American Society of Transplant Surgeons Closing Session, Faculty, Planning Committee, Presenter. San Francisco, CA, July 27, 2014, in conjunction with the World Transplant Congress.
20. ASTS Advanced Leadership Development Program, Part II. American Society of Transplant Surgeons, Four-part interactive Webinar Series. Faculty, Planning Committee, Presenter. Webinar #3 “Staff Development/Mentorship: How to Grow Clinical and Administrative Leaders”. January 16, 2014.
21. ASTS 14th Annual Winter Symposium: Meeting the Challenges of Innovation. Moderator: The OR: Past, Present, Future, January 23-26, 2014, Loews Miami Beach, Miami, FL.
22. ASTS Advanced Leadership Development Program, Part I. American Society of Transplant Surgeons, “Cultivating Innovative and Effective Leadership within a Complex Medical Environment”. Planning Committee, Faculty and presented 2 lectures: “Competing in a World of Accountable Care Organizations (ACO) and Value-Based Purchasing (VBP)” and “Approaches to Compensating the Incentivizing Transplant Professionals”. Kellogg School of Management, Evanston, IL, April 28-30, 2013.
23. Invited Guest Speaker. American Medical Group Association 2013 Annual Conference. Orlando, FL, March 14-16, 2013.
24. Management of Liver Cancer in the Era of Liver Transplantation. University of Kentucky Health Care, Department of Surgery Grand Rounds, Invited Visiting Professor, Lexington, Kentucky, 4/3/2012-4/4/2012.

25. How to Turn an Urban Program Around. Cleveland Clinic, “Emerging Issues in Organ Transplantation, A Colloquium”. Invited Guest Faculty/Presenter. InterContinental Hotel and Conference Center, Cleveland, OH, October 14-15, 2011.
26. Improving or Sustaining Renal Function Over 3 Years with Belatacept or Cyclosporine A (CsA): Insights from the Benefit Study. ESOT Congress, Glasgow, September 4-7, 2011.
27. Beverly & Wilshire: The Expensive Transplant Candidate. ASTS 11th Annual State of the Art Winter Symposium. Hollywood, FL, January 13-16, 2011.
28. Innovative Approaches to Compensating and Incentivizing the Transplant Professional: The Virtual RVU. ASTS 11th Annual State of the Art Winter Symposium. Hollywood, FL, January 13-16, 2011.
29. Transplant Centers, Institutes and Institutional Relationships. The ASTS Leadership Development Program, Northwestern University Kellogg School of Management James L. Allen Center in Evanston, IL, November 7-9, 2010.
30. Commentator: Laparoscopic & Robotic HPB Poster Session. The 9th World Congress of the International Hepato-Pancreato-Biliary Association Meeting. Buenos Aires, Argentina, April 18-22, 2010.
31. Left Hepatectomy, Laparoscopic Liver Surgery. The 9th World Congress of the International Hepato-Pancreato-Biliary Association Meeting. Buenos Aires, Argentina, April 18-22, 2010.
32. Transplant Contracting: How Do You Recover the Hospital/Surgeons Costs? The American Society of Transplant Surgeons 10th Annual Winter Symposium, Ft. Lauderdale, Florida, January 15, 2010.
33. Tips and Tricks in Surgical Technique: Liver Transplantation. CAST 11th Congress of the Asian Society for Transplantation, Beirut, Lebanon; September 2009.
34. Transplant for Hepatocellular Cancer: Milan and Beyond. CAST, 11th Congress of the Asian Society for Transplantation, Beirut, Lebanon; September 2009.
35. Living Donor Liver Transplant: Endless Dilemmas. CAST 11th Congress of the Asian Society for Transplantation, Beirut, Lebanon; September 2009.
36. Complex Hepatic Surgery. American University of Beirut Surgical Seminar Series, Beirut, Lebanon, September 2009.
37. Challenges in Portal Hypertension Management. American University of Beirut Surgical Seminar Series, Beirut, Lebanon, September 2009.
38. Physicians and Surgeons as Engine Drivers/Compensation. American Transplant Congress, Boston, MA, May 30-June 3, 2009.
39. The Transplant Center Perspective – How to Drive Volume While Controlling Quality. American Hepato-Pancreato-Biliary Association Meeting, Eden Roc Hotel, Miami Beach, Florida, March 12-15, 2009.
40. Business Practice Seminar – Transplant Center Models: From Design to Practice. Chair and Moderator. The American Society of Transplant Surgeons 9th Annual Winter Symposium, Marco Island, Florida, January 14-20, 2009.
41. Transplant Surgeon Compensation, Present and Future. The American Society of Transplant Surgeons 9th Annual Winter Symposium, Marco Island, Florida, January 14-20, 2009.
42. Organ Acquisition Costs for Transplant Surgeons. The American Society of Transplant Surgeons 9th Annual Winter Symposium, Marco Island, Florida, January 14-20, 2009.
43. Transplant Contracting Perspectives for Transplant Surgeons. The American Society of Transplant Surgeons 9th Annual Winter Symposium, Marco Island, Florida, January 14-20, 2009.

44. ABC's and Alphabet Soup. ASTS Medicare 101 Workshop. The American Society of Transplant Surgeons 8th Annual State of the Art Winter Symposium. Marco Island, Florida, January 24-27, 2008.
45. Burnout, Work Life Balance and All that Jazz. ASTS Pre-Meeting Course: Preparation for a Career in Transplantation, The American Society of Transplant Surgeons 8th Annual State of the Art Winter Symposium. Marco Island, Florida, January 24-27, 2008.
46. Hepatobiliary Cancer Surgery. The 1st Annual USA-Qatari International Cancer Symposium: State of the Art Therapy of Adult and Childhood Cancers. Speaker and Organizing Committee. Doha, Qatar, April 29, 2007 – May 1, 2007.
47. Challenges and Technical Considerations in Hepatic Resections. International School of Robotic Surgery Two-Week Robotic Course, Visiting Professor, Grosseto, Italy, June 20-30, 2006.
48. Management of Liver Cancer in the Cirrhotic Liver. International School of Robotic Surgery Two-Week Robotic Course, Visiting Professor, Grosseto, Italy, June 20-30, 2006.
49. Ablation Therapy for Liver Neoplasms. Dartmouth-Hitchcock Department of Surgery Grand Rounds, Visiting Professor, New Hampshire, March 6, 2002.
50. Liver Transplantation: Program Development. Iranian Transplant Association Meeting. Teheran, Iran, May, 2000.
51. What is New in Liver Transplantation? Iranian Medical Association Meeting. Teheran, Iran, May, 2000.
52. Ablation Therapy for Liver Tumors. 35th Middle East Medical Assembly. Beirut, Lebanon, May, 2000.
53. Evolution of Organ Transplantation: Myth to Reality. Arab American Medical Association Annual Symposium, Michigan, April 24 1996.

Invited and/or Refereed Local/Regional Meetings:

1. Wellness Rounds, Invited Speaker, “Developmental Approach to Resilience”. Henry Ford Health System, August 8, 2018, Henry Ford Hospital, Detroit, Michigan.
2. Anesthesia Grand Rounds, Invited Speaker, “Emotional Intelligence”. Henry Ford Health System, July 18, 2018, Henry Ford Hospital, Detroit, Michigan.
3. Endocrine Grand Rounds. Invited Speaker, “Resilience in Medicine”. Henry Ford Health System, February 9, 2018, New Center One, Detroit, Michigan.
4. Women's Health Services Grand Rounds. Invited Speaker, “Physician Burn Out”. Henry Ford Health System, February 4, 2015, OFP Gilmour Center, Detroit, Michigan.
5. Advance Planning for End of Life: Tools for Faith & Health Conversations. Invited Expert Panelist, “Facilitating the Conversation”. Henry Ford Health System, Institute for Healthcare Improvement, January 9, 2014, Hotel St. Regis, Detroit, Michigan.
6. Transplant Patient Centered Care: The Henry Ford Experience. M. Abouljoud, P. Kosel-Rozanski, E. Rubinstein. International Safety Symposium, Partnerships in Safety: Engage, Empower, Improve, Atheneum Suite Hotel, Detroit, Michigan; November 10, 2011.
7. Leader as Mentor. Physician Leadership Institute, Henry Ford Medical Group. Developer, Co-director, and Presenter. The Fairlane Club, Dearborn, Michigan, April 1, 2011.
8. J. E. Manning Day 39th Annual Surgical Residents' Competition. The Department of Surgery at Synergy Medical Education Alliance. Invited Judge. Covenant Medical Center, June 3, 2010.

9. First Annual MOTTEP Kountz/Callender/Drew Transplant Symposium. Invited Speaker, “Liver Transplantation 2010: Challenges and Opportunities”. March 26, 2010, Wayne State University School of Medicine.
10. Solutions to the Organ Shortage. The 4th Annual World Summit on Organ Donation by The International Association for Organ Donation and Wayne State University School of Medicine. The Ritz Carlton in Dearborn, Michigan, April 19-20, 2007.
11. Henry Ford Transplant Institute: From Innovations to Practice. 2007 System Wide Board Caucus, Henry Ford Health System, Dearborn, Michigan, November 17, 2006.
12. Burnout, Work, Life, Balance and all that Jazz. Surgical Grand Rounds, Henry Ford Hospital, Detroit, Michigan, October 25, 2006.
13. Surgical Immunology & Organ Transplant. Michigan State University College of Osteopathic Medicine, COGMET, General Surgery Educational Conference, Brighton, Michigan, April 26, 2006. Course Coordinator, Full Day Course.
14. Current management of liver cancer. Michigan Society of Hematology Oncology Annual Meeting, Frankenmuth, Michigan, October 16, 2004.
15. Living donor liver transplantation. Henry Ford Liver Transplant Program Symposium, Troy, November 2001.
16. New therapies for primary liver cancer. American Liver Foundation, Michigan Chapter Liver Update, Lansing, November 2001.
17. Organ Donation: Legislative Update. Midland County Medical Society. Midland, Michigan, February, 1998.
18. Chronic Rejection in Abdominal Organ Transplantation. Great Lakes Chapter of International Transplant Nurses Society. Ypsilanti, Michigan. September, 1997.
19. Organ Donation: A Medical Crisis. South Haven Community Hospital. February, 1997.
20. Organ Donation: The Facts. West Shore Hospital, Manistee, January, 1997.
21. Organ Donation: Where do we go from here? Berrien County Medical Society, January, 1997.
22. Organ Donation: A Medical Crisis. Isabella-Clare County Medical Society, September 1996.
23. Managed Care and Liver Transplantation: UNOS Region 10 Forum, Dearborn, Michigan, March, 1996.
24. Anesthesiology Considerations in Liver Transplantation: Sixth Annual Anesthesiology Symposium, Dearborn, Michigan, August 1995.
25. Arterial Injuries of the Thoracic Outlet: Detroit Surgical Society, March 1990.

Invited Seminars and Grand Rounds

1. Providence Hospital General Surgery Grand Rounds. Invited Speaker. “Advances in Liver Transplantation”. Providence Hospital, March 27, 2019.
2. 2nd Annual Henry Ford Health System Advanced Practice Provider CME/CE Symposium. Invited Speaker. “Perspectives on Mindfulness in Medical Practice”. The Henry Hotel, Dearborn MI, November 10, 2018.
3. Henry Ford Behavioral Health Grand Rounds. Invited Speaker. “Provider Perspectives on Resilience”. Henry Ford Hospital, One Ford Place. October 18, 2018.
4. University of Colorado Hospital Transplant Institute Retreat. Invited Facilitator. Aurora, Colorado, Feb 17, 2017.

5. University of Colorado Hospital Transplant Institute Retreat. Invited Speaker. “Transplant Centers and Institutes: An Evolving Patient-Centered Care Model”. Aurora, Colorado, Feb 17, 2017.
6. 2016 H. M. Lee Memorial Lectureship. Invited Speaker. “Transplant Center and Institutes: An Evolving Patient Centered Care Model”. Virginia Commonwealth University Health, Richmond, Virginia, April 7, 2016.
7. C-Suite Senior Leadership Dinner. Invited Speaker. Roundtable Leadership Discussion. Virginia Commonwealth University Health, Richmond, Virginia, April 5, 2016.

Invited Seminars or Lectures Presented in Last Five Years:

1. Houston Methodist Hospital Grand Rounds. “Updates on Living Donor Liver Transplantation”. Invited Grand Rounds Lecturer, Houston Methodist Hospital, Houston, TX, May 13, 2015.
2. Hackensack University ASTS 15th Annual State of the Art Winter Symposium, “Transplant: The Ultimate Team Sport”, “Transplant Surgeon Pay”. Loews, Miami Beach, FL January 15-18, 2015.
3. ASTS 15th Annual State of the Art Winter Symposium, “Transplant: The Ultimate Team Sport”. “Creating the Home Field Advantage – Teamwork in the OR”. Loews, Miami Beach, Florida, January 15-18, 2015.
4. Yale-New Transplantation Center Surgical Grand Rounds. “Resilience and Medicine: Perspectives from Transplantation”. Invited Grand Rounds Lecturer, Yale New Haven Transplantation Center, New Haven, CT, December 1-3, 2014.
5. Heekin Family Lectureship. Surgical Curriculum Conference, “*Perspectives in Living Donor Liver Transplantation*”, Invited Heekin Family Visiting Professor, University of Cincinnati Health, Department of Surgery, Division of Transplantation Surgery. University of Cincinnati Health, Cincinnati, OH, November 19-20, 2013.
6. Heekin Family Lectureship. Transplant Grand Rounds, “*Transplant Centers and Institutes: Strategic Imperatives*”, Invited Heekin Family Visiting Professor, University of Cincinnati Health, Department of Surgery, Division of Transplantation Surgery. University of Cincinnati Health, Cincinnati, OH, November 19-20, 2013.
7. Physician Leadership Institute. Henry Ford Medical Group, Faculty, Organizer, Presenter, “Time Management for Leaders”, One Ford Place, 2013.
8. Physician Leadership Institute. Henry Ford Medical Group, Faculty, Organizer, Presenter, “HFMG Physician Leadership”, and “Why E.I. is so important”. One Ford Place, April 26, 2013.
9. Management of Liver Cancer in the Era of Liver Transplantation. University of Kentucky Health Care, Department of Surgery Grand Rounds, Invited Visiting Professor, Lexington, Kentucky, 4/3/2012-4/4/2012. Conference Center, September 30, 2011.
10. Transplant Patient Centered Care: The Henry Ford Experience. M. Abouljoud, P. Kosel-Rozanski, E. Rubinstein. International Safety Symposium, Partnerships in Safety: Engage, Empower, Improve, Atheneum Suite Hotel, Detroit, Michigan, November 10, 2011.
11. How to Turn an Urban Program Around. Cleveland Clinic, “Emerging Issues in Organ Transplantation, A Colloquium”. Invited Guest Faculty/Presenter. InterContinental Hotel and Conference Center, Cleveland, OH, October 14-15, 2011.

12. Leader as Mentor. Physician Leadership Institute, Henry Ford Medical Group. Developer, Co-Director, and Presenter. The Fairlane Club, Dearborn, Michigan, April 1, 2011.
13. Beverly & Wilshire: The Expensive Transplant Candidate. ASTS 11th Annual State of the Art Winter Symposium; Hollywood, FL, January 13-16, 2011.
14. Innovative Approaches to Compensating and Incentivizing the Transplant Professional: The Virtual RVU. ASTS 11th Annual State of the Art Winter Symposium; Hollywood, FL, January 13-16, 2011.
15. Recent Innovations in Solid Organ Transplantation. Henry Ford Medical Association 2010 Jubilee Reunion, "Advances in patient Care, Education and Research at Henry Ford Hospital", October 22, 2010, Detroit, Michigan.
16. Left Hepatectomy, Laparoscopic Liver Surgery. The 9th World Congress of the IHPBA, Buenos Aires, Argentina, April 18-22, 2010.
17. Tips and Tricks in Surgical Technique: Liver Transplantation. CAST 11th Congress of the Asian Society for Transplantation, Beirut, Lebanon, September 2009.
18. Transplant for Hepatocellular Cancer: Milan and Beyond. CAST 11th Congress of the Asian Society for Transplantation, Beirut, Lebanon, September 2009.
19. Living Donor Liver Transplant: Endless Dilemmas. CAST 11th Congress of the Asian Society for Transplantation, Beirut, Lebanon, September, 2009.
20. Complex Hepatic Surgery. American University of Beirut Surgical Seminar Series, Beirut, Lebanon, September 2009.
21. Challenges in Portal Hypertension Management. American University of Beirut Surgical Seminar Series, Beirut, Lebanon, September 2009.
22. Portal Hypertension in the Era of Liver Transplantation. Synergy Surgical Grand Rounds, Covenant Healthcare, Saginaw, MI, Thursday, May 28, 2009.
23. Status of Hepatic Transplantation. Munson Medical Center, Traverse City, Michigan, Friday, February 13, 2009.
24. Hepatocellular Cancer. Hagerty Center, Dinner Lecture for Munson Medical Center, Traverse City, Michigan, Thursday, February 12, 2009.
25. Liver Directed Therapies in the Management of Oligometastases. Karmanos Cancer Institute's State of the Art Treatment of Gastrointestinal Cancers Conference, Troy, Michigan, November 8, 2008.
26. Living Donor Liver Transplantation. Children's Hospital of Michigan Anesthesia Grand Rounds, Detroit, Michigan.
27. Radiofrequency of Liver Tumor: Current Status. Integris Baptist Medical Center, Department Grand Rounds CME Conference, Oklahoma City, Oklahoma, October 7, 2008.
28. Port Hypertension: Is There A Role For Surgery? Wyandotte Hospital CME Conference, Wyandotte, Michigan, September 24, 2008.
29. Liver Cancer: In With the New and Out With the Old. Wyandotte Hospital CME Conference, Wyandotte, Michigan, September 24, 2008.
30. Career Development Symposium (Chairman). American Society of Transplant Surgeons Winter Symposium, Marco Island, Florida, January 24-27, 2008.
31. Medicare 101 Workshop (Chairman). American Society of Transplant Surgeons Winter Symposium, Marco Island, Florida, January 24-27, 2008.
32. Portal Hypertension. Providence Medical Center Surgical Grand Rounds, Southfield, Michigan, November 14, 2007.

33. Management of Portal Hypertension in the Era of Liver Transplantation. Synergy Medical Education Alliance, St. Mary's of Michigan, Department of Surgery Grand Rounds, Saginaw, Michigan, October 25, 2007.
34. Management of Colorectal Liver Metastasis. Michigan State University College of Osteopathic Medicine General Surgery Educational Conference, Brighton, Michigan, October 24, 2007.
35. Liver Cancer in the Cirrhotic Liver: A Spectrum of Care. St. Mary's Mercy Hospital, Surgery Grand Rounds, Livonia, Michigan, March 28, 2007.
36. Update on Living Donor Liver Transplantation. 49th Annual Allen Silbergleit, MD, Clinic Day, Innovations in Clinical Medicine, St. Joseph Mercy Oakland, Pontiac, Michigan, November 8, 2006.
37. Management of Bile Duct Injuries after Laparoscopic Cholecystectomy. Genesys Hospital Surgical Grand Rounds, Grand Blanc, Michigan, September 26, 2006.
38. Surgical Therapy for Hilar Cholangiocarcinoma. Genesys Hospital Surgical Grand Rounds, Grand Blanc, Michigan, September 26, 2006.
39. Surgical Management of Choledochal Cysts. Genesys Hospital Surgical Grand Rounds, Grand Blanc, Michigan, September 26, 2006.
40. Organ Donation and Transplantation. Michigan State University College of Osteopathic Medicine, COGMET, General Surgery Educational Conference, Brighton, Michigan, April 26, 2006.
41. Update in the Management of Portal Hypertension. Providence Hospital Surgical Grand Rounds, Southfield, Michigan, December 14, 2005.
42. Laparoscopic Major Hepatic Resections. Providence Hospital Surgical Grand Rounds, Southfield, Michigan, December 14, 2005.
43. Current management of bile duct injuries. Providence Hospital Surgical Grand Rounds, Southfield, Michigan, February 7, 2004.
44. Ablative therapy for liver cancer: a comprehensive approach. Botsford Hospital Surgical Grand Rounds, Farmington Hills, Michigan, February 3, 2004.
45. Evolving trends in living donor and split liver transplantation. Wayne State University Surgical Grand Rounds, Detroit, Michigan, October 8, 2003.
46. The Role of the Liver Surgical Scrub Nurse: A Surgeon's Perspective. University of Michigan Career Lecture, Surgical Technologist Program, April 28, 2003.
47. Role of ablation modalities in the current management of liver tumors. Oncology Grand Rounds, Mount Clemens General Hospital, Michigan, March 12, 2003.
48. Neoral rescue conversion in liver and kidney transplantation: update of the OLN-452 experience. University of Nebraska Transplant Grand Rounds, Omaha, February 12, 2003.
49. Current status of living donor liver transplantation. Henry Ford Hospital, Department of Surgery Grand Rounds, January 31, 2003.
50. Surgical approaches to radiofrequency ablation of liver tumors. Introduction to Radiofrequency Ablation Thermal Ablation of Liver Lesions, Beaumont Hospitals Educational Seminar, Royal Oak, Michigan, January 16, 2003.
51. Update on split liver and living donor liver transplantation. Providence Hospital Surgical Grand Rounds, Southfield, November 9, 2002.
52. Management of bile duct strictures and bile duct injury. Michigan State University General Surgery Education Conference (COGMET), Southfield, Michigan, September 25, 2002.

53. Liver resection for malignancy. Michigan State University General Surgery Education Conference (COGMET), Southfield, Michigan, September 25, 2002.
54. Current management of liver cancer. Providence Hospital Surgical Grand Rounds, Southfield, April 6, 2002.
55. Current management of metastatic liver cancer. Henry Ford Medical Center, Oncology Grand Rounds, Detroit, November 2001.
56. Update in Liver Transplantation. Medical Grand Rounds, Riverview Hospital, Detroit, Michigan, December 2000.
57. Ablative therapy in the management of liver cancer. North Oakland Medical Center, Oncology Grand Rounds, Pontiac, Michigan, November 2000.
58. Organ Transplantation and the Surgical Technologist. Surgical Technology Program lecture, Henry Ford Community College, Dearborn, Michigan, April 2001.
59. Evolving Therapies for Hepatocellular Carcinoma. Surgical Grand Rounds, North Oakland Medical Centers. Pontiac, Michigan, April, 2000.
60. Liver Transplantation for Hepatocellular Carcinoma. Pontiac Osteopathic Hospital Tumor Board Presentation. Pontiac, Michigan, January, 2000.
61. New Therapies for Hepatocellular Carcinoma. Henry Ford Hospital Surgical Grand Rounds, April, 1999.
62. Liver Transplantation: A Surgical Perspective. Gastroenterology Clinical Conference, Wayne State University. Detroit, Michigan, March, 1998.
63. Community Involvement in Organ Donation. The Lions Club, Detroit Chapter. June, 1997.
64. Organ Donation: A Community Perspective. Italian-American Chamber of Commerce. May, 1997.
65. Portal Hypertension: Surgical Perspective. Critical Care Grand Rounds. Henry Ford Hospital. February, 1997.
66. Organ Donation: A Medical Crisis. Muskegon County Medical Society. February, 1997.
67. Update on Surgery for Portal Hypertension. Vascular Surgery Grand Rounds, Henry Ford Hospital. February, 1997.
68. Liver Transplantation. Consortium for Osteopathic Medical Education and Training, Michigan State University, Lansing. January, 1997.
69. Surgery for Portal Hypertension. Consortium for Osteopathic Medical Education and Training, Michigan State University, Lansing. January, 1997.
70. Current Progress in Liver Transplantation. Quarterly staff assembly, Cottage Hospital, June 1996.
71. Medical Center, Pontiac, Michigan, March 1996.
72. Updates in Liver Transplantation: Surgical Grand Rounds, North Oakland Regional.
73. Liver Transplant Update: Saint John Hospital and Medical Center, Detroit, Michigan, July, 1995.
74. Current Topics in Liver Transplantation: Medical Grand Rounds, Saginaw Cooperative Hospitals, Saginaw, June 1995.
75. Liver Transplantation: An Overview: Surgical Grand Rounds, Saint Joseph Mercy Medical Center, Pontiac, April 1995.
76. Current Topics in Liver Transplantation: Surgical Grand Rounds, Henry Ford Hospital, October 1994.
77. Liver Transplantation: Part of the Henry Ford Hospital "Management of End-Stage Vital Organ Failure" symposium, Dearborn, October 1994.

78. New Immunosuppressive Modalities: Multidisciplinary Transplant Conference, Henry Ford Hospital, February 1991.
79. Wound Healing: Henry Ford Hospital Grand Rounds, December 1989.
80. Modulation of neutrophil function by superoxide dismutase: NIH visit, March 1986, University of California, San Francisco.
81. Blood Supply of Tendons; Physiologic Appraisal: Plastic Surgery Grand Rounds, May 1986, UCSF.